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Perinatal depression (PND) has profound consequences for family life, social 
functioning as well as long-term cognitive development for the offspring. Current 
screening is ineffective, with half of all cases undetected. Understanding which 
factors provide the highest risk of PND will benefit screening and the targeting of 
treatment. PND involves interplay between individual chronic and acute disease 
burdens, biological and psychosocial environmental behavioural factors. The 
predictive potential of specific factors and their contribution to severity scores on 
the Edinburgh Postnatal Depression Scale (EPDS) screening tool is explored here. 
This study has employed a multidisciplinary approach to combine psycho-
sociodemographic factors with biomarkers from a population of women screened 
for antenatal (N=1579) and postpartum (N=872) depressive symptoms. Different 
methods of regression modelling have been explored to determine predictors of 
perinatal depression, which has also been compared with a machine learning 
approach. The heterogeneous presentation of symptoms has additionally been 
explored with statistical analysis.  
History of anxiety or depression, young maternal age (18-24) low social status and 
smoking pre-pregnancy were identified as the strongest contributions to antenatal 
scores, whereas depressive symptoms in pregnancy and a history of depression or 
PND exhibited the strongest association with postpartum EPDS. Circulating 
concentration of IL-10 was significantly associated with antenatal EPDS, in addition 
to the ratio of IL-6/IL-10. The inclusion of IL-6 and IL-10 data improves prediction of 
antenatal scores. IL-6 and BDNF concentration were predictive of lower infant birth 
weights. In general the available covariates are better suited to predict EPDS scores 
antenatally than postpartum. Risk factor profiles for antenatal and postpartum 
depression appear to be largely different, supporting the theory that PND is a 
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1.1 Chapter One Abstract 
 
This opening chapter explores the context of the research and the problems which 
are yet to be adequately investigated in the field of perinatal depression (PND). The 
relevant literature has been reviewed to identify these gaps in the knowledge and 
to formulate suitable research questions. Clinical studies and subsequent guidance 
have emphasised the wide scale problems associated with PND, ranging from 
psychiatric effects on the mother, father and extended family, to developmental 
effects both in utero and in childhood, with impacts on social, education and health 
systems. A review of the literature identified two key gaps in the current state of 
the research: a lack of clarity in understanding the pathogenesis of PND, and a bias 
towards postpartum studies with fewer studies paying attention to depression 
during the antenatal period. It is emerging that the effects of PND on the child are 
profound, with noted effects on infant birthweights, gestational length and 
cognitive development, which each have implications for later life.  
A number of systematic reviews and meta-analyses have investigated psychosocial 
risk factors for postpartum depression, and the consensus suggests that six key 
psychosocial risk factors are associated with depression in the postpartum: 
antenatal depression, antenatal anxiety, major life events, social support levels, 
depression history and low self-esteem. Fewer studies have investigated 
psychosocial risk factors for antenatal depression, however a general level of 
socioeconomic depravation and a lack of social support appear to be important in 
the development of depression during pregnancy. A crucial problem identified by 
the literature review is the failure to agree on the definition of perinatal depression; 
for example the terminology used, the time period this covers, the screening 
process and the disease classifications are not consistent, leading to difficulties 
when searching the body of literature. Greater consistency in the field is clearly 
necessary. Assessment of the current service provision for PND revealed that 
further inconsistencies are present across maternity services. Since screening for 
PND is recommended but not mandated, whether or not this is effectively carried 
out will inevitably vary. The evidence suggests that there is a serious lack of 
provision for maternal mental health services, and around half of all cases of PND 
are thought to go undiagnosed.  
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The aetiology of PND is an area currently lacking clarity, however a few main 
biological systems carry the strongest evidence for their involvement in the 
development of maternal depression: the HPA axis, stress-immune interactions 
(cytokine-glucocorticoid circuit), an underlying genetic risk and DNA methylation. 
The theories behind each of their involvement is investigated across this chapter. 
The key gaps in the literature have been scrutinised, leading to the development of 
this study investigating whether a combination of biological and psychosocial risk 
factors can predict depressive symptoms in a cohort of women across Coventry and 
Warwickshire. The aims of this study are presented at the end of this chapter, 
alongside an overview of the study designed to address them. 
 
1.2 Perinatal Depression 
 
Despite the vast improvement in the physical care of pregnant women in the last 
century, the same cannot be said for mental health care. Pregnancy and the 
postpartum period is characterised by increased vulnerability for the onset or 
relapse of a mental illness, and can present periods of psychological and physical 
distress. Remarkable physiological and psychological changes occur around 
parturition which influence maternal health and relationship with the baby. Poor 
mental health stands as a leading cause of maternal morbidity and mortality, and 
the foremost cause of maternal death in developed countries, including the UK, is 
suicide1.  
Depression during pregnancy, around childbirth or within the first year postpartum, 
is collectively termed perinatal depression (PND). PND has profound consequences 
for maternal health, family life, social functioning as well as long-term cognitive 
development for the offspring. Infants of mothers suffering from PND are less likely 
to be positioned safely while sleeping, receive all recommended immunisations, 
and be breastfed2-4. Anxiety disorders including panic disorder, generalised anxiety 
disorder (GAD), obsessive compulsive disorder (OCD), post-traumatic stress 
disorder (PTSD) and tokophobia (extreme fear of childbirth) can present alongside 
PND as well as on their own5. Severe untreated PND can lead to postpartum 
psychosis, a psychotic illness present in 1-2 in 1000 postpartum women, with 
symptoms including hallucinations, delusions and suicidal or homicidal thoughts 
which can become severe rapidly and requires immediate treatment as a 
psychiatric emergency6 7. Since many of its symptoms overlap with those of 
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depression and anxiety, detection and treatment during pregnancy is vital. PND is 
now recognised as a major health burden both for the mother, her family and the 
offspring. The World Health Organisation (WHO) recognises depression as a public 
health priority8, with major depression ranked as the world’s leading cause of 
disability9. The identification of PND is a critical goal10, yet half of cases in the UK 
are undetected11.  
Understanding the origin of the huge under-detection of PND is a timely problem 
to explore. From a clinical perspective, the identification of depression in the 
perinatal period is more complex than depression outside of this period. This is in 
part due to somatic symptoms of pregnancy and the immediate postpartum, such 
as fatigue and changes to appetite, which can be difficult to distinguish from 
depressive symptoms and are often attributed to the pregnancy. Depression is 
surrounded by stigma, and this is especially true for perinatal depression. Societal 
and cultural beliefs contribute to this stigma and fear surrounding PND, often 
preventing women from seeking help and hindering its detection. Pregnancy and 
the birth of a baby carries connotations of happiness, yet for around 1 in 5 
mothers5, this is not the reality. 
A lack of awareness exists around PND, not only from a patient and public 
perspective, but also from health professionals. During pregnancy and postpartum, 
a mother will have regular contact with trained health professionals, with around 
twelve antenatal appointments offered12, providing an excellent opportunity to 
monitor mental as well as physical health. This is not utilised effectively however, 
since questions surrounding mental health are encouraged but not mandated, so 
may often be omitted due to time limitations. A report by the NSPCC on perinatal 
mental health revealed that 41% of mothers were never asked about depression by 
their midwife or health visitor13. Secondly, this report found that 29% midwives had 
not received any training in perinatal mental health, and are therefore ill informed 
to detect symptoms. This is backed by evidence from the Confidential Enquiries into 
Maternal Death in the United Kingdom, which found a high proportion of midwives 
received no mental health training1. Specialist perinatal mental health midwives 
have been introduced in some NHS trusts, but the majority of women will not come 
across these specialists during their care5. 
Depression carries a significant public health impact and is a highly comorbid 
disease. The rates of obesity, cardiac conditions, heart disease and diabetes are 
higher in those suffering from depression than in the general population14. Mental 
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ill health is the largest cause of disability in the UK, costing the economy £105 billion 
per year, which is roughly the entire cost of the NHS, as reported in the Five Year 
Forward View for Mental Health15. This report details the aim to increase NHS 
funding by £365 million over a five year period to meet the needs of women 
requiring a specialist perinatal mental health service. Perinatal depression is a 
specific concern due to a host of health detriments for both mother and child. A 
first of its kind report into the cost of perinatal mental health problems in the UK 
found this amounts to £8.1 billion per year, and over 2/3 of these costs relate to 
effects on the child.16 The report finds that the average cost of one case of PND to 
society is £74,000, of which £51,000 relates to impacts on the child. Maternal 
impacts include health and social care, productivity losses and losses of quality-
adjusted life-years, and infant related impacts measured include pre-term birth, 
infant death, emotional and conduct problems, special educational needs and 
school qualifications. Several preventative interventions for PND are considered to 
be cost effective however, as reviewed by Morrell, Sutcliffe et al., further 
highlighting the importance of detecting women at risk17. 
Postpartum depression (PPD) is closely linked with a higher likelihood of parenting 
and caregiving difficulties18 19, yet early treatment can prevent consequences for 
child development associated with early stress20. Infant bonding and parental 
relationships are compromised, and the detrimental effects on relationships caused 
by PND have been shown to be multigenerational, extending to both grandmother-
parent and grandmother-grandchild dyads21. Effective interventions are available 
to prevent depression postnatally22, but the inability to identify cases results in lack 
of treatment and the continuation of symptoms postpartum. A more effective 
method of identifying high risk women during pregnancy would allow earlier 
treatment and amelioration of the consequences associated with the continuation 
of depression postnatally. 
Across the general population PND is reported to be experienced by an estimated 
10-15% of women23 24, although the prevalence is likely higher. 30% of PPD persists 
over a year, with substantial risk of relapse25 26. The worldwide prevalence of PND 
remains unclear, since the vast majority of meta-analyses comprise of women of 
European ancestry from developed countries, and the rate is estimated to be higher 
in Low and Middle Income Countries (LMICs).  
One recent meta-analysis examined global and national prevalence of PPD, across 
291 studies and 56 countries, in addition to risk factors which may vary between 
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nations27. The study found significant heterogeneity exists across nations, ranging 
from 3% in Singapore to 38% in Chile, and a pooled global prevalence of 17.7%, 
which is higher than previous estimations. National differences were importantly 
not explained by methodological differences, but by health and socioeconomic 
factors. Important factors which increased the national risk of PPD were income 
inequality, maternal and infant mortality, and women of childbearing age working 
≥40hrs per week. This is the largest PPD meta-analysis to date, and lessons must be 
learnt related to the profound impact of economic disparity and importance of 
prioritising maternal-child health. 
Our current knowledge of perinatal depression is inadequate, and this is a crucial 
barrier in its detection and treatment, despite the long-lasting effects capable of 
spanning generations and the cost to society. I have established the need for this 
novel research contribution, as highlighted by areas which have not yet been 
adequately investigated. This introductory chapter will continue to introduce the 
problem of PND and outline any gaps identified within the current literature. This 
Chapter will cover what is currently know, the limitations and gaps in previous 
research, unresolved conflicts in the field that still require further investigation, and 
new developments that will advance the current state of knowledge in the field. 
The Chapter will conclude with the aims of the current project, a brief description 
of the research carried out, and an outline of the chapters of this thesis. 
1.3 Gaps in the Literature 
 
1.3.1 Pathogenesis of perinatal depression 
 
Depression is a multifaceted disease with no single cause. In order to identify the 
means to better identify and treat PND, it is imperative to first understand the 
underlying mechanisms. The pathogenesis of neuropsychiatric disorders such as 
clinical depression appears to be complex and multifactorial and is a field which 
warrants further attention. Our knowledge of depressive physiology remains 
understudied, in particular the aetiology of mental illness in women. 
Epidemiological studies show that women are twice as likely to develop depression 
as men28, yet the majority of preclinical studies in the development of therapeutics 
focus on males29. In particular, our understanding of depression and its mechanisms 
of disease during pregnancy and the perinatal period remains extremely limited. 
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Depression outside of the perinatal period has received considerably more 
attention and multiple categories of biological alterations have been associated 
with its development. Findings consistently report alterations to the inflammatory 
system30 and HPA axis dysfunction31. More recent studies have linked genetic and 
epigenetic alterations with depressive pathogenesis32. The complete aetiology of 
PND is currently unclear, but several hypotheses have been proposed to explain its 
pathogenesis, involving multiple biological systems (Figure 1.1).  
 
The immune response is becoming increasingly implicated in major depression. The 
immune system is thought to play a crucial role, and is considered a major triggering 
factor, mainly characterised by release of cytokines through Toll-like receptor (TLR) 
signalling. PND has been proposed as an immune-related disorder impinging the 
brain and neuroendocrine system33, but an inappropriate inflammatory response 
can pose harm to both mother and baby during what should be a tightly regulated 
inflammatory period. There is inconclusive evidence surrounding the role of 
inflammation in depression during pregnancy and postpartum and this requires 
further investigation outside of major depression. 
The HPA axis is considered central to the pathogenesis of depression34. 
Interconnected individual predispositions including genetics and personal 
psychosocial factors such as exposure to early adversity are believed to cause 
adaptive immune, brain and neuroendocrine changes involved in PND. Stress in 
vulnerable individuals can lead to increased HPA axis activity and high levels of 
circulatory glucocorticoids due to impaired glucocorticoid receptor function, 
Figure 1.1. The overall pathobiological framework for the development of perinatal depression. The 
interactions between different systems during PND, namely the immune, neuroendocrine and brain 
(serotonin), suggest the complexity of this mood disorder. Individual genetic and psychosocial 




although the exact mechanisms of HPA dysfunction in depression are still unclear, 
as covered in a review by Pariante and Lightman31. This review suggests that HPA 
hyperactivity is not a simple consequence of depression, but is a risk factor 
predisposing an individual to depression, alongside genetic factors and early life 
experiences programming molecular changes. They conclude that although altered 
activity of the HPA axis is one of the most consistent findings in biological psychiatry 
over the last forty years, it has not been entirely established. It is important to note 
that this key review covers major depression, and did not assess depression in the 
perinatal period. 
Stress, whether inflammatory, traumatic or emotional, is concurrent with an 
altered HPA response. Physiological changes to the axis during pregnancy, driven 
largely by endocrine factors, can lead to an inappropriate response to stress 
resulting in increased depressive vulnerability. Serotonin dysfunction, which is also 
thought to drive HPA dysfunction, has long been a key target for depressive 
physiology research, and is a major target of antidepressant therapies. Brain 
adaptive responses lead to alterations in serotonin levels which can be a result of 
reduced signalling, increased metabolism and increased reuptake by astroglia35. 
Both HPA and serotonin dysfunctions are emerging as important areas of 
investigation in the pathogenesis of PND. 
Recently, the role of neuroactive steroids in PND has attracted considerable 
interest, especially allopregnanolone, a derivative of progesterone synthesised in 
the adrenal glands, gonads and central nervous system36. Experimental studies 
have linked neuroactive steroids to mood and ability to adapt to stress 37. Increases 
in serum allopregnanolone levels during the third trimester have been correlated 
with alternations in mood, and significantly decreased levels post-partum have 
been observed in women with symptoms of ’baby-blues’ 38. Allopregnanolone plays 
a role in the decreased HPA response to stress in rats during pregnancy 39 and this 
highlights the interaction between neuroactive steroids and the stress system. 
Overall, the immune response, HPA axis dysfunction, and alterations to the 
serotonin system are the three strongest proposed mechanisms for the aetiology 
of PND. Other predisposing factors include genetics, epigenetics and personal 
psychosocial factors which appear to interact with the complex and interconnecting 
systems contributing to PND. Despite their similarities, due to key differences in a 
number of these systems between the antenatal and postpartum periods, the 
underlying hypotheses for depression in the two time periods are also thought to 
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differ. In particular, key differences in the hypothalamic-pituitary-adrenal (HPA) 
axis function are observed from the pregnant to non-pregnant state, largely due to 
the growth of the placenta.  One of the crucial pathological triggers for PPD is 
thought to be the rapid decline in hormones such as oestrogen and progesterone 
following parturition40. This rapid decline in hormones is not present during the 
pregnant state, and therefore the mechanisms for antenatal and postpartum 
depression are thought to differ. This is further supported by the fact that fathers 
can too experience postpartum depression, and is highly comorbid with maternal 
depression, revealing a strong environmental mediating component to PPD such as 
family environment41. The underlying differences will be discussed in further detail 
later in this chapter. 
Further work in perinatal women is required to elucidate the pathobiological 
mechanisms of PND. The investigation of reported associations between the 
immune response and PND may provide an opportunity for the discovery of 
biomarkers to aid its detection. In addition, further distinction between the 
antenatal and postpartum depressive aetiologies will benefit the debate over 
whether they represent distinct syndromes and ensure that appropriate 





1.3.2 Antenatal depression 
 
The impact of postpartum depression is often more apparent than depression 
during pregnancy, with more visible consequences including poor mother-infant 
bonding and an impaired ability to care for the child18. It is likely however that the 
full impact of antenatal depression (AND) has not been realised due to unseen 
effects in utero impacting growth, development, cognitive function and increased 
psychiatric risk42 43, which may not be apparent until later in life, and these effects 
warrant further investigation. Despite established effects of AND on pregnancy 
outcomes and risk for development of PPD, mental health problems in the 
antenatal period have received much less attention than PPD with health 
assessment focusing primarily on maternal and foetal physical health during 
pregnancy.  
Antenatal depression is becoming a leading complication of pregnancy44. Fewer 
studies assess AND, yet it is considered more frequent than PPD, ipso facto 
significantly predicts PPD and carries independent risks42 45. Certain psychosocial 
risk factors have been shown to differ between antenatal and postpartum 
depression, such as maternal education, which has been found to be a risk factor 
for postpartum but not antenatal depression43. This study by Pearson et al. reports 
an interaction between PPD and maternal education but no evidence for an 
interaction between AND and maternal education. Their analyses provided 
evidence that the effect of PND was limited to mothers with a lower education, 
whereas effects of AND were present in mothers with both higher and lower 
education. This study also reported similar patterns of moderation for maternal 
income, another indicator of socioeconomic status (SES). This suggests that PPD 
responds more to environmental challenges, with education and income indicative 
of multiple social and key environmental factors46, whereas effects of AND may be 
more strongly linked to biological and genetic mechanisms.  
Maternal education indicates multiple sources of psychosocial support and more 
positive home environment and positive parenting18, which are likely to protect 
against depression47. The absence of moderation by education on AND is consistent 
with a biological mechanism in utero which is unlikely to be ameliorated by 
environmental factors. This is further supported by the study’s finding that paternal 
depression is not associated with offspring outcomes. Although the study did not 
directly test the biological mechanism operating, this provides indirect evidence 
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that the pathways of AND and PND are different and provides further evidence to 
support the hypothesis of two distinct syndromes with differing aetiologies. 
Antenatal depression appears to pose independent risks for offspring 
development, such as poor foetal growth and lower birth weights48, yet the reasons 
for this are not well defined and the evidence has been inconclusive49 50. 
Developmental effects previously linked to PPD may instead be attributed to AND51. 
Even seemingly inconsequential effects on birth weight can have long-term 
consequences for cognitive development and responses to stress, as well as general 
psychological wellbeing in later life and increased risk of mortality52-54.  
Depression in either the antenatal or postpartum period may represent distinct 
aetiologies, yet perinatal depression can also be considered as a continuous 
pathological process with similarities and differences. The vast majority of the 
current literature focuses on one aspect of PND, either the antenatal or postpartum 
period55-57. This approach fails to capture the continuous pathological process than 
might present as antenatal and/or postpartum depression. Another main limitation 
of research in the field thus far is the tendency to study one element of 
susceptibility, for example only the psychosocial/socioeconomic factors, or only 
genetic factors. In order to really gain a broader understanding of the biology of 
PND, studies should now become multidisciplinary and examine for example how 
psychosocial factors interact with genetic factors or biomarker data, since without 





1.4 PND and Infant Development 
 
Although the majority of previous research on perinatal mental health has focused 
on depression in the postpartum period to date, it is known that the antenatal 
period also represents a time of increased vulnerability for onset or relapse of 
mental health problems including depression, anxiety, psychosis, post-traumatic 
stress disorders and eating disorders58. All of these problems warrant attention, 
occurring at any point in the perinatal period, not limited to the postpartum. 
Biological effects begin to take place in utero, and can continue into the period of 
critical child development after birth, which is explored in the following section.  
It is increasingly apparent that the physical and mental health of the offspring starts 
at conception, and investment in mothers’ mental health is key. A recently 
launched cross party manifesto titled ‘1001 critical days’ galvanises the importance 
of the first 1001 days of life, spanning from conception until age 259. Following its 
relaunch in Parliament, a record number of MPs have supported adopting it as 
Government policy across a number of health-led departments. The NHS Five Year 
Forward View also establishes the need to invest in maternal mental health15, with 
a vast increase in funding for perinatal mental health services over the coming 
years. These early days of life represent a period of rapid growth, and experiences 
in this phase underpin future development. There is also strong evidence that this 
critical period extends to pre-conception60. It is becoming increasingly clear that 
maternal factors during pregnancy, and even pre-conception, can have long-lasting 
effects on children, further justifying the need to prioritise maternal health.  
Untreated depression has been shown to impact the offspring’s life, and a number 
of indicators of infant morbidity are increased61 62. Impairment of woman's physical 
and mental health has acute and longer-term consequences for both mother and 
child, compromising growth and development of the foetus when mothers suffer 
with depressive symptoms during pregnancy63. For example, AND is linked to low 
birth weights (LBW), babies small for gestational age (SGA), and pre-term birth49. 
The exact underlying mechanism is not understood, but cortisol is a possible 
mediator of these relationships, with elevated cortisol levels found in women with 
AND showing slower foetal growth. The study by Diego et al.49 concluded that 
prenatal maternal cortisol levels were associated with 30% of the variance in 
gestational age at birth and 14% of the variance in the rate of foetal growth. A 
limitation of the study is the estimation of foetal weight and growth from scan data, 
but it is a useful study in the field of antenatal depression outcomes, since the 
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majority of studies evaluating offspring outcomes only look at the effects of PPD 
and therefore what is known about the effects of AND is limited. 
Impaired offspring growth and development are also recognised complications of 
postpartum stress64. A review of this subject evaluated the effect of maternal 
depression on offspring’s growth, finding a positive association between exposure 
to depression and impaired weight and length in the child. This effect on offspring 
growth is centred on the first year of life65. This is likely because children under 1 
year are almost entirely dependent on their main caregiver, who is most often the 
mother, for feeding, sleeping, health promoting and development stimulation, and 
depressive symptoms may lead to impaired parenting behaviours, less stimulation 
and less positive mother/child interactions18 66. The underlying reasons for this 
limitation to the first year of life has however not been adequately addressed by 
these studies and requires further examination. In addition, depression in the 
postpartum can compromise parenting activities such as breastfeeding, weaning 
and feeding, in addition to sleeping and health-seeking practices that can affect 
child growth47 66. The quality of maternal care is known to be associated with 
cognitive and psychological outcomes for the child67. 
LBW/SGA babies experience a number of adverse health effects, including cognitive 
impairment. Low birth weight babies are more likely to develop attention-
deficient/hyperactivity disorder (ADHD) and other behavioural issues. On 
controlling for a number of potential confounders, ADHD is reported to be three 
times as likely in LBW babies compared with controls68. Socioeconomic status and 
parental education have been shown to mediate outcome of LBW in some studies, 
and is thought to represent a biological vulnerability associated with environmental 
risk and social disadvantage69 70. Children of mothers who were depressed while 
pregnant show developmental delays later in childhood and enhanced 
susceptibility for diseases in adulthood, identifying programing effects due to 
deranged development19. PND has also been linked to detrimental effects on 
maternal sensitivity and impaired parenting behaviours in the postpartum period18. 
There are noted biochemical footprints of AND on neonates, including elevated 
cortisol levels, a product of the hypothalamic-pituitary-adrenal (HPA) axis, 
fundamental to the hormonal stress response. HPA axis dysregulation is strongly 
linked to depression34, and it is thought a continued rise in cortisol levels during 
pregnancy causes overall dysregulation of the HPA axis71 72. The resulting 
inappropriate response to stress is linked to a susceptibility to physical and mental 
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illness for the offspring in later life73 74. Increased cortisol is additionally associated 
with compromised foetal growth and neurodevelopmental defects49, providing 
further evidence for detrimental effects on infant development. It is increasingly 
apparent that AND and birth weight are interconnected factors, and this 
emphasises the need for early detection and subsequent treatment. 
Evidence suggests that children exposed to either AND or PPD have raised cortisol 
levels which continues into adulthood 75 76, although these effects could be reduced 
by maternal treatment. Placental mechanisms act to protect the foetus from 
harmful levels of glucocorticoids which can compromise foetal growth and 
gestational length77-82, although high levels are thought to overcome the protection 
provided by the cortisol metabolising enzyme 11β-HSD2 which forms a protective 
barrier. This is discussed in further detail later in the chapter. Overall, the 
dysfunction of the maternal HPA axis poses a number of risks for both the mother 
and the offspring. 
Data from the Avon Longitudinal Study of Parents and Children (ALSPAC), a 
longitudinal study which followed child outcomes of more than 14,000 pregnant 
women and their children over 18 years, was used to examine the long-term 
consequences of PPD. Women with moderate to severe PPD at both 2 and 8 months 
postpartum were also at risk of depression 11 years later. Their children were found 
to have a higher likelihood of behavioural problems, lower maths scores and 
increased depression risk aged 1883. Other studies have concluded that educational 
attainment is lower in the children of mothers who suffered from PND54 and 
hyperactivity and conduct disorder are more likely84. This could be a result of 
impaired parenting behaviours and the effects of maternal depression in early life66. 
It is also possible that the association is indirect, and is acting through confounders 
such as socioeconomic status and deprivation, although this is challenging for 
studies to assess comprehensively. 
Antenatal stress and the associated heightened inflammatory response, in 
particular the increased levels of pro-inflammatory cytokine Interleukin-6 (IL-6), is 
known to increase the risk of psychiatric illness and behavioural problems in the 
offspring, and imaging studies in neonates suggest that this acts through effects on 
the developing foetal brain85. In the first human study linking a specific mediator of 
maternal inflammation and the new-born brain, Graham et al. describes an 
association between raised systemic maternal IL-6 concentration in pregnancy and 
larger new-born right amygdala volume and stronger left amygdala connectivity, 
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which is in turn associated with lower impulse control at 24 months. The amygdala 
is of specific interest due to associations with phenotypes including social deficits, 
increased emotional and stress reactivity in animal models, and therefore 
alterations in amygdala integrity might represent a causal role for maternal 
inflammation and risk of offspring psychiatric disorders85. Maternal inflammation is 
a strong candidate for a mediating factor in the effect of PND on offspring 
neurodevelopment. Although cytokines are expressed in the foetal brain during 
normal development86, elevated levels for example in response to maternal 
inflammation trigger alterations in neurodevelopment87-89. PND represents an 
intrauterine condition that influences the offspring’s susceptibility to illness later in 
life, and should be targeted for early intervention and prevention.  
The maternal hormonal milieu is clearly critical to foetal development, as depicted 
in Figure 1.2, representing a developmental window of susceptibility during early 
gestation. The foetal development hypothesis posits that early-life environmental 
factors have long-term consequences on ill health. Although many adverse events 
are unavoidable and unpredictable, recognising the consequences of antenatal 
stress is a crucial first step to developing interventions for women experiencing 
adversity and stress during pregnancy. The failure to recognise the 
intergenerational consequences of maternal stress has far reaching implications if 
this window of opportunity to intervene and focus on prevention is missed62. 
 
Figure 1.2. The maternal milieu is influenced by environmental factors including antenatal stress. 
Early in gestation the foetus is vulnerable to external factors which have direct consequences for 
the placenta and developing foetus. Epigenetic programming is an example of a gene-environment 
interaction, which is affected by factors such as stress and diet, for which there is a developmental 













(folate and choline) 
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1.5 Psychosocial Risk Factors 
 
There are well established risks which increase the prevalence of PPD, such as a 
history of depression and socioeconomic depravation, and the difficulties in 
detecting these especially vulnerable women impedes the current provision of 
care90-92. Previous life events and trauma can increase the risk of depression, and 
there is an observed association between past abuse and PPD93. Additionally there 
are postpartum risk factors to consider such as traumatic birth experience, poor 
maternal physical health after birth and a lack of support at home and clearly, 
antenatal screening cannot identify these. Other important factors include 
unwanted pregnancy, a specific risk factor for suicide1, and teenage pregnancy, 
which doubles the risk of depression94. 
Table 1.1. A summary of the recurring proposed risk factors for perinatal depression split into 
categories: health, lifestyle, socioeconomic and other. 
Health Lifestyle Socioeconomic Other 
History of 
mental disorders 
Smoking Unemployment Unwanted 
pregnancy 
Family history of 
PND 









 Obesity Poor social support Cognitive style 
(e.g. 
neuroticism) 
   Traumatic birth 
 
Previous studies have investigated risk factors for PND, which include psychosocial, 
personal and biological factors. The most commonly recurring risk factors emerging 
from the literature are outlined in Table 1.1. Thorough meta-analyses on the 
subject have suggested the six strongest predictors: antenatal depression, 
antenatal anxiety, major life events, social support levels, depression history and 
low self-esteem23 55 95. Targeting antenatal depression and anxiety for treatment 
could eliminate two of these major predictors subsequently preventing the 
development of postpartum depression. Other factors including unplanned 
pregnancy, being a first-time mother, poor mother-in-law relationship, and poor 
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family support have been suggested as important risk factors for PPD96. It is 
acknowledged that social relationships significantly impact perinatal mental health 
outcomes97. Higher levels of support provided by the partner, the family and the 
social environment is considered crucial for the mother-to-be. The presence of a 
supportive partner in particular is thought to have a buffering effect against the 
stress experienced in the transition to parenthood, protecting maternal mental 
health. Good quality social relationships are also thought to mediate depression 
through the reduction of the depressive symptoms themselves98. 
Fewer studies have focused on specific risk factors for AND. Lower socioeconomic 
position has been related to an increased depressive risk in pregnancy99. This 
particular study reported that this association can be moderated by parity, with 
increased evidence of depressive risk in multiparous women. Social support was 
shown to mediate the association between socioeconomic position and depressive 
risk, with a greater mediating effect for nulliparous women. Overall, this study 
demonstrated a higher risk of AND in women of a lower socioeconomic position, 
driven by social support, which could in turn be mediated by parity. A recent 
Australian study identified similar major risk factors for maternal depressive 
symptoms: a lack of partner support, history of intimate partner violence, and low 
SES100. In addition, antenatal depressive symptoms and assisted delivery were 
associated with postpartum depressive symptoms.  
Maternal sociodemographic factors have been shown to influence AND, such as 
education and income56. It is important to consider how such factors are 
interrelated, for example, maternal occupation can represent social status, and is 
strongly tied to education, income and housing. It is therefore important to 
consider not one single variable but a range of interconnected variables when 





1.6 The Disputed Definition of PND 
 
The definition of perinatal depression is one that invites debate and uncertainty, 
and even the terminology is one of dispute. The ICD-10101 (International 
Classification of Diseases, 10th revision), has no antenatal specifier for depression, 
but does identify disorders occurring in the puerperium (up to 6 weeks postpartum) 
with a separate classification. In contrast, the DSM-5102 (Diagnostic and Statistical 
Manual of Mental Disorders), does specify major mood disorders “with perinatal 
onset”, which it classifies as within pregnancy or within four weeks postpartum. 
The National Institute for Health and Care Excellence (NICE) guidelines in the UK 
however define the postnatal period as 1 year after childbirth5. This lack of clarity 
impedes current screening provision with no clear consensus.  
As described above, under some definitions, ‘postpartum depression’ (PPD) covers 
pregnancy in addition to the postpartum period, and the timing that is considered 
‘postpartum’ greatly varies from 4 weeks to a year following birth. The term 
‘perinatal depression’ (PND) however more clearly refers to both the antenatal and 
postpartum period, and this is the preferred term that is used throughout this thesis 
to describe depression occurring in either the antenatal or postpartum period. The 
question of whether antenatal and postpartum depression represent distinct 
syndromes is also unanswered, and remains a topic of uncertainty. The unresolved 
conflicts in the field surrounding the terminology and timings of onset create 
difficulties in comparing studies and defining PND, and this requires further work 
and clarification. 
Screening for PND is most commonly carried out by midwives and other health 
professionals during a woman’s routine maternity care, but can be carried out in 
other setting such as in primary care. Midwives are best placed to discuss mental 
health with a woman, since ideally a woman will see the same midwife at multiple 
time points throughout her pregnancy, and a sense of trust and rapport is often 
built. The presence of PND can only be confirmed following a clinical assessment, 
however it is commonplace to use a screening tool as a guide. This allows the 
identification of women who are low risk, and ensures that women at the higher 
level of risk are prioritised. It also ensures timely identification of depressive 
symptoms and allows for early intervention during the period of waiting to undergo 
psychiatric assessment.  
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The Edinburgh Postnatal Depression Scale (EPDS), which despite the name is 
validated for use both during pregnancy and postpartum, is a widely used screening 
tool for PND103. It is important to differentiate between a screening tool and a 
diagnostic one. The EPDS is not a diagnostic tool for depression, but it is used to 
screen for symptoms, such as sadness and tearfulness, experienced within the last 
7 days using a 4 point Likert scale (see Appendix A). The EPDS itself comes with 
uncertainties, with different cut-off points used as a positive screen for depressive 
symptoms. In addition, some studies choose to sub-categorise into a screen for 
minor/major depressive symptoms whereas others select a single cut-off point. The 
American Academy of Pediatrics recommends classifying an EPDS score of >10 as a 
positive screen104. 
The EPDS is considered as a unidimensional tool which provides a raw score of 
depressive risk. Despite this, it is believed that the EPDS in fact reveals three distinct 
multiple dimensions of pathology: anxiety, depression and anhedonia105. Specific 
items on the scale have been shown to distinguish between depression and 
anxiety106. Utilisation of this multi-factorial structure of the EPDS would disentangle 
our understanding of the psychological functioning of postpartum women and 
improve targeting of treatment.  
It is becoming increasingly evident that PND exhibits different disease patterns and 
heterogeneity of symptoms, resulting in sub-groups of women with distinct timings 
of onset and remission and different disease progression profiles107. It is highly 
likely that antenatal and postpartum depression represent different clinical sub-
types. Clear distinction between sub-types will improve screening, prognosis and 
treatment of PND. This is especially important in order to identify subtype-specific 
biomarkers and risk factors and differentiate between women with depression in 
pregnancy who recover following childbirth, those who appear to be triggered by 
parturition, and women with depression that continues throughout.  
Timing of onset has been a disputed topic in the field, with screening not routinely 
carried out at consistent points. Despite the recommendation by the American 
Academy of Pediatrics that well-child visits should be carried out in the first 6 
months, it has been shown that PPD can occur any time in the first 12 months and 
may in fact be most prevalent at the 12 month time point, by which time the 
provision of screening and care is often absent108. This suggests that screening at 
12 months postpartum may be beneficial.  
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It has been reported that the temporal prevalence of AND follows a U-shaped 
curve, with the prevalence and severity greater in the first and third trimesters109. 
Other studies suggest that screening during the second trimester could be optimal 
110 111. The literature suggests a very wide range of differing screening time-points 
that no real consensus on the optimal timing exists. One study showed that 
depressive symptoms at 24 hours postpartum was an effective predictor of 
depression 4 months later112, while others suggest screening up to 12 months. 
Taken together this suggests that monitoring of symptoms at regular intervals, of 
which there are numerous opportunities when women come into contact with the 
health service throughout the perinatal period, can only be beneficial to improving 
detection. Further interrogation of the optimal window of detection is required. 
Clearly a number of disputes in defining PND, which are outlined in Table 1.2 are 
currently not resolved, presenting challenges and confusion around PND research 
and clinical practice, and require addressing. 
Table 1.2. A summary of the main challenges in defining perinatal depression. 
Terminology Perinatal/Antenatal/Prenatal/Postnatal/Postpartum 
Depression. 
Difficult to search body of literature. 
 
Timing of onset Antenatal depression not established as 
homogeneous/heterogeneous and is inconsistently 
included/not included in studies. 




Differences amongst health professionals and disputes 
between ICD and DSM classifications. 
Screening Not routinely carried out. 
Different screening tools used. 
Different cut-offs used. 
Timing of screening. 
EPDS assessing symptoms of both depression and 
anxiety. 





1.7 Current Screening and Service Provision 
 
The core features of a depressive episode are a sustained low mood or loss of 
interest in pleasurable activities for at least two week as defined by the ICD-10 
(International Classification of Diseases, 10th revision)101. Standardised screening 
tools can help to identify the key symptoms of depression. Screening for PND can 
dramatically improve outcomes through early intervention113. The 10 question self-
report EPDS is the most commonly utilised screening tool for PND, recommended 
by the National Institute of Clinical Excellence5. It excludes physical effects of 
pregnancy such as fatigue and changes in appetite and is therefore valid for use 
during the perinatal period. Other tools such as the patient health questionnaire 
PHQ9 include questions about appetite, fatigue and sleep and might reflect physical 
effects of pregnancy or the early postpartum rather than depression and are 
therefore unsuitable in the perinatal period114. Nevertheless, medical problems 
contributing to psychiatric symptoms including thyroid abnormalities, iron 
deficiency and nausea and vomiting should still be identified and treated since they 
will likely contribute to the depressive symptoms44. Despite concerns surrounding 
the acceptability of the EPDS for use within different cultures, settings and varying 
cut-off values, it is generally accepted as the most appropriate tool115.  
The available data is based solely on what is known about prevalence of PND. The 
true prevalence is likely much higher, since we know that many women fear seeking 
help or admitting to their depression, and many specifically fear having their child 
taken away from them. The prevalence rates of PND are estimated to be two to 
three times higher in Low and Middle Income Countries (LMICs) when compared 
with high-income countries, with estimated rates from 25% to 40% in some 
settings116 117. This should be taken with caution since PND in LMICs is understudied 
and differences in study design may contribute to these observed differences, for 
example the use of self-report measures is higher in LMICs.  
The Whooley questionnaire is an alternative to the EPDS screening tool 
recommended by NICE commonly adopted by midwives to investigate signs of PND. 
It is a simpler, two question screen asking: “During the past month, have you often 
been bothered by feeling down, depressed, or hopeless?” and “During the past 
month, have you often been bothered by little interest or pleasure in doing 
things?”118. Considering the diagnostic accuracy of identification of antenatal 
depression based on a diagnostic interview, likelihood ratios are 8.2 for the 
Whooley, and 9.8 for the EPDS, meaning the EPDS performs better in correctly 
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identifying major depression119. The difference in accuracy is relatively minor and 
the 2-item item Whooley questions are may be preferable in place of the 10-item 
EPDS in a busy secondary care maternity setting, used as a pre-screen followed by 
the EPDS if a woman answers yes to the Whooley questions. Regardless of the 
screening tool used, in order to confirm depression a clinical diagnostic interview is 
required, and screening is the initial step in identifying possible depression. 
Despite the prevalence of PND, screening is not currently mandated or routinely 
carried out. The inability to reliably detect particularly vulnerable women with 
certain risk factors impedes the current provision of care. Implementing the 
assessment of additional crucial risk factors could improve screening. Disparities 
exist in how PND screening and care is carried out, in particular during pregnancy120. 
Despite the national guidelines, screening is not universally carried out in clinical 
practice, and as a result PND remains highly undetected. There is strong evidence 
to suggest high levels of under-provision for maternal mental health, in particular 
for PND. The literature suggests that only 40% of cases are recognised and 
diagnosed, only 60% of those receive any treatment, and of those who are treated 
adequately, only 30% make a full recovery. This amounts to just 3% of all cases of 
PND ending in full recovery121. Clearly, current service provision is inadequate. 
The stigmatisation of depression is greater in certain cultures, and some languages 
do not even have the words to articulate feelings of depression. The charity 
Acacia122, who work with women suffering from PND, report that many black, Asian 
and minority ethnic (BAME) women often do not understand PND or more 
generally mental health as a concept. Migrant women are a specific population at 
heightened increased risk of PND, and it has been noted that some migrant women 
do not have the language to express mental health as a concept, and it is sometimes 
expressed instead as physical symptoms. This is known as somatisation, the 
presentation of somatic symptoms with unknown underlying cause. Studies have 
shown that PND is often misdiagnosed because of this, due to both language 
barriers and a level of unconscious bias.  
A London based perinatal mental health service (South London & Maudsley NHS 
Trust)123 prioritises migrant women as a high risk group for PND, and their Parental 
Mental Health Team have been aiming to promote awareness of maternal mental 
health and reduce social isolation and improve community engagement in migrant 
communities. They are specifically using an approach known as the ‘Think Family 
Perspective’124 to provide early intervention to women high risk of PND. Another 
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effective intervention used in practice targets young mothers. The Family Nurse 
Partnership, a home visiting intervention, is offered to young first time mothers 
with support from specialist trained family nurses125. Effective interventions do 
exist, yet the difficulty is in detecting the high risk women in order to target the 
interventions to the people most in need. 
The perinatal period can be viewed as a window of opportunity. A woman’s mental 
health and wellbeing prior to pregnancy is indicative of her mental health and 
wellbeing during pregnancy. It is generally accepted that certain groups of women 
are missing out on the necessary support and it is important to identify these 
women in order to improve rates of detection. BAME women are the least likely to 
be asked about their mental health, and this is an example of the Inverse Care 
Law126, which states that those most likely to be in need of support and treatment 
are the least likely to be offered it, and was first set up to improve identification of 
people at risk of cardiovascular disease. This proposes that “the availability of good 
medical care tends to vary inversely with the need for the population served.” 
The inverse care law appears to be especially true for PND. A national survey on 
PND found that non-white, socially deprived, less educated women were least likely 
to be asked about their mental health127. These women likely have multiple 
disadvantages, which increase their likelihood of depression, yet they are not being 
prioritised. It is also thought that the most disadvantaged women are less likely to 
respond or be able to respond to questions regarding mental health, and women 
in disadvantaged areas are less likely to be spoken to in a way they understand. Due 
to these factors hindering detection, it is vital that women are consistently asked 
about perinatal mental health at every available opportunity. 
The treatment of perinatal depression is complex in comparison to depression 
outside of pregnancy. When considering treatment options, pharmacological 
intervention can carry risks during pregnancy, however the risk of both the 
untreated depression and the risk of the drug affecting both the woman and foetus 
are considered. Alongside the recent increase in screening for PND, the 
development of new psychotherapy and non-drug treatments has also increased. 
Personalised treatment of depression has become increasingly commonplace in the 
general population, however there are no guidelines for this type of personalised 
approach in PND. A recent review examining non-drug interventions identifies 
numerous recommended treatments, dependent upon sub-population of PND and 
personal history128.   
35 
 
Women with mild PND can generally be treated with psychological interventions 
including guided self-help, whereas mild to moderate depression is treated with 
higher intensity psychological therapy such as cognitive behavioural therapy (CBT) 
and interpersonal psychotherapy (IPT)129. Subpopulations of PND are thought to 
include gonadal hormonal sensitivity, sleep disorders, attachment insecurity, 
personality disorders, social stressors and trauma history. Subsequent treatments 
can be tailored accordingly. Although non-drug treatments are preferred in mild to 
moderate depression, in women with current or past severe depression 
antidepressants are often necessary. In these cases selective serotonin reuptake 
inhibitors (SSRIs) are first line drugs in pregnancy for unipolar depression5.  
In addition to questionnaires, future screening could be improved by including 
testing for potential biomarkers including markers of the HPA axis and a number of 
genetic variants 130 131. Biomarker research has achieved great success in clinical 
fields such as cardiovascular disease and hepatic disorders, yet in psychiatry a 
biomarker is yet to enter clinical practice, hindered by the lack of a biological gold 
standard132. It is hoped that biomarkers could aid disease diagnosis and prognosis, 
in addition to improving understanding of pathophysiological mechanisms. 
Predictive techniques which include biomarkers to identify high risk women could 
also guide the individual risk benefit analysis used when considering treatment and 
pharmacological intervention5. There is strong evidence that PND is 
heterogeneous107, and therefore clear distinction between sub-types will improve 
screening, prognosis and treatment. This is especially crucial to biomarker studies 
and most notably to genetic studies. 
Despite the effective interventions available22, detection is often hindered by 
somatic symptoms of pregnancy such as fatigue, complicating clinical diagnosis133. 
Effective treatment of PPD is associated with normal child development134, 
however with severe under detection of women at-risk this cannot be effectively 
implemented.  A more effective method of identifying high risk women during 
pregnancy would allow earlier treatment and amelioration of the consequences 




1.8 The HPA Axis and PND 
 
The consideration of psychosocial factors in the development of PND leaves a large 
proportion of the variance unexplained. Activation of dysregulation of biological 
mechanisms such as stress plays an important and powerful role in human 
physiology and behaviour. The body is constantly challenged by intrinsic and 
extrinsic adverse stressors135. The resulting response prepares the body for ‘fight or 
flight’ responses, yet prolonged exposure to stressful stimuli is also physiologically 
damaging and can indirectly affect behaviour in a detrimental way. The concept of 
allostatic load explains the cumulative and potentially damaging effects of stressors 
on the brain and body, with a nonlinear ‘network of allostasis’136 137 (Figure 1.3). 
Homeostasis involves maintaining a complex dynamic equilibrium, but if the stress 
system becomes dysfunctional, the physiological responses to stress will be 
inappropriate and eventually lead to psychiatric or somatic disease135 138. 
Psychosocial factors have long been the focus of PND research, but an increasing 
awareness of the mind-body relationship with human disease is shifting the focus 
to the contribution of biological factors. 
 
Figure 1.3. The stress response and development of allostatic load, adapted from McEwen (1998)137. 
The perception of stress is influenced by personal experiences, genetics and behaviour. The 
physiological and behavioural responses triggered by the brain’s perception of stress lead to 
allostasis and adaptation, and allostatic load accumulates over time with overexposure to various 
forms of stress including immune and endocrine stress. 
Stress, whether inflammatory, traumatic or psychological is associated with 
concurrent activation of the hypothalamic-pituitary-adrenal (HPA) axis139. The HPA 
axis is a fundamental component of the stress response, determining the levels of 
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glucocorticoids as a physiological response to stress, which are known to play a 
regulatory role on the basal activity of the HPA axis and termination of the stress 
response140. During pregnancy, the stress system is altered by a number of 
physiological changes of the HPA axis in pregnancy and postpartum which may 
contribute to depression (Figure 1.4). The temporal patterns of the HPA axis related 
to endocrine alterations throughout pregnancy and the postpartum may help to 
explain the temporal patterns also seen in the presentation of perinatal depressive 
symptoms. As the axis shifts from the non-pregnant to the pregnant state, placental 
steroids and the levels of circulating cortisol rise and continue to rise throughout 
pregnancy, reaching their peak in the third trimester when PND is also thought to 
have its peak incidence109. Dysregulation at this stage could exacerbate symptoms 
of antenatal depression. HPA axis dysregulation is strongly linked to depression 34, 
and it is thought a continued rise in cortisol levels during pregnancy causes overall 
dysregulation of the HPA axis 71 72. As the axis attempts to revert back to the non-
pregnant state, dysregulation coupled with failed re-calibration following delivery 
may represent a critical maladaptation leaving the mother vulnerable to 
reproductive steroid-related diseases including PPD.  
 
Figure 1.4. Both the non-pregnant and pregnant state of the hypothalamic–pituitary–adrenal axis. 
The growth of a new organ, the placenta, alters the HPA axis causing a number of physiological 
changes. 
The HPA axis is responsible for regulation of cortisol levels within the circulation. It 
is activated in response to stress and is central to the biology of PND. The HPA axis 
is regulated by negative feedback and is acute acting in order to rapidly respond to 
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acute stress for a limited period to ensure its potent physiological effects are 
beneficial rather than damaging141. The neuropeptide hormone corticotrophin-
releasing hormone is the primary regulator of the hormonal response to stress 
activating the HPA axis. During periods of acute stress, secretion of 
adrenocorticotrophic hormone (ACTH) and cortisol increases alongside cytokines 
and other inflammatory mediators to act on hypothalamic, pituitary or adrenal 
components, potentiating HPA activity138. Circulating ACTH and inflammatory 
markers regulate the release of glucocorticoids, the final effectors of the HPA axis. 
Corticotropin releasing hormone (CRH), a key mediator of the HPA axis, is released 
only from the hypothalamus in the non-pregnant state, but is also released from 
the placenta during pregnancy. In addition, the concentration of CRH binding 
protein decreases causing further elevations in free CRH.  CRH coordinates adaption 
during stress, and prolonged or increased exposure such as that seen in pregnancy, 
can be detrimental141. 
It is thought that some women have an increased sensitivity to the changes related 
to the HPA axis and reproductive steroids occurring in the perinatal period which 
may leave them vulnerable to depression. Endocrine factors have been a strong 
candidate for a role in PND aetiology, but direct evidence is lacking. A study by Bloch 
et al.142 provided the first direct evidence in support of gonadal steroids in 
development of PPD for a sub-group of women with a history of PPD. In this study 
the authors simulated hormonal conditions related to pregnancy and parturition in 
women with and without a history of PPD. They reported that women with a history 
of PND are differentially sensitive to mood-altering effects of gonadal steroids. This 
provides evidence for the involvement of reproductive hormones in the 
development of PND. Despite the interesting findings and first of its kind approach, 
this was a small study of 16 women, and endocrine levels were not measured during 
the postpartum period and therefore may not be a complete representation of 
postpartum depression.  
Given the neuromodulatory effects of gonadal steroids and the absence of 
abnormal hormone levels in women with PPD143, this may indicate that PPD 
represents a homeostasis deficiency with the failure to compensate for changes of 
gonadal steroid levels. This group with an enhanced hormonal sensitivity may 
represent a subpopulation of women vulnerable to PPD, with altered responses to 
changes in reproductive steroids which interact with the HPA axis.  
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HPA axis dysfunction during the antenatal period may be predictive of an extended 
or more pronounced postpartum HPA refractory period in the puerperium, 
increasing the risk of PPD. Following delivery of the placenta, there is a rapid drop 
in placental CRH (pCRH), and this rapid hormonal decline is thought to contribute 
to depression postpartum144. This could explain why AND is a strong predictor of 
PPD, with a dysfunction during pregnancy leading to failure to readjust the HPA axis 
back to the non-pregnant state appropriately following delivery. 
Unlike the hypothalamic counterpart, cortisol stimulates pCRH production from 
syncytial cells of the placenta in a dose-response manner, generating a positive 
feedback loop causing maternal cortisol and pCRH to increase as gestation 
continues145. Circulating cortisol levels continue to rise as gestation continues, 
increasing three-fold by the third trimester, reaching levels normally expected by 
the hypothalamic-pituitary portal system under stress 71 146. The resulting rise in 
cortisol with the progression of gestation results in levels comparable to that of 
Cushing’s disease and severe depression71 146. The foetus is protected from harmful 
levels of glucocorticoids by the placenta, notably by the action of enzyme 11β-
HSD2, which is able to inactivate excess cortisol largely by oxidation147. Maternal 
anxiety is associated with decreased levels of this enzyme, leaving the foetus 
potentially vulnerable to glucocorticoid exposure and associated risks 82.  
Gene-protein x environment interactions may play a role in HPA axis function 
during pregnancy. It is well established that low maternal socioeconomic status 
(SES) is associated with disease risk in the offspring148 149, and it is possible that this 
may be initiated in utero. A low socioeconomic status (SES) has been linked with 
altered placental mRNA levels of genes involved in glucocorticoid metabolism150. 
The reverse action of HSD11B2, which is thought to provide a placental barrier to 
the passage of maternal glucocorticoids to the foetus, is the regeneration of 
glucocorticoids from their inert forms, and this is catalysed by 11-beta-
hydroxysteroid dehydrogenase type 1 (HSD11B1) 151. Low maternal education 
(indicative of low SES) has been shown to be associated with upregulation of 
placental glucocorticoid receptor and HSD11B1 gene expression, in a study by 
Raikkonen et al 152.  
One possible explanation for this which was not explored in the study by Raikkonen 
et al. is differences in maternal nutrition, and therefore also epigenetic 
modifications, which is likely related to SES. Evidence does suggests that DNA 
methylation is associated with SES and is intergenerational153. The resultant 
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increased HSD11B1 expression in low SES mothers results in glucocorticoid 
regeneration and therefore higher levels of glucocorticoid availability in the 
placenta. It is therefore hypothesised that this will in turn increase foetal exposure 
to glucocorticoids, providing a possible explanation for a number of associations 
between SES and offspring outcomes. 
Antenatal depression represents an intrauterine condition with physiological 
effects on neonates, including elevated cortisol levels, which is regulated by the 
HPA axis. Evidence suggests that children exposed to either antenatal or 
postpartum depression have raised cortisol levels and this continues into 
adulthood75 76, although these effects could be reduced by maternal treatment. 
Dysregulation of the HPA axis during pregnancy may influence exposure of the 
foetus to stress hormones, and is thought to have the ability to program the foetal 
HPA axis. This can result in an inappropriate response to stress, which is linked to a 
susceptibility to physical and mental illness for the offspring in later life73 74. In 
addition, exposure to high levels of glucocorticoids is linked to compromised foetal 
growth and a shorter gestational length77-82. Overall, the dysfunction of the 
maternal HPA axis poses a number of risks for both the mother and the offspring. 
PND appears to exhibit disease heterogeneity, and different symptom profiles are 
often seen for antenatal and postpartum depression. Their underlying aetiologies 
appear to be distinct from one another, and may therefore represent different 
pathologies. As a result it is important to consider that the potential risk factors, 
causes and biomarkers may also differ. AND is associated with HPA hyper-activation 
due to increasing levels of cortisol, caused by placental cortisol-releasing-hormone 
(pCRH) and placental steroids, resulting in the positive feedback of circulating 
cortisol observed during pregnancy. In contrast to this, PPD is linked to lower 
cortisol levels due to mild adrenal suppression and a hypo-responsive HPA axis.  
It can be hypothesised that antenatal and postpartum depression represent 
different clinical sub-types. Two recognised forms of depression in the general 
population are recognised: melancholic and atypical34. Melancholic depression is 
typically defined by a loss of pleasure, depressed mood worse in the morning, 
insomnia and weight loss. Melancholic depression is associated with HPA hyper-
activation. In contrast, atypical depression symptoms are retention of mood 
reactivity, weight gain, hypersomnia and depressed mood worsening throughout 
the day. Glucocorticoid suppression has been observed in atypical patients154. 
Differences in HPA profile could be indicative of sub-type, as it appears that the 
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profile of AND is most similar to melancholic depression, and PPD closer to the 
atypical type. This would help to explain differences in both symptom profiles and 
HPA axis.  
HPA dysregulation is driven by a number of different factors, thought to include 
cortisol, cytokines, and serotonin dysfunction. The orchestrated interplay of several 
neurotransmitter systems in the brain regulates the behavioural, endocrine, 
autonomic and immune responses to stress. Complex interplay occurs between 
these elements, and disruption of the delicate balance due to over-activation can 
alter the HPA axis and its function leading to pathophysiological consequences 
associated with prolonged production of CRH in non-stressful situations.  
Both the immune-inflammatory response and the HPA axis undergo significant 
change throughout pregnancy and the postpartum, and are thought to be linked by 
a complex psychoneuroimmune (PNI) response155. Cytokines are potent activators 
of the central stress response, forming a feedback loop through which the immune 
system and the CNS communicate, and there is evidence that a key inflammatory 
cytokine Interleukin-6 (IL-6) can alone stimulate the HPA axis156. The other 
inflammatory cytokines, tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-
1β) are also thought to play a role in stimulation of the HPA axis. Cytokines are 
thought to act in part on the HPA axis through stimulation of the central 
catecholaminergic and CRH neuronal systems via ascending spinal pathways, while 
other inflammatory mediators including serotonin may increase activation via 
endocrine effects156. 
During pregnancy, a balance must be maintained between protection against 
pathogens and tolerance against the semi-allogenic foetus, requiring an adaptation 
to immune system function which is not fully understood. It is now believed that 
although the majority of pregnancy is concurrent with a shift towards an anti-
inflammatory state which acts to protect the foetus from rejection157, the immune 
response is split into three stages in pregnancy. The early stages of pregnancy, in 
the first and early second trimesters, is thought to represent a pro-inflammatory 
state to assist with implantation and placentation158. At this stage an inflammatory 
environment is required to adequately repair the uterine epithelium and remove 
cellular debris following to the blastocyst breaking through the epithelial lining of 
the uterus to implant, and the trophoblast replacement of the endothelium and 
vascular smooth muscle of the maternal blood vessels to secure the placental-
foetal blood supply159. The second immunological phase of pregnancy is a period of 
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rapid foetal growth and development, and the predominant immunological feature 
is an anti-inflammatory state, while late into the third trimester the mother again 
enters a pro-inflammatory state, which is believed to prepare for parturition, 
promoting uterine contraction, delivery of the baby and rejection of the placenta, 
and this continues postpartum160.  
The inflammatory response and HPA axis, which are both in flux throughout 
pregnancy and postpartum, interact via the cytokine-glucocorticoid feedback 
circuit, in order to alert the CNS to a stressor, simultaneously limiting a prolonged 
pro-inflammatory response and regulating further cortisol secretion161. 
Dysregulation of this cytokine-glucocorticoid feedback circuit has been implicated 
in the development of PPD, and evidence suggests that cytokine/cortisol 
dysregulation may in fact be protective against depression postpartum. A study by 
Corwin et al. found that dysregulation of this circuit after giving birth may protect 
women against depressed mood155. They reported that in healthy women, a sudden 
increase in pro-inflammatory cytokines did not result in increased cortisol secretion 
and instead this response is blunted. In women who developed PPD, cytokine 
stimulation of cortisol is instead robust and negatively affects mood. It therefore 
seems that these women experience an early postpartum return of hypothalamic 
responsiveness, whereas in healthy women, the ‘dysregulated’ paradox of high 
cytokines and low cortisol is in fact protective against depressive symptoms. The 
cytokine-glucocorticoid feedback circuit was also found to be inactive in women 
who did not develop PPD, further suggesting that this ‘dysregulation’ may in fact 
be beneficial at this particular time of life. This demonstrates the significant 
changes to both the innate immune response and HPA axis across the perinatal 
period, and may help to explain why some women are more prone to developing 




1.9 Circulating Biomarkers 
 
As described in section 1.7, pregnancy and the postpartum are becoming 
increasingly recognised as periods of life characterised by tightly regulated 
inflammatory states162. In the general population, a wealth of evidence links major 
depression and a heightened inflammatory response, yet this is not confirmed in 
PND. A review of the current literature on the link between postpartum 
inflammation and PPD assessed in full 19 studies on the subject, and concluded that 
findings are inconclusive, and both hyper- and hypo- activation of the HPA axis have 
been associated with perinatal depression163. It is thought that disruption of the 
cytokine-glucocorticoid circuit diminishes the ability to limit inflammation, 
ultimately resulting in dysregulated cytokine production and cortisol secretion164 
165. 
A key pro-inflammatory cytokine is interleukin-6 (IL-6), a 23.7kDa cytokine with two 
disulphide bonds that is secreted mainly by T-cells and macrophages. IL-6 induces 
an acute phase response and plays an essential role in differentiating B cells into 
immunoglobulin-secreting cells166. Interleukin-10, also known as cytokine synthesis 
inhibitory factor (CSIF), is an important anti-inflammatory cytokine. It is a 20.5kDa 
glycosylated homodimeric cytokine with two disulphide bonds. It is produced by a 
range of cell types such as T-cells, macrophages, and mast cells. IL-10 inhibits the 
synthesis of numerous cytokines that suppress Th1 pro-inflammatory responses 
and promote phagocytic uptake167. 
It is important to consider not only pro-inflammatory cytokines, as many studies 
have done, but also the balance between pro- and anti-inflammatory cytokines 
such as IL-6 and IL-10155. Pro-inflammatory cytokines coordinate the non-specific 
immune response, whereas anti-inflammatory cytokines both provide negative 
feedback to suppress inflammation and support the type 2 specific immune 
response168. The interplay between these types of inflammatory response, 
coordinated by opposing cytokines, may prove beneficial in the exploration of 
cytokines and PND.  HPA variability may play a role in the effects of the evoked 
inflammatory response, and may explain why some women are more sensitive to 
the inflammatory stimuli of pregnancy and childbirth than others, possibly 
contributing to the development of depression.  
A pilot study131 conducted by our laboratory prior to the commencement of this 
current project found that a limitation was the lack of a suitable biomarker to detect 
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the presence of the underlying disease and hormonal over-activity of the HPA stress 
axis. This study will investigate whether a reliable circulating biomarker will 
strengthen the link between genetic susceptibility and disease phenotype, and this 
is a key aim and novel concept in PND studies. A model for the role of the innate 
immune system interacting with the HPA axis in the development of PPD has been 
proposed (Figure 1.5) 169. Both systems undergo dramatic change during pregnancy 
and postpartum. Investigating associations between the immune response and 
PND may provide an opportunity for the discovery of biomarkers. A detailed 
systematic review by Serati et al.170 summarises the state of the art of biological 
markers investigated for their involvement in the pathogenesis of depression. The 
authors cover findings from 1969-2015 on the subject, with 127 papers included in 
the review following application of inclusion and exclusion criteria. A summary of 
the findings is given in Table 1.2. The most robust associations have been reported 
with the HPA axis, hormonal changes, IL-6, vitamin D, fatty acid and BDNF. 
Table 1.3. A summary of biomarker studies investigating perinatal depression pathophysiology as 





Immunological studies Endocrinological 
studies 
BDNF Iron C-reactive protein Allopregnanolone 
5-HTTLPR Biopterin IL-6 Cortisol 
FADS1/FADS2 Homocysteine TNF-α NR3C1 mRNA 
ESR1 Zinc IL-8/IL-10 pCRH 
HTR2A B12/Folate Inflammatory cytokines Estrogen 
OXTR Vitamin D IgG/IgM/IgA Testosterone 
MAOA/COMT DHA status MIF CRH/ACTH 
TPH2 HDLs Cortisol ChromograninA/protein 
GR EPA/DHA fish oil  Alpha amylase 
CRH-R1 PUFAs  Beta-endorphin 
TTC9B/HP1BP3 BDNF   
 
The release of cytokines associated with depression is thought to cause a response 
similar to that of a stressor171. Interleukin 6 (IL-6) is a pro-inflammatory cytokine, 
and may represent a suitable biomarker, explaining a possible link between 
pregnancy driven inflammation and depression. Pro-inflammatory cytokines 
influence the HPA axis by stimulation of hypothalamic CRH production, in turn 
causing ACTH and cortisol levels to rise. Increased plasma concentrations of IL-6 
have been identified in patients with major depression, and is a potential 
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contributor to the pathogenesis of depression acting through stress-immune 
interactions to increase ACTH and cortisol production as seen in Figure 1.5172. Pro-
inflammatory cytokines are also able to alter the metabolism of neurotransmitters 
including serotonin and dopamine, and disrupt synaptic plasticity through 
alterations in growth factors such as BDNF, all of which are thought to be involved 
in the pathogenesis of depression173. A study that investigated immune activation 
in postpartum blues also found signs of an activated immune response, including 
increased IL-6 serum levels and markers of other pro-inflammatory cytokines such 
as IL-1β174. A role for macrophage migration inhibitory factor (MIF), also a pro-
inflammatory cytokine, has also been implicated in major depression175.   
Alterations in neurotransmitter function of serotonin, norepinephrine and 
dopamine are primary targets for current antidepressant treatments, but this 
emerging understanding of the role of inflammation in the pathogenesis of 
depression could provide targets for novel treatment strategies. Patients with a 
history of non-responsiveness to conventional antidepressant treatments have 
been found to have increased plasma concentration of IL-6 when compared with 
Figure 1.5. Stress-immune interactions. (a) Activation of NF-κβ through Toll-like receptors 
(TLR) of microglial cells including TLR-4 occurs as a response to a stressor leading to an 
inflammatory response including (b) the release of pro-inflammatory cytokines mediated by 
the inflammasome and activation of caspase-1. These cytokines cross the blood-brain barrier 
to participate in pathways indicated in depression including altered serotonin (5-HT) and 
dopamine (DA) metabolism, alterations in brain derived neurotrophic factor (BDNF), 


























responsive patients176, and those with increased inflammation prior to treatment 
appear less likely to respond to antidepressants177. The inhibition of pro-
inflammatory cytokines or targeting of antagonists might represent an alternative 
therapeutic strategy in those who do not respond to traditional treatments, and 
these individuals may be particularly suited to treating the unique pathophysiology 
of PND.  
Despite generally inconsistent findings in studies investigating the 
psychoneuroimmune response of depression, elevated expression of peripheral IL-
6 is most consistently observed in major depression according to a meta-analysis of 
24 studies178. The relationship between circulating levels of IL-6 and modulation of 
depressive phenotype remains under investigation. There is evidence to suggest 
that IL-6 is able to cross the blood-brain-barrier (BBB) to come into contact with the 
CNS and alter brain function, either directly on neurons or indirectly via microglia 
and other immune cells of the CNS179. This is further supported by a study finding 
the intracranial infusion of IL-6 increases depressive type behaviour in animal 
studies180. These studies may lead to therapeutic strategies which target IL-6, but 
also suggests that the implication of IL-6 in depression could be utilised as a 
potential biomarker. 
Brain-derived neurotrophic factor (BDNF), an important growth factor belonging to 
the neurotrophic family, may represent another biomarker of interest. It is the most 
widely expressed neurotrophin in the CNS with the highest levels of expression in 
the hippocampus, amygdala, neocortex, and cerebellum, and is also expressed by 
neurons and glial cells181. Outside of the nervous system BDNF is expressed in the 
placenta, heart, lung and skeletal muscle as well as cell types including fibroblasts 
and platelets, although the majority originates from the CNS. It is produced as 
proBDNF in response to neuronal activity or inflammatory stimulation and is 
cleaved before associating into mature homodimeric proteins. It exists both in its 
free form and bound to its transmembrane receptor, TrkB.  
BDNF can cross the blood-brain barrier and a high correlation between serum and 
hippocampal BDNF has been reported182 183. Both pro-inflammatory cytokines and 
progesterone have been shown to regulate BDNF expression. BDNF is largely 
recognised for its neurotrophic functions in the developing nervous system, 
including differentiation, synaptic connectivity and neuronal repair and survival184. 
More recently, a role for BDNF in the pathophysiology of stress and depression has 
been investigated185. It is thought that the function of BDNF in neuron survival is 
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relevant to the heightened vulnerability of hippocampal neurons following stress, 
and an early model indicated that BDNF expression in the rat brain is regulated by 
stress186.  
Following on from earlier animal models, clinical, pharmacological and post-
mortem studies have provided evidence for a role for BDNF in depression. Reduced 
gene expression of BDNF has been described in post-mortem brains of suicide 
victims187. Another study of post-mortem hippocampal tissue found increased 
BDNF immunoreactivity in subjects treated with antidepressants compared with 
those who were not, further supporting the notion that BDNF may be regulated by 
antidepressants and is involved in the pathophysiology of major depression188.  The 
exploration of post-mortem brain tissues highlights the importance of BDNF in 
human psychopathology, yet a method to measure it in a clinically relevant way is 
required in order to assess and treat depression. BDNF is present in human blood 
and is stored in platelets, from which it can be released into plasma189. Reduced 
serum levels of BDNF have been observed in drug-free depressed patients, and 
levels have been shown to be inversely correlated with clinical status, returning to 
normal following successful treatment with antidepressants190.  
The association between BDNF and depression may be sex dependent, with BDNF 
levels associated most strongly with depression in women, which may be explained 
by a reported association between BDNF and circulating sex hormones191. In 
addition to major depression, evidence suggests that BDNF is associated with 
PPD192. A recent study demonstrated a strong association between reduced serum 
BDNF levels at delivery and depression 3 months postpartum, suggesting BDNF 
could be predictive in screening193. A single nucleotide polymorphism (SNP) in the 
pro-domain of BDNF results in a substitution of a methionine for valine at codon 66 
(Val66Met), which leads to decreased protein secretion, has received much interest 





1.10 Genetic Risk 
 
It is well established that depressive illnesses are associated with high heritability, 
and a family history of depression is a key risk factor for PND, suggesting a role for 
genetic factors in susceptibility. Studies have indicated that perinatal depression 
may in fact have a higher heritability than depression outside of the perinatal 
period, with one twin study reported that genetic factors were responsible for 25% 
of variability for PND diagnoses197 185. Studying genetic factors has the potential to 
reveal the biological underpinnings of the sub-types of PND and investigate possible 
genetic differences between them. This could allow for an individual susceptibility 
to be measured using genetic information in screening. 
As described in detail earlier in this chapter, abnormal HPA axis responses to stress 
have been described in PND, possibly due to enhanced sensitivity to gonadal 
steroids during pregnancy, and failure to return to normal, post-delivery. The HPA 
axis is central to the biology of PND, stimulating the release of glucocorticoids. 
Negative feedback inhibition is required, which is dependent on the presence of 
functioning receptors. Glucocorticoids act on receptors within target tissues, which 
includes the hypothalamus and pituitary, causing inhibition of the axis through 
Figure 1.6. Schematic of the HPA axis interaction with glucocorticoid receptors (GRs). Circulating 
glucocorticoids bind to GR outside the brain (pituitary) and can also cross the blood brain barrier 
(BBB) to bind inside the brain (hypothalamus). Activated GR induces a feedback inhibition signal 
leading to reduction of HPA activity. Mechanisms regulating this inhibition include GR expression 
and function and environmental effects such as early life trauma through epigenetic mechanisms 


















feedback inhibition on adrenocorticotrophic hormone-releasing factor (CRF) and 
vasopressin (AVP) from the hypothalamus, and on ACTH from the pituitary31. The 
mechanism is outlined in Figure 1.6. The hyper-activation of the HPA axis associated 
with depression is thought to be related to reduced feedback inhibition by 
endogenous glucocorticoids.  
At least two types of glucocorticoid receptor (GR) have been identified within the 
brain; the mineralocorticoid receptor and glucocorticoid type 2 receptors, which 
have different affinities for corticosteroids198. Type 2 receptors have a lower affinity 
for cortisol and are believed to have a more important role in stress response 
regulation when glucocorticoid levels are elevated199. The role of GR in stress 
response regulation during depression is supported by data obtained during 
antidepressant therapy. Long term antidepressant therapy has been shown to 
upregulate GR in the brain, and is thought to reverse the inhibition of negative 
feedback on the HPA axis by glucocorticoids31. These exact mechanism of 
antidepressant effects on HPA regulation is unclear, but it is thought to relate to 
the multidrug resistance protein transporter, P-glycoprotein, which limits the 
availability of cortisol in the brain200.  
HPA axis dysfunction has been reported in people with a family history of 
depression198 201. Many studies have investigated polymorphisms of the GR and 
corticotrophin releasing hormone receptors with depression in a non-pregnant 
population. The CRH receptors are G protein coupled receptors with seven 
transmembrane domains. CRH receptors exist in two forms, CRHR1 and CRHR2, 
which are 70% homologous in sequence202. Different isoforms of both receptors 
have been identified and type 1 receptor is mainly located in cerebellar and sensory 
centres whereas type 2 is often associated with peripheral tissues203. Several 
studies have investigated polymorphisms of the CRHR1 and CRHR2 gene for 
association with depression and anxiety disorders204-212. Other studies have 
focussed on the association between CRHR1 receptors and cortisol levels in 
children213. 
Further evidence from our laboratory suggests an association between SNPs of 
genes controlling HPA activity (CRHR1 and NR3C1) and increased risk of PND131. This 
prospective cohort pilot study (Coventry and Warwickshire Genetic Association of 
Postnatal Depression – CW-GAPND) demonstrated that this HPA sensitivity may be 
genetically determined. The glucocorticoid receptor (NR3C1) and corticotrophin 
releasing hormone type 1 receptor (CRH-R1) genes are strongly implicated in 
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depression208 214. The pilot study targeted these genes and identified two SNPs, Bcl1 
(rs41423247) and rs242939 SNPs of the NR3C1 and CRH-R1 genes, which were 
associated with raised scores on the Edinburgh Postnatal Depression Scale (EPDS) 
131. This provided the first evidence that specific SNPs of genes involved in stress 
responses may contribute to an increased risk for PND and may represent 
promising genetic biomarkers. As this was a relatively small study of 200 patients, 
further validation is needed. 
A systematic review on the subject of genetic factors of PND found a number of 
potential contributors, although results have been inconsistent194. This may be due 
to a lack of controlling for potential confounding variables, which are crucial to such 
studies. The review did however indicate that the timing of onset of symptoms may 
play a significant role in genetic effects. For example, the MAOA and COMT genes 
were found to be associated at 6 and 8 weeks postpartum but not at 12 weeks215. 
The transient nature of this finding indicates that these polymorphisms may be 
associated with onset but not persistence of depressive symptoms. This is 
consistent with a number of other studies which have found genes to be associated 
with the early postpartum period only, and may explain the mixed results reporting 
inconsistent or no genetic associations with depression194.  
Overall these association studies suggest that women may be most susceptible to 
genetic factors during a specific vulnerability window which includes late pregnancy 
and early postpartum, and it is thought that this may be associated with alterations 
in oestrogen levels. These findings additionally hint at a gene x environment (G x E) 
interaction in the development of PND. DNA methylation studies may help 
disentangle these effects and link environmentally or physiologically challenging 
events, including hormonal changes, to gene expression levels. 
Genetic association studies, of which there has been a surge in recent years, 
describe potential associations between a number of different genes, which are 
described in a systematic review by Figueiredo et al.194. Although those of the 
glucocorticoid and CRH receptors stand out, recent studies have also linked genes 
including 5-HTT, FADS1/FADS2, MTHFR, MAOA, COMT and OXTR with PND194. 
BDNF, discussed in the previous chapter as a potential biomarker, has also been 
genetically linked with PND196. The systematic review also noted that almost every 
study that evaluated associations between SNPs and environmental stressors 




Large scale genetic studies are becoming increasingly popular to study depression 
and anxiety in the general population, and transferring this to the field of perinatal 
depression would provide an excellent opportunity for research. A current large 
genetic study of PPD in the US is utilising technology with the PPD ACT app, the first 
mobile health app used to study psychiatric genetics216. Women are able to 
download a phone application, using it to complete eligibility and informed 
consent, as well as EPDS screening, and they are sent a saliva collection kit if they 
wish to participate in DNA analysis. Within its first year, the app has recruited 7344 
women with a history of PPD and 2946 DNA samples have been banked. Studies 
such as this are leading the way in PND genetics research. A limitation of a number 
of these studies however, is the sole focus on genetics, rather than the 
interrogation of data with a combination of biomarkers from the different 
implicated mechanisms of disease. These large scale studies have additionally not 
addressed the heterogeneity of PND, which now requires investigation in relation 
to genetic factors. 
In summary, it is thought that genetic factors play a role in the susceptibility of 
perinatal depression. Our laboratory has previously reported an association 
between SNPs of the NR3C1 (GR) and CRH-R1 genes and increased risk of PND. As 
described in this Chapter, glucocorticoid and CRH receptors are fundamental to the 
regulation of the HPA axis and dysfunctions in these genes are implicated in the 
pathogenesis of depression. It is increasingly recognised that genetic variants with 
discrete functional effects in genes regulating the HPA axis may alter susceptibility 
to stress-related psychiatric disorders. A previous study from our laboratory has 
crucially demonstrated an association between specific SNPs of these genes in 
postpartum depression. This now requires investigation in a larger cohort, and the 
combination of multiple other risk factors, to align with the multifaceted nature of 




1.11 DNA Methylation 
 
The diathesis-stress model of depression helps to explain why some people are 
more vulnerable to stress whereas others can withstand stress. Diathesis refers to 
specific vulnerabilities that affect how individuals respond to stress. These 
vulnerabilities can include a predisposition caused by genetics, neuro-regulatory 
systems, personality and cognitive style. The double-hit hypothesis explains that a 
further second ‘hit’ or stressor is required in predisposed individuals to trigger the 
development of the disease, in this case PND. Epigenetics may represent an 
example of this second hit in PND, depicted in Figure 1.7, whereby early 
environmental stress triggers a series of epigenetic mechanisms to programme the 
HPA axis and 5-HT system for survival in a harsh environment as a survival 
mechanism217. These individuals are subsequently maladapted for a ‘normal’ 
environment according to the mismatch hypothesis218, leading to inappropriate 
stress responses which are known to contribute to depressive pathophysiology.   
The formation of the epigenome is a critical process largely established during 
gestation, which directs cell fate and normal development. DNA methylation 
patterns are formed and shaped during the perinatal period, when the epigenome 
is sensitive to environmental changes including nutrition, stress, and endocrine 
disruption219. Throughout life a number of fixed and transient changes to the 
epigenome occur in response to exogenous and endogenous stimuli, leading to its 
reprogramming. This epigenetic programming begins in utero, but continues as an 
adaptive response throughout life to environmental exposures. Animal studies 
have demonstrated that the restriction of B12 and folate during pregnancy affects 
Figure 1.7. The stress-diathesis model of depression vulnerability and ‘double hit’ hypotheses 
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foetal DNA methylation patterns220, while humans exposed to famine in utero 
appear to have altered DNA methylation in adulthood221. 
Both the HPA axis and serotonergic (5-HT) system are repeatedly associated with 
depression222, yet their dysfunction alone appears inadequate to cause depression 
and an environmental cue is often implicated. The perinatal environment clearly 
plays an important role in PND, and epigenetics may provide the missing 
connection between the HPA axis, 5-HT system and depression. Environmental 
stress triggers epigenetic alterations, and it is thought that DNA methylation is a 
key component in depression vulnerability. The epigenetic embedding of 
inflammatory pathways is a model which links early life adversity and increased risk 
of maternal depression223. This model proposes that early life adversity embeds a 
pro-inflammatory DNA methylation signature which underlies a predisposition to 
PND. At a gene specific level, the methylation status of both BDNF and SLC6A4, 
genes associated with both depression and PND, has differentiated between 
healthy controls and patients with major depression224 225, and further studies in a 
cohort of perinatal women represents a future direction which is yet to be explored. 
DNA methylation now warrants attention as a candidate for a biomarker of PND 
risk. 
DNA methylation, an essential form of epigenetic variation, is characterised by the 
addition of a methyl group to the fifth carbon in the cytosine ring, resulting in 5-
methylcytosine (5-mC). It is especially prevalent in CpG-rich regions of the genome, 
CpG islands, which are predominantly found in gene promoter regions226. DNA 
methylation plays an essential role in gene regulation and expression, and is 
catalysed by methyltransferases227. In the study of disease aetiology, the 
importance of epigenetics is becoming increasingly clear, in particular the role that 
DNA methylation plays.  
The mechanism of DNA methylation is catalysed by DNA methyltransferases 
(DNMTs), of which a number of different forms exist, including DNMT1, DNMT3a 
and DNMT3b. Each plays a different important role in the maintenance of DNA 
methylation patterns. The silencing of gene expression by DNMTs can occur 
through both direct and indirect mechanisms. The first involves the binding of a 
transcription factor to a DNA recognition sequence, thus preventing the binding 
required for gene activation228. The second mechanism acts by targeting proteins 
such as MeCP2, which are known to supress transcription229. If DNA methylation 
occurs at repressor sites then the effect is the reverse, and an increase in 
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transcription occurs. DNMTs act as epigenetic regulators, with resultant effects on 
the genome.  
DNA methyltransferases use S-adenosyl-L-methionine (SAM) as the donor of 
methyl groups227, which utilise the folate-dependent de novo synthesis of one-
carbon units230. DNA methylation influences gene expression and depends on the 
availability of methyl groups from SAM. Humans ingest methyl groups 
predominantly in the forms of dietary choline, but can also originate from 
methionine and methyltetrahydrofolate (methyl-THF) in addition to vitamins B-6 
and B-12, due to their closely linked metabolic pathways231. The pathways intersect 
at the formation of methionine from homocysteine, where choline is a substrate in 
the betaine homocysteine methyltransferase pathway. A diet deficient in methyl 
donors is associated with hypo-methylated DNA both globally and at specific genes. 
It is therefore important to consider dietary intake of methyl-sources in 
methylation-based studies. 
Pregnancy is characterised by the readjustment of metabolic pathways and 
micronutrient deficiency, often leading to anaemia. Nutrient metabolism is 
important in the methylation cycle. Folate, a nutrient involved in methyl group 
metabolism, can therefore influence epigenetic status. DNA methylation status has 
been directly correlated with folate levels232. The benefits of folic acid in pregnancy 
are widely recognised, and periconceptual supplementation is recommended by 
the Department of Health due to its role in the prevention of congenital 
malformations including neural tube defects (NTDs)233. In addition, there is 
evidence that higher folate intake during pregnancy is associated with improved 
cognitive ability in the offspring234. A deficiency of B12 and folate during pregnancy 
can lead to anaemia, which has its own set of complications that can affect the 
unborn offspring, potentially predisposing them to infection and disease later on in 
childhood and adult life235. 
The role of maternal nutrient intake in offspring neurodevelopment is poorly 
understood, and the molecular mechanism of folate’s role in this is yet to be 
determined. Epigenetic mechanisms constitute a likely link, and one possible 
mechanism is DNA methylation. There is evidence for an association between 
increased folate intake in pregnancy and DNA methylation changes in the 
offspring236. It has also been shown that folic acid supplementation during 
pregnancy can have significant effects on DNA methylation of genes related to brain 
function237, including BDNF, which is closely linked with depression190.  
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A recent Japanese study examined the role of diet in psychological distress during 
pregnancy, finding that fish intake, specifically intake of omega-3 polyunsaturated 
fatty acids (n-3 PUFAs), significantly reduced the risk238. Evidence suggests that n-3 
PUFAs can modulate inflammation, and an emerging mechanism for exerting these 
anti-inflammatory effects is through epigenetic modifications including DNA 
methylation239. Omega-3 fatty acid deficiency is implicated in PND, driven both by 
its depletion during pregnancy and lactation, and a lack of dietary intake, especially 
in Western cultures. Micronutrient deficiency, namely omega-3 deficiency, is 
importantly an easily modifiable factor through supplementation. The demand of 
omega-3 during pregnancy is very high due to foetal growth and development, and 
this is particularly high during the third trimester when foetal brain development is 
occuring240.  It is thought that omega-3 dietary intake is insufficient even to cover 
the body’s normal demands, and this may explain why levels can decrease by up to 
50% during pregnancy and can fail to recover for up to 26 weeks postpartum241. 
Populations consuming more seafood and omega-3 such as Japan and Iceland also 
have a lower prevalence of PPD242. Other environmental factors are associated with 
omega-3 fatty acids, for example lower levels have been observes in smokers243. 
PND has been linked with altered DNA methylation patterns. Oestrogen driven DNA 
methylation changes have been found in women at risk of developing PND. Two 
biomarker loci at the HPIBP3 and TTC9B genes, which both have key roles in 
oestrogen signalling, could act as indicators of PND, with observed differences in 
CpG methylation levels within promoter regions244. Use of these epigenetic 
biomarkers predicted PPD with 80% accuracy. The underlying risk in this group 
might be related to an increased sensitivity for epigenetic change in response to 
normal levels of circulating hormones during pregnancy. This study supports the 
idea of a link between pregnancy related steroid hormones, methylation and 
depression. 
Women appear to have an increased susceptibility to epigenetic modifications 
during specific periods, coinciding with progressively changing oestrogen levels 
during pregnancy, suggesting oestrogen may drive changes in gene expression. This 
also supports a number of findings in genetic studies, which suggest a sensitive 
period to genetic factors during late pregnancy and the early postpartum. This 
epigenetic reprogramming may represent a molecular mechanism of 




DNA methylation studies can elucidate some of the associations identified in the 
literature. For example, the study of placental DNA methylation at the leptin 
receptor locus has elucidated a potential link between antenatal mental illness and 
poor foetal growth245. In addition, DNA methylation profiles within the SLC6A4 
serotonin transporter gene have been shown to moderate the association between 
the 5-HTTLPR polymorphism and cortisol stress reactivity246.  Recently, methylation 
at the oxytocin receptor (OXTR) has also exhibited significant associations with 
PND, and supports the hypothesis of PND specific sensitivity to epigenetic 
reprogramming at oestrogen targets 247. A negative relationship between OXTR 
methylation and antenatal serum oestradiol was identified, and OXTR and 
oestradiol additionally appear to interact with one another to influence the ratio of 
progesterone and allopregnanolone. These findings are consistent with other 
studies which point to an increased sensitivity to oestrogens at an epigenetic level 
in women at risk of PND244. The epigenetic level of variation can provide a more in-
depth biological rationale for of a number of the biomarkers proposed in the 
current literature.  
It has been reported that DNA methylation can ‘program’ child behaviour as a result 
of prenatal and early exposure to maternal depression225. This important study 
examined the methylation status of the SLC6A4 promoter and found significantly 
lower methylation levels in pregnant women experiencing depressive mood in the 
second trimester. Decreased methylation in the infants at two CpG sites in this 
promoter was also identified. The enzyme Methylenetetrahydro-folate reductase 
(MTHFR), which regulates the availability of methyl groups from methyl-THF and 
subsequent levels of methylation, was interrogated and a variant associated with 
depressed mood during pregnancy identified. This study demonstrated the effect 
of prenatal exposure to depression on gene-specific DNA methylation patterns, 
supporting a hypothesis for an epigenetic mechanism for programing offspring 
development and behaviour. MTHFR is also known to interact with folate status to 
influence DNA methylation232, highlighting a further epigenetic alteration 
associated with PND which is modified by nutritional status. Furthermore, evidence 
suggests that folate supplementation may represent a protective factor against 
depression248. 
Human prenatal exposure to depression has also been associated with methylation 
at the glucocorticoid receptor NR3C1 promoter in new-born infants and alterations 
to their HPA stress-responses 249. Maternal care in the rat has been shown to affect 
the offspring’s HPA stress response and this involves changes in methylation to the 
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glucocorticoid receptor and expression levels of the NR3C1 expression250. The 
effect of maternal care on DNA methylation has also been shown to be broad, and 
not confined to single candidate gene promoters, demonstrated by microarray 
analysis in the mouse251. DNA methylation appears to be a mediating factor 
between maternal depression and offspring HPA axis effects. Animal studies have 
demonstrated that the epigenetic regulation of imprinting in the offspring is 
influenced by nutrients involved in methyl group metabolism in pregnancy252 253. 
Overall these studies suggest that nutrient metabolism, DNA methylation and PND 
are interconnected, with potentially long-lasting effects spanning generations. 
It is important to note that these epigenetic effects can stem from environmental 
causes such as environmental stress. An epigenetic component is apparent in 
psychiatric illness, and in particular in relation to suicidal attempts. This has been 
demonstrated both through polymorphisms and global DNA methylation levels. 
Polymorphisms at epigenetic regulatory genes DNMT1 and DNMT3b have been 
associated with suicidal attempts in psychiatric patients, in addition to increased 
global DNA methylation in the same patients254. Genes associated with depression 
have also been studied for methylation changes. Increasing methylation at the 
SLC6A4 promoter has been reported in people with a history of depression, which 
was higher in females than males255. A study investigating maternal depression 
identified reduced maternal and infant methylation of the SLC6A4 promoter at 
specific CpG sites225.  
In addition to gene-specific methylation changes, global DNA methylation changes 
can also represent a biological response to environmental exposures256. The 
response to early life adversity can be observed in both central and peripheral 
systems and therefore reflects a useful biomarker217. A crucial consideration when 
studying DNA methylation in depression is a suitable and clinically relevant 
biomarker as a proxy for the brain. Although some DNA methylation patterns are 
tissue specific, others appear to have similar patterns in peripheral cells as the 
brain, as is the case with BDNF224. Other human studies in mental illness have found 
similar methylation patterns in peripheral cells as the brain for a number of genes257 
258. Furthermore, although the pattern cannot be expected to be identical in the 
brain, it can still provide useful information to indicate an epigenetic response 
which may represent biological sensitivity to stress.  
The epigenome is dynamic and responds to changes of micro- and macro-
environments over time259. It is closely interconnected with lifestyle, and it is 
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thought to be associated with maternal exposures. The epigenome provides an 
interface between environmental influences and the static inherited genome, and 
can help explain gene-environment interactions. Factors such as age, disease and 
lifestyle influence our epigenome. The response to nutritional variation is a change 
in phenotype, and from an evolutionary perspective, producing multiple 




1.12 Summary of Key Gaps in the Literature 
 
 The inability to detect PND seriously impedes the provision of care, with at 
least 50% of women suffering from undiagnosed and untreated PND. 
Therefore, screening and prediction of depressive risk requires a novel 
approach.  
 Risk factors which can predict antenatal and postpartum depressive 
symptoms are key to prioritising the most vulnerable women.  
 In addition to psychosocial risk factors, the literature suggests that 
screening turns to biomarkers to identify high-risk women.  
 A number of avenues are under preliminary investigation to explore 
biomarkers of PND, which require further validation.  
 The literature repeatedly reports the theory of dysregulation of the HPA 
axis in PND and therefore this is an appropriate focus for emerging 
biomarker studies.  
 Genetic and epigenetic research has identified a number of candidates for 
contribution to PND, namely that of the glucocorticoid and CRH receptors.   
 Studies which focus on a few select targets will be beneficial to assess 
suitability for use in a hospital laboratory setting.   
 An important role for the immune response in PND is emerging, and 
inflammatory markers could provide a useful window into the 
inflammatory response underlying depressive symptoms.  
 The interaction between psychosocial and biological risk factors in the 
development of PND is rarely explored simultaneously 
 The full temporal progression of depressive symptoms is often not 
investigated to include both the antenatal and postpartum periods – the 
majority of studies only focus on one.  
 Our understanding of the heterogeneity of PND is limited, in particular the 
temporal patterns of symptom onset and remission, and this should be 
addressed when assessing risk factors.  
This summarises the key gaps in the knowledge as identified by a review of the 
literature, which has been explored across this chapter. Research to validate 
biomarkers and psycho-socioeconomic risk factors has the potential to predict 
the likelihood of a woman developing PND. This in turn could significantly 
improve early diagnosis and subsequent treatment, preventing lasting damage 
which can affect future generations of affected families.  
60 
 
1.13 Brief Description of Study and Project Aims 
 
The central aim of this multidisciplinary project is to profile women at risk of 
perinatal depression by investigating a number of different susceptibility 
mechanisms including genetic/epigenetic, immune and psychosocial predictors. I 
aimed to investigate HPA axis sensitivity by testing the genetic status of patients for 
SNPs of the glucocorticoid receptor and CRH-R1. An additional sub-study 
investigates epigenetic susceptibility through the analysis of differences in 
maternal blood DNA methylation during pregnancy as a preliminary exploration of 
the usefulness of global DNA methylation in PND. The analysis of circulating 
cytokines has also been carried out for participants as a potential biomarker for the 
underlying depressive symptoms. The three main arms of research in the current 
study based on the literature are psycho-socioeconomic factors, genetic factors, 
and biomarkers.  
This prospective cohort study was designed to investigate distinct patterns of 
perinatal depressive symptoms associated with recurrence or persistence from 
pregnancy to the postpartum period and profile psycho-social risk factors in each 
group in women recruited from NHS secondary care antenatal clinics. Biological 
samples from these women have been analysed to investigate the underlying 
pathology of PND. Taken together, this project combines the psychosocial risk 
factors with biological data and aims improve our understanding of the underlying 
causes of PND and investigate whether predictors could be used to improve the 
screening process. 
Overall this aims to profile women at risk of perinatal depression by investigating 
different susceptibility mechanisms. This is addressed by the following core 
research questions: 
1. Can psycho-socioeconomic factors predict antenatal and postpartum 
depressive symptoms? 
2. Is perinatal depression heterogeneous and can the timing of 
onset/remission be predicted from risk factors? 
3. Do cytokines and neurosteroids IL-6, IL-10 and BDNF act as markers for 
perinatal depression? 
4. Does HPA axis sensitivity provide a marker for perinatal depression by 
genotyping target SNPs? 
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5. Is there is a difference observed in global DNA methylation patterns 
between women with perinatal depression and women without? 
6. Do the investigated biomarkers improve prediction of perinatal depressive 
symptoms when compared with psycho-socioeconomic factors? 
This thesis answers these research questions across seven Chapters. Following on 
from this opening chapter which has introduced the context of the research and 
the problem which has not yet been adequately investigated, I will describe the 
research and methodology used in the present study to collect research data in 
Chapter 2. This will be followed by a chapter of results for each of the three arms 
of the study – psychosocial (Chapter 3), genetic (Chapter 4) and circulating 
biomarkers (Chapter 5). A final analysis chapter combines the data from each of the 
three arms and comprises the main analysis of the project in Chapter 6. The thesis 
concludes with a chapter to discuss of the findings of the project, where this sits 





2 Materials and Methods 
 
2.1 Chapter Two Abstract 
 
This chapter presents the methods used in the study which are designed to answer 
the research questions and aims as outlined previously in Chapter One. A 
prospective cohort study was designed, which expands and improves on a 
preliminary pilot study. The study population is described, with parallel studies 
running in two different locations, resulting in two separate study cohorts. 
Restrictions and limiting conditions on the project have been considered, and it will 
be important to consider these in relation to any findings of the study. The 
techniques used in the project are described here in detail, including the method 
to screen for depressive symptoms, utilising the Edinburgh Postnatal Depression 
Scale, and the laboratory experimental techniques and materials used in the 
biomarker studies. All variables recorded as part of the study are listed in Tables 
2.5 and 2.6. Finally, statistical methods used in the analysis of study data are 
described, for both psycho-socioeconomic and biomarker data.   
2.2 Overview of the Experiment/Design 
 
This study was designed with the central aim to collect data relating to perinatal 
depression screening and associated risk factors, both biological and psycho-
sociodemographic. The study design is a prospective cohort study, in the setting of 
secondary antenatal care. Women were invited to participate during pregnancy 
and biological samples were collected in addition to questionnaire data from PND 
screening and routine NHS data collection. Statistical methods were applied to all 
data, with the aim to disentangle complex risk factors and quantify their 
contribution to PND risk. 
This project formed part of the Coventry and Warwickshire Genetic Association of 
Postnatal Depression (CW-GAPND) study, NIHR CRN Portfolio Study ‘Biomarkers of 
Perinatal depression’ (Study IRAS ID: 21234). To validate findings of the pilot study 
in an independent replication cohort, this phase of the study aimed to recruit a 
further 2000 women from University Hospitals Coventry and Warwickshire (UHCW) 
and South Warwickshire NHS Trusts, based upon a 70% completion rate. In addition 
to genetic risk factors, psycho-sociodemographic risk factors have been 
investigated, in addition to the suitability of circulating biomarkers in screening. 
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This phase of the study has included a second follow up screening postpartum 
allowing for postpartum depressive risk to be included, and for disease progression 
and trajectories in individual women to be followed. 
This study includes assays for biomarkers, with the aim to find a relevant biomarker 
of PND, especially in women with increased genetic susceptibility of HPA 
dysregulation. In addition, determination of DNA methylation epigenetic markers 
in maternal blood offers added value and this area of investigation was included in 
the project. The study will utilise methods which will avoid the need for DNA 
sequencing, in order to determine suitability as a cost-effective and clinically 
relevant method for adoption by screening programmes. Ease of use in a hospital 
laboratory setting will also be assessed. 
The research design included six main elements in the methodology: 
1. Patient recruitment, screening and preparation of patient samples 
2. Analysis of EPDS scores and psycho-sociodemographic data 
3. Investigation of genetic susceptibility targeting specific SNPs and their 
influence on depressive symptoms (EPDS score) 
4. Investigation of circulating biomarkers 
5. Investigation of epigenetic susceptibility (DNA methylation) 
6. Data analysis and development of prediction and statistical modelling 
There were three main arms to the project (Table 2.1) – psychosocial risk, genetic 
risk and the use of a circulating biomarker. A timeline of data collection and analysis 
is demonstrated in Figure 2.1. 
Table 2.1. The three arms of the study and areas of investigation for each aspect. 






Circulating biomarkers IL-6, IL-10, BDNF 
Genetic Genetic variation 
SNPs associated with depression risk 
Bcl1, rs242924, rs242939 









This thesis uses data collected as part of the Coventry and Warwickshire Genetic 
Association of Postnatal Depression (CW-GAPND) study. The prospective 
recruitment of participants to the study was led by research midwives at two 
hospitals, University Hospital Coventry (University Hospitals Coventry and 
Warwickshire NHS Trust, UHCW) and Warwick Hospital (South Warwickshire NHS 
Foundation Trust, SWFT). The study was in the first instance initiated at Warwick 
Hospital, followed by UHCW. Recruitment began in 2014 and remains ongoing, 
although data collection for the purpose of this thesis ceased in January 2019. 
UHCW is a large University teaching hospital in Coventry, in contrast to Warwick 
Hospital which is a smaller hospital based in the smaller nearby town of Warwick. 
Midwives invited women to participate in the study during routine antenatal clinic 
visits. Ethical approval for this study was obtained from the National Research 
Ethics Services, UK Health Research Authority (REC reference 09/H1203/69). All 
participants had given informed consent.  
The two cohorts represent two populations of women living in the Coventry and 
Warwickshire area in the UK. According to the most recent Census data from 2011, 
the population of Coventry is 66.6% White British, whereas Warwickshire has a 







notably higher percentage of White British residents, at 88.5%260. The national 
average is 79.8%, indicative of Coventry’s diversity, with a higher proportion of 
black and minor ethnic population (BME) compared to the national average. 
Warwickshire is less diverse, with a higher proportion of White British residents 
than the national average. 
Despite their proximity in distance, the two areas are in many ways in stark 
contrast. Warwickshire is amongst the 20% least deprived areas in the country 
according to the Index of Multiple Deprivation (IMD) rank of average score261. On 
the other hand, Coventry is the 38th most deprived area; 18.5% of the population 
live in neighbourhoods which are in the 10% most deprived nationally. Data for this 
study has been collected from both areas, and differences between our study 
populations will be investigated. 
2.4 Location  
 
All biological samples were sent to the Coventry and Warwickshire Pathology 
Service (CWPS) at UHCW where they are stored. In this laboratory I can access 
specialist techniques required for the project that are not available at the University 
research environment, such as clinical grade molecular diagnostics. It allows access 
to patient samples and information, in addition to advanced equipment. The 
laboratories are run to Medical Laboratory accreditation standards as determined 
by the United Kingdom Accreditation Service (UKAS), and therefore all research 
delivered here will be to a high standard.  
The majority of the equipment needed for this project was available in the 
pathology department including DNA extracting platforms and LightCycler® PCR for 
SNP genotyping. All laboratory work was carried out in the UHCW Pathology 
Department, except for cytokine profiling which was performed using the Meso 
Scale Diagnostics (MSD) platform at the University’s Clinical Sciences Research 
Laboratories, a Warwick Medical School department based at UHCW.  
2.5 Restrictions and Limiting Conditions  
 
Participation in this study is largely random, since all women attending the 
antenatal clinic were invited to participate. It is however possible that an element 
of bias is involved in the decision to partake in a research study. For some, stigma 
unfortunately remains around depression due to cultural or family/personal 
beliefs, and this may influence the decision whether or not to participate.  
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The completion of both protocol arms is dependent upon participants responding 
with their postpartum screening at 6-8 weeks, and failure to do so results in 
incomplete data. Participants who failed to return the follow up were contacted by 
telephone and/or post but a number of women still did not complete this and 
therefore were excluded from postpartum analysis, but were still included in 
antenatal data analysis. Some women may have moved out of the area or changed 
contact details and were no longer contactable. It is also possible that those who 
fail to submit the follow up EPDS are more likely to be suffering from depression. 
The protocol includes biological sample collection at one time point during the 
study, and therefore biomarkers cannot be directly compared from antenatal to 
postpartum time points. The study has been made as easy as possible for women 
to complete the protocol, with the follow up by telephone or post. This benefits 
protocol completion and a further visit to the hospital with a new born baby would 
certainly result in higher failure to complete cases. Patients were involved in PPI 
during the preliminary design of the study especially regarding the methods of 
remote communication post-delivery. This was prior to my involvement, however 
PPI is a very important part of study design and I would endeavour to include 
further PPI in future work. 
PND screening for the purpose of the study was conducted with the EPDS screening 
tool, which although widely used and validated is not a diagnostic tool. Therefore 
we are limited by referring to ‘depressive risk’ rather than confirmation of PND 
status. Screening is however not usually mandated and therefore this study 
benefits all participants by ensuring they are receiving additional care to the 
standard level in the NHS. All women who screen positive in the study are referred 
through NHS protocols and will receive treatment that they may not have 
otherwise had due to lack of detection. 
Laboratory work was based at the hospital Pathology laboratories, which are busy 
clinical environments where clinical work must take priority over research. Space, 
resources and availability of equipment is dependent upon the clinical workload of 
the laboratory. During periods with increased operational demand such as the 
winter pressures, disease outbreaks, and urgent sample testing, access to the 
laboratory was restricted. The logistics of sample storage in this laboratory also 
presented difficulties, with blood, saliva, extracted DNA and plasma samples for 
each participant from two hospitals resulting in thousands of biological samples 
which were stored and often not readily accessible for quick analysis. The large 
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scale nature of this study presented challenging logistics for one person to manage 
in terms of sample processing and analysis. 
2.6 Sampling Technique  
 
PND screening 
Perinatal depression was assessed during two distinct time points during 
pregnancy, using the most validated and widely used self-report screening tool for 
depression during the perinatal period, the Edinburgh Postnatal Depression Scale 
(EPDS)103 (Appendix A). The EPDS is designed specifically for postnatal use but is 
also validated for antenatal use as a pre-screening tool for depression and in 
particular in research103. The EPDS does not include questions about somatic 
complaints, fatigue and changes in appetite, as these complaints would not help to 
distinguish depressed from non-depressed women during pregnancy and 
postpartum103.  
The 10 item EPDS is the most commonly used tool to screen for minor and major 
depression, and is recommended by NICE5. The scale has a maximum score of 30, 
and a score of 10 or above indicates the presence of depressive symptoms. 
Although there is no consensus agreement on the most appropriate cut-off, for 
screening purposes a cut-off score of 10 is widely cited to indicate possible major 
or minor depressive disorder103 262, whereas the cutoff of 13 is typically used for 
identifying major depressive disorder (MDD) (predictive accuracy characteristics 
reviewed in the Systematic Evidence Review for the US Preventive Services Task 
Force263). In this study women who scored ≥10 were considered as screening 
positive for PND, as recommended by the American Academy of Pediatrics104. This 
cut-off has a reported sensitivity of 0.81 and 0.86 for detection of both major and 
minor depression264.  
The time-points at which the EPDS was carried out was based on previous studies 
to include the peak incidence periods. The antenatal EPDS assessment was carried 
out between 24–29 weeks gestation (T1) at a hospital visit. Since there is no 
consensus agreement on the most appropriate assessment time, T1 was chosen to 
study depressive symptoms early in the third trimester, during the transition period 
between 2nd and 3rd trimester where women experience most of the uncomfortable 
physical symptoms of pregnancy, such as tiredness, difficulty eating or sleeping. 
This period is also associated with the most dramatic changes in hormonal milieu, 
especially placental hormones that control stress responses and may trigger rapid 
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mood changes, and has been suggested as an optimal screening time due to the U-
shaped pattern of temporal onset resulting in higher prevalence in the third 
trimester109. This stage in pregnancy is where most women have routine antenatal 
assessments, therefore translation of this research protocol in clinical practice will 
not impact on resources allocation in the current healthcare model by introducing 
an additional hospital visit.  
All participants were contacted following delivery of their baby and asked to 
complete a second EPDS at 6–10 weeks postpartum (T2) via post or telephone. 
Most cases of PPD arise in the 1 to 6 months following childbirth which is the 
recommended screening period according to the American Academy of 
Pediatrics104. Generally, it is most common for PPD begin sometime within the first 
3 months postpartum and therefore T2 was designed to capture the majority of the 
women who will go to develop PPD265 266. The hard copies of EPDS questionnaires 
were collected, both at the antenatal and postpartum time points, resulting in 
matched paired observational data. 
Blood sampling 
Upon giving informed consent for their participation in the study, participants 
agreed for their biological samples to be used for the purpose of research. 
Participants provided 2 x 5mL venous blood samples in EDTA collected during an 
antenatal appointment by a research midwife. One vial of whole blood was stored 
at 4°C until DNA extraction. The additional sample was centrifuged immediately 
after receipt in the laboratory and the plasma fraction stored at -80°C until required 




2.7 Procedures  
 
DNA extractions 
Genomic DNA was extracted from whole blood using the EZ1 extraction instrument 
(Qiagen, Hilden, Germany) with the Qiagen EZ1 DNA Blood 200µl Kit & DNA Blood 
Card. Whole blood samples were placed on a blood roller mixer for a minimum of 
5 minutes, following which 200 µl blood was pipetted into 2mL polypropylene tubes 
under sterile air flow cabinets. Cartridges from the Qiagen extraction kit were 
inserted into the extraction instrument and samples were placed in their 
corresponding positions, with a labelled 1.5mL elution tube in place to collect 
eluted genomic DNA. EZ1 machines were UV light treated after each extraction to 
prevent contamination. DNA samples were eluted in 100 µl elution volumes. The 
quality and quantity of the extracted DNA was then assessed using Nanodrop 
spectrophotometer analysis using the A260/A280 ratio. The limit of acceptance for 
samples to be considered high-purity was 1.7-1.8. DNA samples were stored at -
80°C prior to SNP genotyping. 
SNP genotyping 
DNA samples were prepared for allele-specific PCR analysis to genotype 
participants for the selected SNPs. SNPs genotyped were the Bcl1 SNP of the 
glucocorticoid receptor NR3C1 (dbSNP NCBI identifier rs41423247), and 2 SNPs of 
CRH receptor CRH-R1 (rs242924 and rs242939). Genotyping was carried out with 
the capillary based LightCycler® instrument (Roche Diagnostics Ltd, Burgess Hill, 
UK), which uses real-time detection to minimise sample handling and 
contamination risk. The instrument uses heated air to allow rapid ramping. The 
amplified DNA is quantified using a DNA binding dye. Finally, melting curve analysis 
is employed to accurately and rapidly detect polymorphisms. 
Primers and probes for detection of the chosen SNPs were synthesised for 
LightCycler® analysis by TIB MolBiol (Berlin, Germany). A set of hybridization probes 
consists of a pair of oligonucleotide probes which can bind on a DNA template, one 
labelled with fluorescein at its 3'-terminus [3FL] and the other labelled at its 5'-end 
with LightCycler® Red dyes [5LC]. HybProbes hybridize on the PCR product and emit 
a fluorescence signal based on Fluorescence Resonance Energy Transfer (FRET)267.  
For primer design a gap of one to four bases between the probes is recommended. 
A Forward primer, Reverse primer, Fluorescein probe (Sensor) and Internal 
LightCycler® Red 640 labelled primer (Anchor) were designed and synthesised for 
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each SNP to be genotyped (Table 2.2). The Sensor probe is designed to include the 
target mutation position in the centre of the probe, where it exerts the greatest 
influence on melting temperature, and the probe spanning the mutation must have 
a different Tm than the partner anchor probe. Primers and probes for LightCycler® 
analysis were designed by Tib MolBiol. 
Table 2.2. Primer and probe sequences for SNP genotyping with the Roche LightCycler®. 
SNP rs41423247 rs242924 rs242939 
Forward CAA AgA gCC CTA TTC 
TTC AAA C 
AgA CTT AAA Tag AAg 
gTC CAC AAg C 
TCC ACT TCC AgA gTg ATC 
CTC gT 
Reverse AAA AAA AgA gAA 
AAA TCA AAC gAA 
ggg CTg CCT Agg gCA 
TgT 
ggC Tgg CTg CAA AAg gTg 
Sensor 
[3FL] 
CTC TTA AAg AgA TTC 
ATC AgC AgA CA—FL 
ggA CCC TCT CCA TTT 
TTg C--FL 




LC640-AAC TTg TCT 
ACT TTA Tgg CAA gAA 
CCC Tg—PH 
LC640-Cag Cag Cag CCA 
TgC CCA ggA- PH 
LC640-TgT gTg gCC TCC 
gTg TTC Agg—PH 
 
 
All primers and probes were delivered as lyophilised oligonucleotides and were 
reconstituted in PCR grade H20 to produce stock solutions. For PCR reactions, a final 
product of 0.5µM of each primer/probe was used. Optimisation of PCR conditions 
was carried out as part of the original pilot study and therefore optimal reagent 
concentrations and cycle conditions had been determined.  
The LightCycler® 2.0 Carousel System was used (Roche), and Melting Curve Analysis 
was employed for genotyping. The genomic DNA samples were added to 
LightCycler® FastStart DNA Master HybProbe mastermix (Roche), primers and 
probes. Reaction mixtures were prepared in a sterile PCR grade cabinet and 
pipetted into pre-cooled glass capillaries (LightCycler® capillaries 20 µl & 
LightCycler® cooling block, Roche). Genomic DNA samples were added to produce 
a 10µl total volume for PCR using 2.5 µl genomic DNA as a template and 7.5µl 





Table 2.3. Amplification mixture preparation for LightCycler® PCR reactions. 
Reagent Volume per sample (µl) 
H20 3.7 
MgCl2 0.8 
Primers/probes 0.5 each (Forward, Reverse, Sensor, Anchor) 
FastStart DNA HybProbe 1 
 
The PCR mixture was prepared in glass capillaries which were capped and 
centrifuged at 2000g for 15 seconds. Prepared capillaries were placed into the 
Carousel and inserted into the LightCycler®.  
Chosen parameters for PCR and melting curve analysis consisted of an initial 
denaturation step of 95°C for 10 min followed by an amplification stage of 40 cycles 
of 10 s at 95°C, 10 s at 53°C and 20 s at 72°C. After amplification, the melting curve 
analysis was performed in one cycle of 95°C for 20 s followed by 40°C for 20 s and 
then ramping to 85°C. A single cooling cycle of 40°C for 30 s was then employed. A 
temperature transition rate of 20°C/s was used at each step. 
Each PCR run included a wild type and heterozygote control confirmed by 
sequencing, in addition to a negative control (PCR grade H20 replaced DNA sample), 
allowing 29 samples to be analysed per run. All laboratory methods were carried 
out blind to EPDS status. SNP genotype was determined as wild type, heterozygous 






Figure 2.4. (a) Melting curve analysis for Bcl1 demonstrating 3 controls used in each PCR run. Negative 
control (flat line), wild type (single peak at 56°C) and heterozygote (one peak at 61°C and one peak at 60°C). 
(b) An example output from a run including controls and samples, with homozygotes (HOM) producing a 
single peak at 61°C. 
Figure 2.2. (a) Melting curve analysis for rs24294 demonstrating 3 controls used in each PCR run. Negative 
control (flat line), wild type (WT) (single peak at 60°C) and heterozygote (HET) (one peak at 60°C and one 
peak at 52°C). (b) An example output from a run including controls and samples, with homozygotes (HOM) 
producing a single peak at 52°C. 
Figure 2.3. (a) Melting curve analysis for rs242939 demonstrating 3 controls used in each PCR run. Negative 
control (flat line), wild type (WT) (single peak at 57°C) and heterozygote (HET) (one peak at 57°C and one peak 
at 64°C). (b) An example output from a run including controls and samples, with homozygotes (HOM) 












Melting peaks of controls were used to correctly determine the genotype of each 
sample by comparing peaks. A summary of minor allele and genotype is shown in 
Table 2.4. 
Table 2.4. Summary of minor allele mutation and melting temperatures for all 3 SNPs genotyped 
for wild type (WT) and homozygous (HOM) forms. 
SNP Alleles WT Tm (°C) HOM Tm (°C) 
CRHR1 
rs242924 C to A 60 52 
rs242939 A to G 57 64 
GR 
bcl1 (rs41423247) C to G 56 61 
 
Biomarker analysis 
All biomarker analyses were performed on plasma samples during the same 24 
hour period for each patient sample to prevent freeze-thaw cycles and minimise 
variability. Plasma samples were thawed to room temperature and centrifuged at 
2000g for 3 minutes to remove particulates. Levels of Brain Derived Neurotrophic 
Factor (BDNF), pro-inflammatory cytokine Interleukin-6 (IL-6) and anti-
inflammatory cytokine Interleukin 10 (IL-10) were quantified. Prior to running each 
assay, all reagents were brought to room temperature unless otherwise stated.  
BDNF 
As described in Chapter 1, both free and bound forms of BDNF exist, and an assay 
was chosen to detect levels of free BDNF. Free rather than bound BDNF was 
measured in order to ensure the active circulating levels of BDNF were detected, 
since free BDNF is less affected by protein binding and is considered more 
biologically active. The measurement of free BDNF is more highly cited in the 
literature and therefore more comparable data was available. BDNF levels were 
quantified with an enzyme-linked immunosorbent assay (ELISA) using Human Free 
BDNF Immunoassay kits manufactured by R&D Systems (Minneapolis, USA). The 
assay uses a quantitative sandwich enzyme immunoassay technique as depicted in 
Figure 2.5.  
A 96-well ELISA plate was pre-coated with BDNF antibody. Assay diluent was added 
to each well in addition to 50 µl prepared standard/sample – the plate was covered 
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with an adhesive plate seal to prevent evaporation and incubated at room 
temperature for 2 hours. Human Free BDNF conjugate was then added to each well 
and incubated for a further 1 hour.  
Each well was aspirated and washed with wash buffer 3 times – wash buffer 
concentrate, provided in the kit, was diluted with ddH2O to produce wash buffer. 
The plate was blotted following each wash on absorbent paper. After the final wash 
the plate was thoroughly blotted to ensure complete removal of liquid. Substrate 
solution was mixed immediately prior to addition due to light sensitivity, and added 
to the plate following washing for a 30 minute incubation protected from light. 
After 30 minutes incubation, stop solution was added and the optical density (OD) 
1. 96 well plate coated 
with BDNF antibodies 
2. Standards/samples 
added to plate and 
BDNF antigen binds 
2 hour incubation 
3. Conjugate added and 
attaches to bound 
BDNF 
1 hour incubation 
Wash and blot plate x3 
4. Substrate solution 
added and blue 
coloured solution 
produced 
30 minute incubation 
5. Stop solution added to 
halt reaction and 
prompt colour change 
to yellow. Optical 
density determined.  
Figure 2.5. The main steps involved in the procedure carried out during the BDNF assay. 
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of each well was determined using a microplate reader (Tecan, Switzerland) at 
450nm, with wavelength correction at 540nm. 
Samples were run in duplicate and the mean OD was calculated. The concentration 
of BDNF for each sample was determined using a 4PL logistic curve based on the 
concentration of the standards. The coefficient of variation (CV), standard deviation 
(SD) and standard error of the mean (SEM) were calculated for each sample. CV 
values <20% were considered acceptable. 
 IL-6/IL-10 
Cytokine quantification of IL-6 and IL-10 were detected using a V-plex multiplex 
custom antibody detection assay manufactured by Meso Scale Diagnostics (MSD, 
Maryland, USA), the Proinflammatory Panel 1 Human Kit. This assay is a sandwich 
immunoassay, pre-coated with capture antibodies on independent and well-
defined spots. Specialised custom made plates were pre-coated with both IL-6 and 
IL-10 antibodies in specific spots in the wells, allowing both assays to be run in 
1. Plate pre-coated with 
capture antibodies in 
specific spots within 
wells. 
Wash x3 prior to use 
4. Read buffer added to 
facilitate electro-
chemiluminescene 
when voltage applied 
and light is emitted – 
instrument measures 
light intensity 
3. Detection antibody 
solution added (IL-6 
and IL-10 antibodies) 
with SULFO-TAG 
label 












Figure 2.6. Main steps in the method for quantifying IL-6 and IL-10 with the MSD V-plex assay. 
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duplex on one plate. Both assays were performed simultaneously to ensure 
consistency and to avoid freeze-thaw of the sample.  
Samples and a solution containing detection antibodies conjugated with 
electrochemiluminescent labels (MSD SULFO-TAG™) were added over a course of 
incubation periods. Analytes in the sample bind to capture antibodies immobilised 
on the electrode surface of the plate. A buffer was then added to create the 
appropriate chemical environment for electrochemiluminescence and the plate 
was loaded into an MSD instrument where a voltage is applied to the plate causing 
captured labels to emit light. The instrument then measures the intensity of 
emitted light which is proportional to the amount of analyte in the sample to 
provide a quantitative measure.    
The plate was washed 3 times with wash buffer (ddH2O, 5x PBS + 0.05% Tween-20) 
prior to use. Plasma samples were diluted 2-fold in diluent containing protein, 
blockers and preservatives, and diluent alone was used as the zero calibrator. An 8-
point standard curve was generated by dilution of the calibrator as appropriate. 
After initial experiments, a number of samples had concentrations at the lower end 
of the curve, so it was required to add an additional standard to improve accuracy 
at the lower end of the curve. A total of 9 standards were assayed to generate a 
standard curve allowing 39 samples to be assayed in each plate. 
Samples and standards were added directly to the plate and plates were sealed and 
incubated shaking (500rpm) on a plate shaker at room temperature for 2 hours. At 
the end of the incubation period, detection antibody solution containing IL-6 and 
IL-10 antibodies was added. After washing the plate x3, detection antibody solution 
was added to each well and incubation was repeated as before for 2 hours. The 
plate was then washed as before, and read buffer was added to all wells. The plates 
were read using the MSD Sector Imager analyser. The Discovery Workbench 
software is used to analyse the signal produced by each well, which corresponds to 
a concentration as determined by the standards assayed on the plate. A standard 
curve can then be produced, from which the concentration of all included samples 
is calculated based on the corresponding signal. 
All samples/standards were assayed in duplicate and mean concentrations were 
calculated. Custom layouts were created for each plate in MSD Discovery 
Workbench analysis software. Known concentrations of standards were inputted 
and Standard Curves were calculated, allowing sample concentrations and CV 
values to be determined.  
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Global DNA methylation 
Global DNA methylation levels were assayed using EpiGentek MethylFlash (New 
York, USA), a method utilising absorbance-based quantification of global DNA 
methylation by specifically measuring levels of 5-methylcytosine (5-mC) in an ELISA-
based format. The high sensitivity assay was used, with a detection limit of 0.2ng 
methylated DNA, and no cross-reactivity to unmethylated cytosine or 
hydroxymethylcytosine268. DNA is bound to strip wells with a high DNA affinity. The 
methylated fraction of DNA is detected with capture and detection antibodies and 
is quantified by measuring absorbance. Absolute quantification of 5-mC is 
calculated using a standard curve.  
100ng genomic DNA was used for each sample as recommended, with a 260/280 
ratio >1.6 as the lower limit of acceptance for purity. Controls and standards were 
prepared in duplicate. Binding solution was added to each well, followed by sample 
5. Stop solution added to stop 
enzyme reaction and trigger 
colour change to yellow. OD 
measured. 
4. 5mC detection solution 
added until highest 
concentration turns deep 
blue 
1 hour incubation 
Wash x3 
3. 5mC detection complex 
added 
2. Controls/DNA samples added 




1. Preparation of genomic DNA 
samples 
Figure 2.7. Main steps of the method used to quantify 5-mC% with the MethylFlash assay. 
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DNA/controls. Plates were sealed and incubated at 37°C for 1 hour. 5-mC Detection 
Complex Solution was mixed at the end of the incubation period, containing 
detection antibodies. 
Plates were washed x3 with wash buffer adjusted to pH 7.2-7.5, prior to addition of 
5-mC Detection Complex Solution and incubation for 50 minutes at room 
temperature. Plates were washed x5 and detection solution added for 3-4 minutes, 
gently shaking, until the colour in the highest concentrated standard turned deep 
blue in the presence of methylated DNA. Stop solution was then added to all wells 
to stop the enzyme reaction and a blue to yellow colour change occurs. As soon as 
the colour change completed, absorbance was measured using a microplate reader 
(Tecan) at 450nm. The amount of methylated DNA is proportional to the OD 
reading, which was calculated using the standard curve measurements. Unlike 
other methods, MethylFlash is able to directly quantify actual levels of global DNA 
methylation. 
The samples were assayed in duplicate, and the mean OD values for each sample 
was calculated, along with standard deviation and coefficient of variation (CV). The 
% DNA methylation was calculated using the equation: 
(Average OD of sample – Negative control OD / SLOPE * 100 [ng DNA]) * 100 
Correlation analysis and linear regression modelling were performed using IBM 
SPSS Statistics Version 24. 
A second method was tested to assess DNA methylation which differs from other 
ELISA-based kits. The LINE-1 Global DNA Methylation Assay from Active Motif (La 
Hulpe, Belgium) was used in an initial experiment with a small number of samples, 
which determines the methylation levels of LINE-1 (long intersperses nuclear 
elements-1) retrotransposons, which are well established as a surrogate for DNA 
methylation269. Fragmented DNA was hybridized to biotinylated LINE-1 probes, 
which were subsequently immobilized to a streptavidin-coated plate. Washing and 
blocking steps followed. Methylated cytosines were quantified with an anti-5mC 
antibody, HRP-conjugated secondary antibody and chemiluminescent detection 
reagents. Samples could then be compared against a standard curve generated 
from standards with a known concentration of LINE-1. The assay is able to detect 
DNA methylation as low as 0.5%. Following the initial experiments this method was 
not selected for the analysis, partly due to the large quantity of DNA the assay 
requires (1µg) and the added complexity of the method when compared with the 
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MethylFlash method, which would not be suitable for quick use in a clinical 
laboratory. MethylFlash is a more highly cited and comparable method, whereas 
the LINE-1 assay is a new technique, and therefore MethylFlash was used to 
quantify DNA methylation in this study. 
Psycho-socio-economic data collection 
Data surrounding the psycho-socio-economic status of participants were extracted 
from the NHS Booking forms. Covariates which may be involved in depressive risk 
were selected for data extraction. A full list of covariates selected is available in 
Tables 2.5 and 2.6. Data was further extracted from the Health, Social and Family 
Health forms, which are routinely completed during the initial antenatal booking 
visit by a midwife. This is used routinely across the NHS using standardised 
questionnaires, and is designed to obtain information about pre-existing medical 
conditions and socio-demographic characteristics, in addition to questions about 
pregnancy and lifestyle. Lifestyle Update forms were also completed at routine 
antenatal visits as part of normal procedures, from which data was also collected 
for this study. These forms include a number of known risk factors for PND and 
these measures were included in the present analysis. These form were completed 
in hard copy and the responses for each of the variables were extracted and 
inputted into SPSS (Version 24).  
In total responses were available from 1579 participants from the main recruitment 
site at Warwick Hospital. Postpartum follow-up rate was 55% at the time of data 
analysis for this thesis, and so complete responses were available for 872 Warwick 
participants. Responses from University Hospital Coventry participants were 
available for 448 participants. Postpartum follow-up rate was 67% leaving a final 





2.8 Materials  
 
Name Supplier Catalogue number Use 
EZ1 Advanced XL Qiagen 9001874 Nucleic acid 
purification 
EZ1 DNA Blood 200µl Qiagen 951034 Nucleic acid 
purification 





















04929292001 Real-Time PCR 





12239272001 Real-Time PCR 
Primers and Probes TIB MolBiol Designed to order Real-Time PCR 
MethylFlash Methylated 
DNA 5-mC Quantification 
Kit (Colorimetric) 
EpiGentek P-1034-48 Quantification of 
global DNA 
methylation 






DBD00 Quantification of 
human free BDNF 
GENios microplate reader Tecan 16129904 Analysis of ELISA 
based assays 




K151A9H-1 Quantification of 
human IL-6 and IL-
10 
Sector Imager Meso Scale 
Diagnostics 
R31QQ-3 Quantification of 
human IL-6 and IL-
10 




Centrifuge MiniSpin Eppendorf 5452000060 Sample 
preparation 
Vibrax VXR Basic Orbital 
Shaker 
IKA 0002819002 Sample 
preparation 






2.9 Variables  
 
All variables selected for inclusion in the study are shown in Table 2.5. Variables 
were carefully selected based on the literature to include specific risk factors for 
PND23 55 95. For example, ‘anxiety’ is a known risk factor for antenatal depressive 
symptoms. This link has been well established and is likely attributable to the 
pressures of motherhood including the potential financial strain270 271. Covariate 
‘social status’ is indicative of socioeconomic status (SES), which is a well-established 
risk factor for PPD55 95. Low social status also often indicates adversity in life.  
26 variables were selected for extraction from the forms, 4 of them numerical 
integer values and 22 factorial covariates with factor levels indicated in Table 2.5. 
Additional collected variables for the smaller Coventry cohort are displayed in Table 
2.6.  
Table 2.5 Data extracted for each covariate selected for main study (Warwick Hospital). 
Covariate Question 
Education To what level have you been in 
education? 








Social status What is your current employment 
status/level? 
Higher managerial/professional 
Diploma level professional 
Self employed 
Lower level supervisory/technical 
Semi routine/routine 
Unemployed/student 












Alcohol (pre-pregnancy) Did you drink alcohol during the 12 
months before conception? 
Yes 
No 
Drinking (in pregnancy) Do you currently drink alcohol? 
Yes 
No 




Cigarettes (in pregnancy) Do you currently smoke? 
Yes 
No 

















Do you currently have anxiety? 
Yes 
No 
Depression Have you ever had depression? 
Yes 
No 
Do you currently have depression? 
Yes 
No 
Past History PND Have you ever had perinatal depression? 
Yes 
No 
Family History PND Has anyone in your family ever had 
perinatal depression? 
None 
1st degree relative 
Other relative 
Support What is your current support status? 
Unsupported 
Supported 
Parity Number of previous children? 
        (N) 



















Gender of baby Male 
Female 
Weight of baby (grams) 
Twins Yes 
No 
Gender of twin 2 Male 
Female 
Weight of twin 2            (grams) 
Gestational length           (days at delivery) 
Mode of delivery Normal vaginal birth 
Instrument assisted 
Emergency C section 
Elective C section 
Induction of labour Was labour induced? 
Yes 
No 







Table 2.6. Additional data collected for participants from UHCW. 
Covariate Question 
























Birth complications None 
Induced 
Postpartum haemorrhage 






2.10 Statistical Treatment  
 
2.10.1 Psycho-socioeconomic data 
 
Following recruitment, responses from all participants for selected variables were 
inputted into an electronic data file using SPSS (version 24). The antenatal EPDS 
score was also available at the stage and this was added to the dataset. At a later 
stage once postpartum EPDS data was collected the dataset was updated with the 
postpartum EPDS score in order to maximise data use. Missing data was excluded 
from the analysis but participants were not excluded on the basis of missing data 
in order to maximise the available data. The cohorts were approached separately 
for the statistical analysis – those who completed antenatal EPDS only, and those 
who completed both antenatal and the follow-up postpartum EPDS.  
The EPDS was used in a pre- and post-measures design, and approached as both a 
linear score, and dichotomised with a cut-off value in order to explore its use as a 
screening tool. The raw EPDS score was interrogated in order not to constrain the 
EPDS data to dichotomous groups – this enabled analysis of the relationship 
between the data collected from the variables and EPDS score. Rather than splitting 
women into high vs low risk groups, for this part of the analysis we instead 
interrogated the data to investigate which factors contribute higher scores on the 
EPDS. 
Antenatal and postpartum EPDS scores were recorded, together with the profiling 
of psychosocial, lifestyle and pregnancy related information. This data is routinely 
gathered during antenatal hospital visits, and in this prospective study data was 
utilised to investigate whether distinct patterns of onset and persistence of PND 
symptoms from pregnancy to the postpartum period are associated with different 
risk profiles. This stage of the analysis was based on modelling by discretization, by 
applying well-established cut-offs to determine ‘low’ or ‘high’ risk of PND. In 
addition, data analysis using the full EPDS scale explored the usefulness of 
covariates as predictors of either antenatal or postpartum EPDS scores in order to 
identify covariates that can support a “predictive” model capable of forecasting 
raised EPDS scores. A second aim of the statistical analysis was to detect whether 
systematic differences between antenatal and postpartum EPDS scores exist, 
potentially hinting at different aetiologies. Finally, the analysis explored whether 
data collected based around risk factors for PND can also be used to predict two 
interconnected offspring outcomes, birth weight and gestational length. 
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Table 2.7. The main steps in the analysis of data and a summary of the purpose of each method. 
Statistical treatment Purpose 
Data input Hard copies of questionnaires and EPDS 
forms transferred into SPSS format and 
variables coded numerically  for ease of 
analysis 
Exploratory analysis Identify prevalence of depressive risk in 
the study population and to understand 
the cohort characteristics 
Dichotomisation with EPDS Participants dichotomised into ‘high’ or 
‘low’ risk dependent upon EPDS cut off 
score to allow for clinically relevant 
analysis 
Division into risk groups Risk groups defined by dependent upon 
timing of onset/remission based on EPDS 
to allow exploration of trajectories 
Chi squared/correlations Identifies potential correlates/risk factors 
associated with antenatal and postpartum 
EPDS scores 
Penalised regression Uses raw EPDS scores to increase 
statistical power and identify both 
distinguishing and common covariates 
across antenatal and postpartum risk. 
Factors contributing to average score and 
difference between scores can be 
explored 
Multinomial logistic regression Allows for ‘group analysis’ based on risk 
groups to further understand associations 
between risk factors and the three groups 
with distinct trajectories. Relative risk 
values are generated. 
Exploratory linear regression modelling Exploration of the contribution of specific 
risk factors to prediction of EPDS scores. 
Identifies and ranks the most important 






Linear regression modelling 
Data collection was completed for this project in January 2019. The number of 
recruited participants from Warwick Hospital, the main recruitment site, totalled 
1579 – all of these women had completed the antenatal EPDS. To explore factors 
associated with antenatal EPDS, variables were prepared for linear regression 
modelling. 
Variables were chosen based on Chi squared (χ2) analysis for categorical variables, 
bivariate correlation for continuous variables, and point-biserial correlation for 
dichotomous variables. Those with significant correlations at this stage were 
selected for model inclusion. The final variables entered were past history of 
depression, past history of anxiety, smoking pre-pregnancy, social status and age. 
In order to allow for inclusion in linear regression, variables were recoded into 
dummy variables for social status and age, coded 0/1 for each level of the factor. 
Remaining variables were dichotomous and therefore eligible for linear regression. 
All selected variables were entered into the model to assess their prediction of 
antenatal EPDS score. Baseline categories were selected based upon either ‘no’ for 
yes/no answers such as history of depression, or on the modal group such as age 
category. Hierarchical entry was used, inputting variables in order of theoretical 
importance based on previous work. Multicollinearity was assessed in addition to 
residual plots and non-zero variance. Linear regression analysis was repeated for all 
participants who completed postpartum follow up, with the additional variable of 
antenatal EPDS score included in the analyses. The smaller study population 
recruited at Coventry Hospital was analysed in the same manner. There were some 
differences in data collected by the two different hospitals which can be seen in 
Tables 2.5 and 2.6. 
Detailed statistical analysis sub-group 
A sub-group of participants were selected for the most comprehensive analysis – 
the first 480 women to have completed the postpartum follow up. This cohort has 
undergone the most in depth statistical analysis based on psycho-socioeconomic 
data alone, and in addition both biomarker and genetic data has been collected and 
investigated for these participants.  
The main aim of the statistical analysis was to investigate PND heterogeneity 
according to symptom progression profiles based on timing of onset and remission. 
This involves the evaluation of the predictive value of risk factors and identification 
of systematic differences between antenatal and postpartum EPDS scores. This sub-
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study analysed paired observational data from participants that completed the 
protocol resulting in 960 complete observations (n=480). 
Classification of risk trajectories 
For the first stage of the analysis a cut-off score was used to classify patients as high 
vs low risk for depression during pregnancy or postpartum. This also allowed us to 
characterise distribution of scores and subgroup patients according to temporal 
patterns and possible recurrence of depressive symptomatology. A new variable 
‘Group’ was created and participants were re-categorised into a Group dependent 
upon EPDS score trajectory (Figure 2.5). 
 
 
Figure 2.8. There are four possible disease trajectories for PND dependent upon 'Group'. Mean 
antenatal and postpartum EPDS scores are shown for each group. Red dotted line indicates cut-off 
for positive screen. 
 
EPDS scores were recoded into variable ‘Group’ dependent upon EPDS score – as 
explained in section 2.6, a score of <10 was considered a negative screening results, 
and a score of ≥10 was considered a positive screening result, for both minor and 
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interrogated with a higher cut-off score ≥13, which has been recommended to 
screen for major depression.  
Table 2.8. Groups as defined by depression trajectory based upon EPDS screening (cut off 
≥ 10). 
Group Antenatal screen Postpartum screen 
0 0 – Negative 0 - Negative 
1 0 – Negative 1 - Positive 
2 1 – Positive 0 - Negative 
3 1 – Positive 1 - Positive 
 
The aim of this statistical analysis had three parts: (i) the investigation of distinct 
patterns of onset and persistence of PND symptoms from antenatal to the 
postnatal period; (ii) an exploration of the potential for covariate data gathered 
routinely from women during hospital visits to predict EPDS scores: (iii) to test the 
degree to which severity of antenatal and postpartum depression as well as the 
change in severity across the two periods was associated with distinct covariates 
risk profiles.  
In order to determine the contribution of individual factors to depressive 
symptoms, a comprehensive statistical analysis was designed with the aim of 
building a full picture of their prediction of EPDS score. The analysis included (a) 
dichotomised EPDS scores to define a binary outcome of depressive symptoms in 
order to obtain estimates of effects and their significance that are more robust to 
potential misspecifications of the regression models;  (b) development of 
regression models for the raw EPDS scores in order to increase power and to detect 
subtler effects of covariates; (c) evaluation of the predictive performance of the 
regression models in comparison to a state-of-the-art machine learning prediction 
method. The statistical analyses were carried out with the guidance of 
biostatistician Dr Lorenz Wernisch, a co-author on the publication. 
Multinomial logistic regression – group analysis 
A number of potential risk factors for PND, which were identified in the published 
literature and available in this study, were selected for in the present analysis such 
as age, ethnicity and social status among many others (Table 2.5). All selected 
variables were first analysed for statistical significance of associations between 
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potential risk factors and AND/PND through chi-squared (χ2) tests. Odds ratios (OR) 
and the associated 95% confidence interval (CI) were obtained for variables that 
demonstrated statistical significance during chi-squared analysis. Pre- and post-
delivery variables for EPDS scores were created to conduct independent analysis 
between the risk factors. 
A p-value of <0.05 was considered indicative of a statistically significant difference. 
All risk factors with a p<0.05 in univariable analysis, either pre-delivery or post-
delivery, were identified and included in a multinomial logistic regression model to 
study the relationship between group classification and risk factors with STATA 
commands mlogit and mlogit,rrr to obtain relative risk and p-values. To simplify 
analysis four individuals with missing data were excluded resulting in N=476. 
Covariates with low frequencies in some levels were merged.  
Overall low risk group (Group 0) was used as the baseline category. Relative risk 
values were calculated to provide a better understanding of the magnitude of 
association between risk factors and each group. Statistical analyses were 
conducted with IBM SPSS Statistics Version 24 and STATA/SE 14.0. 
Penalised regression and prediction 
The first phase of the analysis used multinomial logistic regression to identify the 
risk imposed by individual factors on each risk group. The next phase was to look in 
further detail at these contributions and specifically how EPDS score is affected 
from the antenatal to postpartum time points. Regression modelling should take 
into account the large number of covariates, many of which are multi-level, and 
therefore a penalised regression model was selected. To simplify the regression 
analysis, 6 individuals of the 480 with missing values in some covariates were 
removed. Since this amounts to about 1% of the data, the effect on the statistical 
results were considered negligible. 
To determine the optimal model of prediction, a linear model with elastic net 
regularization was used272. Parameter alpha was set to 0.5 with equal weight given 
to Lasso and ridge regularisation in order to improve prediction accuracy of the 
model. This leads to a spare regression with unimportant variables removed, and 
highly correlated variables remain in the model when two or more variables explain 
the outcome equally well. The prediction accuracy may be improved by shrinking 
coefficients to zero with this approach. R package glmnet was used for this model. 
A standard linear model was also used to obtain corresponding p-values. 
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Differences and commonalities between antenatal and postpartum EPDS scores 
were also explored. This analysis aimed to investigate specific covariates that would 
explain a drop or rise in antenatal to postpartum EPDS scores. The ‘average’ EDPS 
score [APA score = (T1 + T2)/2] can be seen as an indication of overall perinatal 
depression not specific to either an antenatal or postpartum time point; identified 
covariates contributing to the average score would indicate common underlying 
factors. The ‘difference’ in EPDS scores [DPA score = (T1 − T2)] corresponds to the 
improvement or worsening in EPDS score from the antenatal to the postpartum 
time point; covariates contributing to the difference of T1 to T2 score, would 
indicate differentiating factors. 
Finally the possibility of a stratification of patients based on the results of the 
questionnaires was explored. To explore whether the regression model would be 
suitable for prediction, and not only to find important covariates of EPDS scores, 
predictions derived from the model were compared with predictions from a state-
of-the-art machine learning prediction algorithm, extreme gradient boosting, 
utilising the xgboost R package. In addition, the analysis aimed to establish how far 
an EPDS score in the third trimester could directly predict an EPDS score at 6-10 
weeks postpartum. The predictive power under a range of cut-off values was 
assessed with measurements of the area under the ROC curve.  
Negative Predictive Values (NPV) and Positive Predictive Values (PPV) were 
calculated to explore the predictive capacity. PPV was calculated using the number 
of ‘true positives’ i.e. those with the risk factor who screened positive on the EPDS, 
and ‘false positives’ i.e. those with the risk factor but did not screen positive on the 
EPDS. PPV = (true positives)/ (true positives + false positives). NPV was calculated 
with the ‘true negatives’, i.e. those without the risk factor who screened negative 
on the EPDS, and the ‘false negatives’, i.e. those who do not have the risk factor but 
did screen positive on the EPDS. NPV = (true negatives)/ (true negatives + false 
negatives). Sensitivity and specificity were then calculated. The interpretation of 
these values will demonstrate the usefulness of this risk factor in the clinic. 
2.10.2 Statistical analysis of laboratory data 
 
The laboratory analysis of biomarkers from patient blood samples was carried out 
for a selection of participants with complete antenatal and postpartum EPDS 
scores. This group was interrogated for relationships between biomarkers, EPDS 
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score and psycho-socioeconomic variables. Concentrations of circulating 
biomarkers were calculated from the results of the IL-6, IL-10 and BDNF assays.  
BDNF data 
As described earlier in this chapter, BDNF concentration was calculated with the 
use of a Quantikine ELISA kit. Mean absorbance, calculated as optical density (OD), 
was determined. The coefficient of variation (CV), standard deviation (SD) and 
standard error of the mean (SEM) were calculated for each sample. Mean 
concentration and coefficient of variability (CV) was generated for each sample. The 
CV for each sample is defined as the ratio of standard deviation (σ) to the mean (µ): 
CV=σ/µ, and is calculated as a percentage (x 100). The average of the individual CVs 
is reported as the intra-assay CV.  CV <20% was considered acceptable. Standard 
curves were generated from the concentration of standards with known 
concentrations by using a 4-parameter logistic (4-PL) curve-fit as shown in Figure 
2.6. Mean OD of each sample was compared against the curve to determine the 
sample concentration.  
 
Figure 2.9 A 4-PL logistic curve was generated for each plate following the completion of BDNF 
assay. 
The lowest level of detection (LLOD) is the lowest measurable value that is 
statistically significant from zero and is calculated by adding two standard 
deviations to the mean OD value of several zero standards – the corresponding 































concern for this assay, since BDNF levels tended to be at the higher end of the 
curve.  
IL-6/IL-10 data 
IL-6 and IL-10 concentrations were calculated similarly following MSD assays using 
MSD V-Plex Custom Cytokine assays as previously described. Known concentrations 
of standards were used to determine unknown sample concentrations based on 
the standard curve. An example of the standard curve for an IL-6 assay and the 
associated calculations are shown in Figure 2.7 and Table 2.9. The median LLOD for 
the MSD assays were 0.06pg/mL for IL-6 and 0.03pg/mL for IL-10. 
 
  
Figure 2.10. The standard curve generated by the standards on an IL-6 MSD assay with 
calculated sample concentrations plotted next to the standard curve in red. 
95 
 
Table 2.9. Concentrations (pg/mL) of the 9 points of the standard curve based on the corresponding 
signal generated in each well. Each standard was inputted in duplicate and mean and CV values 
were calculated. 
Sample Conc. Signal Mean Signal Calc. Conc. Mean Conc. % CV (Calc. 
conc.) 
S001 750 1013433 1001322 801.61 792.14 1.69 
S001 750 989211 1001322 782.68 792.14 1.69 
S002 188 253319 247226 204.56 199.71 3.43 
S002 188 241132 247226 194.87 199.71 3.43 
S003 46.9 55521 55183 46.00 45.73 0.85 
S003 46.9 54844 55183 45.45 45.73 0.85 
S004 11.7 12867 13013 10.91 11.04 1.56 
S004 11.7 13158 13013 11.16 11.04 1.56 
S005 2.93 3269 3202 2.81 2.75 2.95 
S005 2.93 3135 3202 2.70 2.75 2.95 
S006 0.732 806 811 0.68 0.68 0.82 
S006 0.732 815 811 0.69 0.68 0.82 
S007 0.183 263 263 0.20 0.20 0.00 
S007 0.183 263 263 0.20 0.20 0.00 
S008 0.04575 118 123 0.06 0.07 8.52 
S008 0.04575 127 123 0.07 0.07 8.52 
S009 0 48 46 0.00 0.00 NaN 
S009 0 43 46 0.00 0.00 NaN 
 
Concentrations were log transformed to achieve normality in order to prepare for 
statistical analysis, to aid the interpretation of patterns and to meet the 
assumptions of statistical testing. Concentrations were calculated for IL-6, IL-10 and 
BDNF, and a ratio of IL-6/IL-10 was also determined. Reference ranges were 
calculated for each biomarker to highlight any outliers (±1.96 SD). Positive 
Predictive and Negative Predictive Values (PPV/NPV) were calculated for the 
biomarkers using the reference rage as a cut-off as previously described to 
determine the accuracy of this test. ‘Healthy’ patients with EPDS <10 were 
compared with those screening positive for antenatal depression. Associations 
between biomarkers and EPDS score, as well as psycho-socioeconomic variables 
were then tested for statistical significance. Patient concentrations of each 
biomarker were entered as continuous variables into linear regression models to 




Calculation of biomarker z-scores         
In order to generate an overall inflammatory score to input into the analysis, z-
scores were calculated using combined data from each of the biomarkers. The 
method used was based on other studies analysing the effects of inflammatory 
biomarkers273. The study mean (µ) for each biomarker was first calculated based on 
individual biomarker concentrations (x), in addition to the standard deviation (σ). 
The z-score for each biomarker was calculated using: (x - µ)/σ. These were then 
combined for IL-6, IL-10, IL-6/IL-10, and BDNF. Direction of expected association 
was taken into account when generating z-scores.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Genotyping data 
Genotyping data was interpreted as either ‘presence’ or ‘absence’ of the minor 
allele, due to the relatively small sample size (N=480). The number of copies of the 
allele was additionally explored in the analysis in terms of contribution to 
depressive risk. Frequencies of each of the three genotyped SNPs were determined 
and compared to the published allele frequencies. Chi squared (χ2) tests were then 
used to examine whether differences between observed and expected genotype 
frequencies are significant using the equation:  
2 =  (observed - expected)2 
                    expected 
 
Odds ratios and 95% confidence intervals were calculated for each SNP. 
Correlations were examined to test for any significant associations between the 
selected variables and SNP status. This was carried out for those participants with 
and without a family history of PND to test for any differences when a known family 
association is present. Relationships between genotype and depressive risk were 
explored, in addition to any genetic associations with Average (APA) and Difference 
(APA) EPDS scores. 
In Chapter 6 of this thesis, the combined analysis of psycho-socioeconomic data 
and laboratory data is presented. The main study cohort that the laboratory work 
explores comprises of women who completed the full study protocol. Biomarker 
data from the laboratory aspect of this study is available for these women, and 
findings from this cohort will be described in Chapter 4. In addition, genetic data is 
available for selected participants with complete data; results from this analysis is 
presented in Chapter 5. For this final group, full EPDS scores, biomarker data and 
genetic data are available. These cohorts have been analysed separately, as 
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displayed in Figure 2.11, and modelling has additionally been applied to identify key 
psycho-socioeconomic risk factors, which can be seen in the relevant Chapters. 
Combined analysis of biomarker, genetic and psycho-socioeconomic data are 
presented in Chapter 6. 
  
Figure 2.11. The study cohorts involved in the project with tests performed for each 
group and frequencies in each cohort. 
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3 Results: Psycho-socioeconomics 
 
3.1 Chapter Three Abstract 
 
This study aims to explore the relationship between certain factors linked with 
lifestyle, health and social factors, and PND. This chapter address aims 1 & 2: ‘Can 
psycho-socioeconomic risk factors predict antenatal and postpartum symptoms of 
PND?’ and ‘Is PND heterogeneous and can timing of onset/remission be predicted 
from risk factors?’ This analysis will investigate independent or alternatively inter-
related risks that exert different effects on depression susceptibility during 
different stages of pregnancy as women progress from the antenatal period to the 
early postpartum period. This additionally explores the heterogeneity question - 
whether antenatal and postpartum depression are themselves distinct syndromes, 
or whether an umbrella category of perinatal depression will suffice.  
The study comprises of women who completed the antenatal EPDS at time point 1 
(N=1579) and those who completed both the antenatal and postpartum EPDS at 
time points 1 and 2 (N=872). Analyses are presented in this chapter into two main 
parts – associations with antenatal EPDS score and associations with postpartum 
EPDS score. A sub-group of N=480 was first the target of a statistical pilot study 
based on the predictive potential of psycho-socioeconomic factors. This reveals 
that a history of anxiety and social status are the two biggest predictors of antenatal 
depressive symptoms, while a history of depression or PND and a family history of 
PND contributed most to postpartum depressive symptoms. Figure 3.5 depicts the 
key factors characteristics to influence both antenatal and postpartum scores as a 
result of regression modelling. It was found that the covariates recorded in this 
study are better suited to predicting antenatal EPDS scores than postpartum scores. 
The heterogeneity of PND was next explored, with risk groups based on the 
trajectories of depressive symptoms, supporting the theory of heterogeneity in 
PND. Important findings from this sub-group are then explored and validated in the 
larger cohort, which is presented later in the combined analysis in Chapter 6. 
Laboratory analysis of biomarkers and genetics has also been carried out for the 
sub-group and is presented in Chapters 5 and 6. The sub-group analysis explores 
the heterogeneity of PND, with an in depth look at EPDS changes, whereas the main 
analysis explores the specific contribution of risk factors to EPDS score. 
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The study comprises of a further group of women recruited from a secondary site, 
Coventry Hospital (UHCW), and this data has been analysed in the same fashion 
and is presented in this chapter. Statistical analyses have been carried out for those 
who completed antenatal EPDS (N=448) and both antenatal and postpartum EPDS 
(N=302). When comparing the Warwick and Coventry cohorts, both distinct and 
shared risk factors have been identified, such as a young age, lack of support and a 
history of anxiety contributing to antenatal depressive symptoms across both 
cohorts. Differences and similarities between the two study populations are 
presented in this chapter. 
The chapter opens with an examination of the general characteristics of the study 
cohorts to assess the ability to generalise these findings to a wider population and 
to explore any potential bias in the results. For the initial statistical analysis, 
exploratory analyses were carried out, observing differences between controls and 
cases, defined by a score on the EPDS ≥ 10. A more detailed picture of these 
associations was then explored further with linear regression modelling, to assess 
the ability of selected factors to predict EPDS score. This tested whether using the 
EPDS in pregnancy can predict postpartum outcomes, and to assess whether this is 
optimised with use of a cut-off score or a raw score. This chapter presents these 
results of the statistical analyses conducted to test the relationships between 
psycho-socioeconomic variables and PND.  
 
3.2 Sub-Group Analysis 
 
3.2.1 EPDS score distributions & cohort characteristics 
 
The sub-group consisted of 480 matched pairs with completed antenatal and 
postpartum EPDS scores recruited from Warwick Hospital. In this group a 
prevalence of 11.5% was identified for antenatal (n=55) and 14.8% (n=71) for 
postpartum depressive symptoms. This falls within the estimated 10-15% shown by 
other studies. Initial analysis showed that the majority of the women in the data 
set were White British (84.6%), educated to a minimum of degree level (55.9%), 
were in the 30-34 age group (37.7%), had a 1st trimester BMI of 18.5 – 24 (47.9%), 
had a social status of higher managerial/professional (35.2%), were not on any 
medication (84.6%) or Omega 3 supplements (76.3%), and had consumed alcohol 
before pregnancy (68.3%) but did not drink during pregnancy (97.3%). The majority 
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did not have a history of anxiety (86.7%), or depression (89.6%), did not smoke at 
any time prior to pregnancy (88.8%), did not smoke during pregnancy (96.5%) and 
had no family history of PPD (84.0%). The great majority were supported (98.3%), 
44.8% had one child prior to the pregnancy, and 52.1% delivered a baby boy.  
Distribution and frequencies of EPDS scores are displayed in Figure 3.1 (studies 
comparing the antenatal (T1) and postpartum (T2) EPDS scores are also shown in 
the Penalised Regression analysis and prediction section). Groups were created 
with the use of a cut-off score to classify patients according to temporal patterns 
of depressive symptoms. Using the cut-off of 10 to categorize EPDS scores as ‘high’ 
or ‘low’ risk, the risk trajectory defined by EPDS scores during pregnancy and 
postpartum period determined classification of participants into four groups for the 
initial analysis (Table 3.1). Group 0 represents a low risk trajectory, Group 3 an 
overall high-risk trajectory, and Groups 1 & 2 transient risk trajectories with either 
an increase (group 1) or decrease (group 2) in postpartum EPDS scores.  
Table 3.1. Distribution of the cohort within created Group variables. 
Group Total N % 
0 - Overall Low Depressive Risk 379 79.0 
1 - Low antenatal risk, High risk postpartum 46 9.6 
2 - High antenatal risk, Low risk postpartum 30 6.3 
3 - Overall High Depressive Risk 25 5.2 
 
Those with raised EPDS scores postpartum only (group 1) represented the largest 
group of ‘high risk’ patients with 45% of the total (n=101). Group 1 had a median 
antenatal EPDS score of 6 and median postpartum score of 12. The proportion of 
women with raised EPDS either antenatally (group 2) or at both assessment time 
points (group 3) was 30% and 25%, respectively. Group 2 has a median antenatal 
score of 13 and postpartum score of 6, whereas Group 3 exhibited the highest 
median values with an antenatal EPDS median score of 15 and postpartum EPDS of 
16. Patients from group 3 (high risk both antenatally and postpartum) appear to 
exhibit the most severe symptoms according to EPDS scores; median values of both 
antenatal and postpartum scores were within the moderate depression range as 
proposed by McCabe-Beane274. In contrast median values of raised EPDS in groups 
1, and 2 were within the mild depression range. 
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Previous studies also investigated predictive accuracy of the antenatal EPDS for 
postpartum EPDS at different cut-offs. For a comparison with these studies the use 
of different cut-offs was explored in this study. Using a cut-off of 10, the distribution 
of ‘at-risk’ patients across the three groups was 45% in group 1, 37% in group 2 and 
28% in group 3. Increasing the cut-off to 13 (to include patients with MDD 
symptoms only) did not significantly alter the relative distribution of each group, 
with a similar distribution of 43%, 30% and 27% for groups 1, 2 and 3 respectively 
(Figure 3.1b). However, decreasing the cut-off to 8 shifted the relative distribution 
of ‘at-risk’ patients and resulted in approximately equal numbers across the three 
groups (34% in group 1, 32% in group 2 and 34% in group 3): this redistribution was 
characterised mainly by an increase in the size of both groups 2 and 3 and a 
concomitant reduction by 10% in the size of group 1. Figure 3.1a demonstrates a 
higher number of women scoring 8/9 in the antenatal EPDS compared to 
postpartum EPDS, resulting in the inclusion of more women at risk of AND in groups 
2 and 3 when the cut-off was lowered to 8. 
It has been proposed that the EPDS score correlates with symptoms severity103 274: 
scores below 10 are suggestive of minimal depression, 10-12 of minor depression 
and ≥13 of major depression. In our cohort of the 55 women screening positive for 
antenatal depressive symptoms, 45% had scores in the 10-12 range (at risk of minor 















Group 1 Group 2 Group 3
Figure 3.1. (a) Distribution of antenatal and postpartum EPDS scores within the cohort. Dashed 
line indicates cut-off score of 10 used to indicate depressive risk. (b) Comparison of distributions 
using cut-off scores of 8, 10 and 12. 
(a) 
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screening positive for postpartum depressive symptoms, 48% had EPDS scores in 
the 10-12 range, whilst 52% scored ≥13. 
3.2.2 Shifts between severity risk categories 
 
Table 3.2 further classifies women who screened ‘positive’ in the EPDS into two risk 
categories: risk of minor depression (10-12), and major depression (≥13). In 
addition to moving from a negative to a positive screen for depressive symptoms 
and vice versa, women also shifted in severity category. These severity shifts were 
also bidirectional with observed increases as well as decreases in EPDS scores from 
antenatal to postpartum period.  
79% (n=379) of women remained in the low risk category throughout the period of 
the study (24 weeks of pregnancy up to 10 weeks postpartum), whereas 21% of 
women had raised risk of PND during pregnancy or postpartum or both. Group 1 
included 46 women who were low risk during pregnancy, but moved to high risk 
postpartum: 64% exhibited EPDS scores in the minor depressive risk category (10-
12) and 37% had scores in the MDD risk category (≥13). Likewise, group 2 includes 
women (n=30) who shifted to low-risk postpartum (<10) from high risk during 
pregnancy: 60% had antenatal EPDS scores in the minor category, whereas 40% had 
scores in the MDD category. Group 3 included a small number of women (n=4) who 
had their antenatal EPDS scores increased from the minor risk category to MDD risk 
category postpartum, whilst only two women with high (≥13) antenatal EPDS scores 
shifted to the minor category postpartum. Moreover, in 64% women in group 3, no 
differences in the severity category were observed. 
Table 3.2. Cross-tabulation of antenatal (AND) and postpartum depressive symptoms (PPD) risk 




Total ≤ 9 10-12 ≥13 
Antenatal score ≤ 9 379 29 17 425 
10-12 18 3 4 25 
≥13 12 2 16 30 





3.2.3 Multinomial logistic regression – group analysis 
 
Initial bivariate chi-squared analysis identified 11 potential correlates associated 
with antenatal/postpartum depressive symptoms, which were further analysed 
(Tables 3.3 and 3.4). All risk factors with a p<0.05, either pre- or post-delivery, were 
included in a multinomial regression model for the group analysis. The p-value for 
this model was .0002 and the overall model is therefore statistically significant. The 
low risk group was used as a baseline category. Relative risk values (RR) were 
calculated to give a better understanding of the magnitude of association between 
covariates as risk factors and the three groups with distinct risk trajectories. (Table 
3.5). 
Table 3.3. Odds ratios and 95% CI for all variables which demonstrated significance in Chi-squared 
analysis for antenatal depressive symptoms. 
Factor OR 95% CI 
Age 1.064421 0.7882357, 1.437377 
Social status 1.465595 1.191677, 1.802476 
Support 0.4204886 0.0773037, 2.287221 
Education 0.7729944 0.6347195, 0.9413929 
Medication 1.034493 0.8022022, 1.334048 
History of depression 2.295905 1.073715, 4.909291 
History of anxiety 2.089739 1.025862, 4.256915 
Gestational length 0.9734467 0.955314, 0.9919235 





Table 3.4. Odds ratios and 95% CI for all variables which demonstrated significance in Chi-squared 
analysis for postpartum depressive symptoms. 
 
Table 3.5. Relative Risk (RR) values for significant variables within each at risk group. 
 
For group 1 (high postpartum score only), significant risk factors were found to be 
past history of PPD (N=27) and past history of depression (N=50). In group 2 (high 
antenatal score only), risk factors were a past history of anxiety (N=64), age <24 
(N=44) and ethnicity other (N=43), although it is important to note that 84.6% of 
the cohort were White British. An age of 40+ also increased the risk of being in 
Group 2 (RR=4.17) but this association was not quite significant and was relevant 
to <10% of the cohort. In group 3 (high antenatal and postpartum score), past 
history of depression was the only significant risk factor.  
 
3.2.4 Penalised regression analysis and prediction 
 
In the previous section covariates were identified which constitute major risk 
factors for either group 1 (history of PPD, history of depression), group 2 (history of 
anxiety, ethnicity, age), or group 3 (history of depression). It is likely that 
dichotomising EPDS scores results in loss of statistical power; it also depends on 
specific cut-off values. The regression analysis was then repeated on the full range 
of EPDS scores without dichotomisation. The relationship between the antenatal 
Factor OR 95% CI 
History of PND   3.287746 1.287778, 8.393746 
Family history of PND   1.530038 0.8929046, 2.621797 
History of depression 3.208556 1.661414, 6.196427 
Group Risk factors 
1 – High postpartum risk Past history of PPD (p=0.017, RR=3.78) 
Past history of depression (p=0.034, RR= 2.76) 
2 – High antenatal risk Past history of anxiety (p=0.013, RR= 3.55) 
Ethnicity - Other (p=0.006, RR= 5.19) 
Age - <24 (p=0.010, RR= 6.39) 
3 – Overall high risk Past history of depression (p=0.045, RR=3.51) 
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(T1) and postpartum (T2) EPDS scores, with a correlation of 0.5002, is shown in 
Figure 3.2. The deviance from perfect correlation and alignment can be attributed 
to any systematic change (drop or increase) in depressive symptoms from before 
to after delivery, but also to unexplained variability (noise) in the acquisition of 
EPDS scores.  This analysis aimed to elucidate the underlying characteristics 
contributing to this observed deviation between antenatal and postpartum EPDS 
scores by looking at the association between severity, timing and covariates. We 
examined distinguishing as well as common covariates across antenatal and 
postpartum scores 
  
Figure 3.2. Ante- vs postnatal EPDS scores for 474 individuals (correlation 0.5002). Points are jittered 
randomly for better visibility. Sections of the graph represent groups created in the previous 
analysis. Mean EPDS scores are shown for each group. 
 
In the following section linear as well as nonlinear regression analyses are 
presented for the antenatal and postpartum EPDS scores, for the difference 
between them and finally for their average. The purpose of these four analyses is 
to explore whether covariates contributing to a high antenatal score are different 
from covariates contributing to a high postpartum score and which covariates 
















Antenatal EPDS score 
Variables contributing to a linear model for antenatal EPDS scores were selected 
using penalised regression. Coefficients for the selected variables were calculated 
by standard linear regression. Coefficients with a p< 0.05 are shown in Table 3.6. 
Table 3.6. Significant covariates of a linear model for antenatal EPDS scores. Positive or negative 
coefficients indicate by how much the EDPS score increases or decreases with the covariate. 
Covariate Coefficient p-value 
Social status - Routine/semi-routine 1.768 <0.001 
Social status - Unemployed/student 3.887 0.004 
Education > 18 years -1.373 0.033 
BMI ≥30 - Yes -0.581 0.037 
Alcohol pre-pregnancy - Yes 0.813 0.049 
Family history of PPD, 1st degree relative - Yes 1.391 0.012 
Past history of anxiety - Yes 2.314 <0.001 
 
Covariates that appeared particularly important in the prediction of antenatal EPDS 
scores were ‘past history of anxiety’ contributing around 2 points toward the EPDS 
score, the most significant contribution in terms of a p-value, with further 
contributions identified from social status of ‘unemployed/student’, contributing 
almost 4 points towards the antenatal EPDS score, and ‘semi-routine/routine’ work 
contributing about 1.8 points. Other significant contributions come from a ‘family 
history of PPD’ as well as ‘alcohol consumption’. Marginal protective effects were 
identified from education beyond 18 years and a higher BMI. A model was also 
fitted adding all pairwise interactions. However, the cross validated mean squared 
prediction error was unchanged indicating that adding interactions does not 
improve predictive power and therefore such models or any models with higher 





Postpartum EPDS scores  
As previously described a linear model for postpartum EPDS scores was selected 
using penalised regression. Coefficients with a p<0.05 are shown in Table 3.7. Fewer 
covariates were identified as significant compared to the antenatal EPDS score 
model. ‘Past history of depression’, ‘past history of PPD’ and ‘family history of PPD’ 
contributed about 2.8, 2.2, and 1.8 points to the postpartum EPDS, respectively. 
Information about pre-existing illness and associated medication as well as level of 
education improved prediction accuracy although their effect was not statistically 
significant.  
Table 3.7. Significant covariates of a linear model for postpartum EPDS scores. 
Covariate Coefficient p-value 
Past history of PPD - Yes 2.204 0.014 
Past history of depression - Yes 2.788 <0.001 





3.2.5 Differences and commonalities between antenatal and postpartum 
EPDS scores 
 
Systematic differences between antenatal and postpartum EPDS scores were next 
explored in terms of potentially different sets of covariates, and covariates that 
would explain the drop or rise in antenatal to postpartum EPDS scores observed in 
many subjects. Therefore, we investigated within-person patterns of change by 
analysing the contribution of covariates to the differences and averages of 
postpartum (T2) and antenatal (T1) EPDS scores. The ‘average’ EDPS score [APA 
score=(T1+T2)/2] can be seen as an indication of overall perinatal depression not 
specific to either an antenatal or postpartum time point; identified covariates 
contributing to the average score would indicate common underlying factors. The 
‘difference’ in EPDS scores [DPA score= (T1-T2)] corresponds to the improvement 
or worsening in EPDS score from the antenatal to the postpartum time point; 
covariates contributing to the difference of T1 to T2 score, would indicate 
differentiating factors. The relationship between difference and average score is 
illustrated in Figure 3.3a. The two components are also indicated as average and 
Figure 3.3. (a) A schematic of the relationship between contribution of covariates identified by a linear 
model to the differences and averages of postpartum and antenatal EPDS scores. The ‘average’ EDPS 
score at T1 and T2 time points (APA score) can be seen as an indication of overall perinatal depression 
not specific to either an antenatal or postpartum time point. The ‘difference’ in EPDS scores (DPA 
score) corresponds to shifts in EPDS score from the antenatal to the postpartum time point indicative 
of improvement or worsening. (b) Representative case studies of cohort patients with covariates that 
shift DPA and APA scores. Subject #5 who had two covariates with negative coefficients, a ‘previous 
history of anxiety’ and a ‘social status of student/unemployed’, exhibited a significant drop in the DPA 
score. Subject #482 had a covariate with positive coefficient, a ‘previous history of depression’ and 
exhibited an increase in the DPA score. In this patient, the covariates ‘past history of PPD’ as well as 
‘past history of depression’ might contribute to the APA score. Subject #196 had covariates with both 
negative and positive coefficients, a previous history of anxiety’ and ‘previous history of depression’ 
and exhibited a small increase in the DPA score. In this patient, the APA score was also influenced by 
at least 3 covariates with positive coefficients, such as ‘family history of PPD’, ‘past history of 





difference axes in Figure 3.3b shown with real example case studies. Their 
correlation with different sets of predictors is discussed in the following section.  
Difference between postpartum and antenatal EPDS score 
Covariates which contribute to the DPA score were explored in order to find 
correlates explaining why some individuals exhibited a drop in score from before to 
after delivery while others showed the opposite effect. Table 3.8 shows significant 
coefficients of a linear model selected by penalised regression. Negative 
coefficients indicate a decrease from antenatal to postpartum EPDS score, while 
positive coefficients indicate an increase. The clinical significance of a 1 point 
change in EPDS score represents a “small change”, 2-3 points a “medium change” 
and 4 points or higher a “large change”275.  
Based on this regression analysis one would expect covariates that contribute to T1 
EPDS score (Table 3.6) but not T2 EPDS score (Table 3.7) to exert negative 
coefficients in this analysis, since they can explain antenatal but not postpartum 
depressive symptoms. Conversely covariates that show up in Table 3.7 but not 
Table 3.6 are expected to have positive coefficients in the difference analysis, since 
these covariates are associated with postpartum but not antenatal depressive 
symptoms. This was confirmed in our analysis: two differentiating factors between 
antenatal and postpartum scores were a ‘past history of anxiety’ or a social status 
of ‘student/unemployed’. In the current analysis they were both associated with a 
drop in the EPDS score by over 2 points from before to after delivery. The reverse 
was also observed, and a ‘past history of depression’, which was significant for 
postpartum EPDS score only (Table 3.7) contributed to an increase in the EPDS 
score by about 2 points. 
Table 3.8. Significant covariates of a linear model for the difference of antenatal to postpartum 
(DPA) EPDS scores. 
Covariate Coefficient p-value 
Social status - unemployed/student -2.664 0.040 
Past history depression - yes 2.036 0.003 




Average of postpartum and antenatal EPDS scores 
Significant covariates, which contribute to the average of postpartum and antenatal 
EPDS scores indicate subject characteristics underlying both scores and are shown 
in Table 3.9. As expected, a ‘past history of PPD’ as well as ‘past history of 
depression’ and a ‘family history of PPD’ contribute to a higher average EPDS score. 
In contrast, a longer gestation is associated with a reduction in score. Slightly 
surprising, obesity might contribute marginally to a reduction in score, but the 
overall effect was weak. These findings are summarised in Figure 3.3, depicting 
examples of representative case studies. 
Table 3.9. Significant covariates of a linear model for average antenatal and postpartum (APA) EPDS 
scores. 
Covariate Coefficient p-value 
Social status - routine/semi-routine 0.890 0.027 
BMI ≥30 - yes -0.198 0.023 
Alcohol pre-pregnancy - yes 0.764 0.039 
Past history of PPD - yes 1.737 0.021 
Past history depression - yes 2.027 0.001 
Family history of PPD - 1st degree relative 1.574 0.002 
Gestation length / days -0.029 0.029 
 
Prediction of EPDS scores 
Finally, we explored the possibility of a stratification of patients based on the results 
of psychosocial covariates alone without taking EPDS scores into account. To 
explore whether the regression model is powerful enough for prediction of EPDS 
scores as well (and not only for finding important covariates of EPDS scores), we 
compared predictions derived from the four linear models (for antenatal and 
postpartum EPDS, and average and difference EPDS) with predictions from a state-
of-the-art machine learning prediction algorithm, extreme gradient boosting 
(xgboost).  
Table 3.10 shows the result of a ten-fold cross validation (repeated 10 times) of the 
correlation of predicted scores with the measured scores. Interestingly, the linear 
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models perform comparably (or even slightly better) than the state-of-the-art 
machine learning prediction algorithm, which depends very little on any statistical 
assumptions. This indicates that a simple linear model is able to capture most of 
the signal in the data that is suitable for prediction. Prediction accuracy is highest 
for antenatal EPDS score, lower for the postpartum score, and in between for the 
APA score. The available covariates are better suited to predict depression before 
rather than after birth.  
Table 3.10. Ten-fold cross validated correlation of prediction of EPDS scores with original scores 
based on predictors using penalised linear regression (elastic net), linear regression (linear), and 
extreme gradient boosting (xgboost). In brackets the standard deviation based on 20 random 
iterations is displayed. AN= antenatal; PP= postpartum 
 elastic net linear  xgboost 
AN EPDS 0.25 (0.02) 0.27 (0.02) 0.24 (0.02) 
PP EPDS 0.19 (0.02) 0.18 (0.02) 0.16 (0.02) 
DPA EPDS 0.13 (0.03) 0.15 (0.03) 0.13 (0.02) 
APA EPDS 0.21 (0.02) 0.22 (0.02) 0.22 (0.02) 
 
It seems particularly difficult to predict the DPA score, i.e. the change in EPDS score 
from before to after delivery, however a comparison of using psychosocial 
covariates alone versus antenatal scores to predict the postpartum score has been 
done. This reveals a correlation of 0.19 predicting from psychosocial covariates, 
compared with a correlation of 0.50 when predicting from antenatal scores. This 
demonstrates that antenatal EPDS scores are still much better predictors of 
postpartum EPDS scores than generic psychosocial covariates. 
Another way to assess prediction accuracy from a more practical perspective is to 
inspect PPV and NPV when turning predicted scores into predictions of depressive 
symptoms at an EPDS cut-off ≥10 (or ≥ 0 for the DPA score). In this analysis the PPV 
was defined as the percentage of women predicted to have more severe depressive 
symptoms, who actually exhibit EPDS scores ≥10, while the NPV is the percentage 
of women predicted to have minimal symptoms who actually have EPDS<10. The 
result is shown in Table 3.11 for the linear and the xgboost predictor (due to the 
penalisation the absolute score value of the elastic net regression is not 
representative). The comparatively high correlation for antenatal EPDS score in 
Table 3.10 translates into a PPV of around 45% and a NPV of about 85% for the 
linear model and the xgboost predictor. As expected from the weaker correlation, 
predictive performance for the other scores is less impressive. 
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Table 3.11. Ten-fold cross validated positive predictive value (PPV) and negative predictive value 
(NPV) for prediction of depression based on predictors using linear regression (linear), and extreme 
gradient boosting (xgboost). In brackets the standard deviation based on 20 random iterations is 
displayed. AN= antenatal; PP= postpartum 
PPV / NPV linear % xgboost % 
AN EPDS 43(8) / 86(0.1) 47(5) / 86(0.1) 
PP EPDS 32(7) / 81(0.1) 37(6) / 81 (0.1) 
DPA 61(1) / 50(2) 61(1) / 48(2) 
APA 38(7) / 88(0.1) 36(5) / 88(0.1) 
 
Previous studies also investigated predictive accuracy characteristics of the 
antenatal EPDS at different cut-offs276. To carry out a comparison study the analysis 
aimed to establish the predictive performance of the antenatal EPDS score at 
various cut-off values (Table 3.12). To assess the predictive power under a range of 
all possible cut-offs the area under the ROC curve was measured obtaining a value 
of 0.76 shown in Figure 3.4, which confirms previous studies276. Further details on 
predictive performance of the antenatal and postpartum EPDS score are shown in 
Table 3.12. These results are essentially identical to previous studies albeit 
requiring a slight shift in the EPDS cut-off to obtain similar levels of NPV and PPV. 
Table 3.12. Predictive performance of antenatal EPDS score at various cut-offs for a postpartum 
EPDS score ≥ 10 (standard error in brackets). The area under the ROC curve for all cut-offs (see Figure 
3.4) is 0.756.   
 Cut-off ≥ 15 Cut-off ≥ 10 Cut-off ≥ 5 
Sensitivity % (95% CI) 16.3 (3.9) 39.1 (5.1) 79.3 (4.2) 
Specificity % (95% CI) 99.0 (0.5) 90.8 (1.5) 56.5 (2.5) 
PPV % (95% CI) 78.9 (9.4) 50.7 (5.9) 30.5 (3.0) 






Figure 3.4.  ROC curve (convex hull) for prediction of postpartum EPDS score ≥ 10 from antenatal EPDS 










3.3 Warwick Hospital Cohort 
 
Recruitment of participants at Warwick was completed in the five year recruitment 
window from 2014-2019. A total of 1579 participants were recruited and screened 
for PND.  Mean gestation at recruitment was 28 weeks. Although this study is still 
open, at the time of writing, postpartum follow up rate was 55%, with 872 complete 
postpartum screening results.  
3.3.1 Antenatal EPDS – exploratory analysis 
 
EPDS scores ranged from 0-26. In this cohort 16.7% of women screened positive for 
AND, using a score ≥10 on the EPDS. The mean antenatal EPDS score was 5.68 
(SD=4.395). Cohort characteristics for all participants who completed antenatal 
screening (N=1579) are presented in Table 3.13. Women from this cohort were 
generally White British, 30-34 year old first-time mothers with a high social status 
and educated to degree level. They tended to be of good health as non-smokers, 
not taking medication, with a healthy BMI. 
Table 3.13. Cohort characteristics of the study population. Continuous variables are expressed as 
the mean (standard deviation) and categorical variables are expressed in N (%) at each factor level. 
National averages are shown where available277. 
Covariate N (SD) / Mean (%) National average 
Gestation - recruitment (days) 195.9 (5.9)  
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Mode of delivery 
Normal vaginal birth 
Instrument assisted 
Elective C section 





























Women were most commonly (34.6%) aged 30-34.  A high majority of the sample 
were White British (80%). The majority of the sample (43.6%) were primiparous 
(first time mothers). Most women were of a ‘higher managerial/professional’ level 
social status (38.8%). A very high proportion (97%) of women identified as 
‘supported’. Women were most commonly educated to degree level (32.1%). 
A majority (65.8%) drank alcohol in the 12 months prior to conception, although 
almost all (97.9%) stated that they did not drink alcohol during pregnancy, with only 
2% of women reporting drinking alcohol in pregnancy. 83.5% of women were non-
smokers in the 12 months prior to conception – this rose to 95.7% non-smokers 
during pregnancy, with just 4% stating they smoked during pregnancy. 84.7% of 
women were not taking medication during pregnancy. Of those who did take 
medication, the majority took Thyroxine (N=82) or ‘Other’ (N=81). 25.6% of women 
were taking an Omega-3 supplement during pregnancy. BMI was most commonly 
in the category 18.5-24 (39.8%). 
7.9% of women had a past history of PND. 16.5% of the sample had a past history 
of depression. 18.9% had a history of anxiety. 13.6% had a family history of PND. 
Mean total gestational length was 39.4 weeks. Mean birth weight was 7.66 lbs 
(3473.69 grams). 51.4% of babies were male. 50% of deliveries were natural vaginal 
births. Labour was medically induced in 33% of women. 4.7% of babies were born 
premature. 
The first stage of exploratory analysis involved a comparison of controls (N=1315) 
and cases (N=264), defined by EPDS ≥ 10, which found significant differences for a 
number of the selected covariates between the groups. A comparison of the two 
groups is displayed in Table 3.2. Chi-squared and correlation analyses were 
conducted as appropriate.  
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3.3.2 Chi squared & correlation analysis 
 
A comparison of cases and controls was first carried out to identify variables 
displaying statistical significance between the two groups (Table 3.14). Results of 
bivariate analyses are presented in Tables 3.15 and 3.16.  
Table 3.14. Characteristics of study participants (EPDS cut off 9/10) for antenatal depression. 
Significance of Chi squared/correlation statistics are presented. 
Covariate Controls 
(n=1315) 




Mean (SD) / N 
(%) 
p value 
Gestation - recruitment (days) 195.89 (6.142) 195.93 (4.547) 0.886 
Total gestation – delivery (days) 276.68 
(11.099) 











Birth weight (g) 3486.25 
(536.302) 
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p value 
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Mode of delivery 
Normal vaginal birth 
Instrument assisted 
C section in labour 

































Results of bivariate analyses are presented in Tables 3.3 and 3.4. Ten covariates 
were identified as having a significant association with a positive antenatal EPDS 
screen: education, social status, supported, smoking pre-pregnancy, smoking in 
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pregnancy, past history of depression, past history of PND, past history of anxiety, 
mode of delivery and gestational length. 
Table 3.15. Correlation coefficient r and significance reported for continuous variables with p<0.05 
for antenatal depression, using EPDS ≥ 10. 
Covariate r p-value 
Total gestation (days) -0.082 0.015 
 
Table 3.16. Significant values in chi-squared analysis - antenatal depression. For variables with >2 
categories, odds ratios (OR) are presented to compare to a selected baseline group (a). OR values 
were not calculated for variables with any expected counts <5 (b). 






35-39 years    
40-45 years 
>45 yearsb 








































Diploma level Professional 
Self Employed 
Low level supervisor/Technical 
Semi routine/Routine 
Unemployed/Student 











3.3.3 Regression modelling 
 
Results of the linear regression modelling are presented in Table 3.17. In the final 
model (R2 =.14***), variables which improved the model’s prediction of EPDS score 
were history of depression and anxiety, smoking pre-pregnancy, age, education, 
mode of delivery, social status, past history of PND and BMI. 14% of the variance is 
explained by the included predictors. The most important predictors are a past 
history of depression and anxiety, contributing over 2 points to the score each. 




0.014 6.043 2.19 
Smoking in pre-pregnancy 
No 
Yes 
0.000 32.872 2.42 
Smoking in pregnancy 
No 
Yes 
0.004 8.221 2.16 
Past history of depression 
No 
Yes 
0.000 105.669 4.40 
Past history of PND 
No 
Yes 
0.000 27.780 2.80 
Past history of anxiety 
No 
Yes 
0.000 77.095 3.50 
Mode of delivery 
Normal vaginal birtha 
Instrument assisted 
C section in labour 
Elective C section 







Unemployment adds 1.5 points to the score, and age of either 18-24 or 40-45 adds 
around 1.4 points. Smoking pre-pregnancy adds 1.1 point to the score.  
The link between educational level and EPDS score suggests that the lowest level 
of education (no exams) is associated with protection against depressive 
symptoms, but this was not found to be statistically significant although it improved 
the model, and must be interpreted with caution due to the small sample size of 
this category (N=21, 1.3%). Women with a planned Elective C-section had a 
significantly increased risk, although interpretation of this is limited since it is 
unknown whether the C-section was planned prior to EPDS screening. Higher social 
status is associated with lower antenatal EPDS (higher managerial and supervisor), 
whereas all levels below this have a risk of increased EPDS score. BMI is difficult to 
interpret, with a higher BMI appearing to be related to lower EPDS scores.  
The optimal model shown includes all variables that improve prediction, based on 
exploratory regression modelling. The initial stepwise modelling found the optimal 
model explains 15% of the variability in scores. For categorical variables, levels 
which improve the model’s prediction are shown. 
Table 3.17. Results of a linear regression model with antenatal EPDS score as the outcome (N=1579) 
with a number of selected predictor variables based on exploratory modelling. 
 B SE B β 
Constant 
Age 





(baseline – degree level) 
No exams 
Mode of delivery 
(baseline – normal vaginal birth) 
Elective C section 
Social status  
(baseline – Higher managerial/professional) 
















































 B SE B β 
Unemployed/student 
 




Past history depression 
 
















































R2 = .14, F=18.253. *p<.05, **p < .01, ***p < .001.  
 
3.3.4 Postpartum EPDS – exploratory analysis 
 
872 participants of the study completed the postpartum EPDS. This screening 
identified a prevalence of 19.8% (N=173) for PPD, based on EPDS ≥ 10. Scores on 
the EPDS ranged from 0-26 with a mean score of 5.96 (SD= 4.640). Cohort 
characteristics of all participants who completed the postpartum EPDS are 
displayed in Table 3.18. 
Table 3.18. Cohort characteristics for all participants who completed the study protocol with 
postpartum follow up. Continuous variables are expressed as the mean (standard deviation) and 
categorical variables are expressed in N (%) at each factor level. 
Variable N (SD) / Mean (%) 
Gestation - recruitment (days) 196.05 (5.966) 







Birth weight (g) 3474.32 (537.021) 
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Family history of PND 
No 












Mode of delivery 
Normal vaginal birth 
Instrument assisted 







Variable N (SD) / Mean (%) 
Elective C section 166 (19.4) 













Women were most commonly primiparous, aged 25-29, White British, educated to 
Degree level and in a Higher Managerial/Professional occupation. Women were 
generally healthy with a BMI of 18.5-24 and not taking any Medication. 68.3% of 
women did drink alcohol in pre-conception, falling to 2.6% during pregnancy. 88.4% 
were non-smokers, rising to 97.7% in pregnancy. 12.7% had a past history of 
depression, 6.5% of PND, and 15.3% of anxiety. A family history of PND was present 
in 13.8% of women. Babies were most commonly born by normal vaginal delivery 
(53.6%), with 19.5% electing for a C section. Labour was not induced in the vast 




3.3.5 Chi squared & correlation analysis 
 
A comparison of cases and controls was first carried out to identify variables 
displaying statistical significance between the two groups (Table 3.19). Results of 
bivariate analyses are presented in Tables 3.20 and 3.21. Significant variables 
associated with postpartum EPDS based on correlation or Chi-squared analyses 
were: antenatal EPDS score, positive antenatal EPDS screen, total gestation (days), 
parity, education level, past history of depression, past history of PND, and past 
history of anxiety. 
Table 3.19. Characteristics of study participants (EPDS cut off 9/10) for postpartum depression. 
Significance of chi-squared analysis is reported / point-biserial correlations for continuous variables. 
 Controls 
(n=699) 




Mean (SD) / N (%) 
p 
value 
Antenatal EPDS 4.57 (3.353) 8.57 (5.094) 0.000 





Gestation - recruitment (days) 196.05 
(6.338) 
196.08 (4.146) 0.924 
Total gestation – delivery (days) 277.04 
(10.757) 












Birth weight (g) 3487.04 
(531.547) 





































Mean (SD) / N (%) 
p 
value 


































































































































Diploma level Professional 
Self Employed 











































































































































Family history of PND 
No 





















Mode of delivery 
Normal vaginal birth 
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Table 3.20. Correlation coefficient r and significance reported for continuous variables with p<0.05 
for postpartum depression, using EPDS ≥ 10. 
Covariate r p-value 
Antenatal EPDS score 0.339 0.000 
Total gestation (days) -0.077 0.033 
Table 3.21. Variables significant in chi-squared analysis - postpartum depression. For variables with 
>2 categories, odds ratios (OR) are presented to compare to a selected baseline group (a). OR values 
were not calculated for variables with any expected counts <5 (b). 
Covariate p value Χ2 Odds ratio 








































Past history of depression 
No 
Yes 
0.000 50.811 4.25 
Past history of PND 
No 
Yes 
0.000 29.062 4.12 
Past history of anxiety 
No 
Yes 
0.003 8.876 1.87 
 
3.3.6 Regression modelling 
 
Results of the optimal linear regression model selected for prediction of 
postpartum EPDS scores are shown in Table 3.22. In the final model (R2 = .24***), 
eleven predictors made significant contributions to postpartum EPDS score: 
screening positive in antenatal screening (EPDS≥10), past history of depression, 
past history of PND, parity (4 or 5 previous children), age <18, smoking, drinking, 
gestational length and BMI (35-39). Despite the contribution of educational level 
and medication to prediction in the model, these variables did not reach statistical 
significance. 24% of the variance in EPDS scores can be explained by the model. 
Table 3.22. Results of a linear regression model with postpartum EPDS score as the outcome (N=872) 
with a number of selected predictor variables. 
 B SE B β 
Constant 
 
















 B SE B β 
Past history depression 
 
Past history PND 
Parity (baseline – 0) 
4 
5 
Education (baseline – Degree) 
Diploma level 









Total gestational length 






























































 R2 = .24. *p < .05, **p < .01, ***p < .001. 
 
To explore whether the addition of raw EPDS scores would improve the model, the 
model was re-run with antenatal EPDS score as a further predictor variable in place 
of the cut-off screen (Table 3.23).  
Table 3.23. Results of a linear regression model with postpartum EPDS score as the outcome (N=872) 
predicted by a number of selected predictor variables, including antenatal EPDS score. 
 B SE B β 
Constant 
 
Antenatal EPDS score 
 






















 B SE B β 
Past history PND 
Parity (baseline – 0) 
4 
5 
Education (baseline – Degree) 
Diploma level 









Total gestational length 

























































R2 = .32. *p < .05, **p < .01, ***p < .001. 
 
Overall the model now predicts 32% of the variability in postpartum EPDS scores 
(R2 = .32), which is an improvement on 24% when using the cut-off in place of raw 
score. The model was also run excluding antenatal EPDS completely, to test the 
importance of adding this to the model. The model predicts just 15% of the 
variability without antenatal EPDS, which demonstrates its predictive power in the 
model. Overall, prediction is improved with the inclusion of antenatal EPDS 
screening in the model, and is further improved still by inputting EPDS as a raw 
score rather than a dichotomised cut-off value. 
 
In this cohort a number of important variables for both antenatal and postpartum 
EPDS have been identified by linear regression modelling. Since antenatal EPDS 
exerts a strong influence over postpartum EPDS scores, variables predicting 
antenatal EPDS can be considered as indirectly influencing postpartum EPDS score, 




Figure 3.5. Variables predicting antenatal EPDS in regression modelling indirectly influence 






















3.4 Coventry Hospital Cohort 
 
A total of 448 women were recruited at the antenatal stage at University Hospital 
Coventry and Warwickshire (UHCW), known as the Coventry Hospital cohort. 
Postpartum follow up rate for this cohort was 67% resulting in 302 participants with 
complete postpartum screening results. Mean gestation at recruitment was 29 
weeks. 
3.4.1 Antenatal EPDS – exploratory analysis 
 
Screening identified a prevalence of 18.1% for AND in the study population, using 
a score ≥10. EPDS scores ranged from 0-21 with a mean score of 5.85. Cohort 
characteristics are presented in Table 3.24. 
Table 3.24. Cohort characteristics of the study population. Continuous variables are expressed as 
the mean (standard deviation) and categorical variables are expressed in N (%) at each factor level. 
Covariate N (SD) / Mean (%) 
Gestation - recruitment (days) 202.59 (22.36) 






































Covariate N (SD) / Mean (%) 
30-34 years 






































































































Family history of PND 
No 






Mode of delivery 
Normal vaginal birth 
Instrument assisted 
Elective C section 























70.5% of women were White British. The majority were aged 30-34, with a BMI of 
18.5-24. Most were in full time employment (55%). 53% of women owned their 
own housing. 48.7% were first time mothers. 68.5% of women did not drink alcohol 
pre-pregnancy. 99.3% did not report drinking during pregnancy. The majority of 
women were non-smokers (88.4%), rising to 94.6% during pregnancy. 11.6% of 
women had a family history of PND. Almost all women (97.3%) were supported in 
their pregnancy. 
The majority of women had no obstetric history (69.7%), although 24.3% had 
suffered with previous miscarriage. 50.4% of babies born were female. The majority 
of deliveries were normal vaginal deliveries (55.4%). Mean total gestation was 38.8 




Chi squared & correlation analysis 
A comparison of cases and controls was first carried out to identify variables 
displaying statistical significance between the two groups (Table 3.25).  
Table 3.25. Characteristics of study participants from the Coventry cohort for cases and controls 




Mean (SD) / N (%) 
Cases 
(n=81) 
Mean (SD) / N (%) 
p 
value 
Gestation - recruitment (days) 202.62 (23.32) 202.47 (17.47) .905 











































































Mean (SD) / N (%) 
Cases 
(n=81) 






































































































Mean (SD) / N (%) 
Cases 
(n=81) 





















































Family history of PND 
No 











Mode of delivery 
Normal vaginal birth 
Instrument assisted 
Elective C section 





































Results of the bivariate analyses are presented in Table 3.26. Four covariates had 
significant associations with a positive antenatal screen: age, ethnicity, housing and 
a family history of PND. 
Table 3.26. Significant values in chi-squared analysis - antenatal depression, Coventry cohort. For 
variables with >2 categories, odds ratios (OR) are presented to compare to a selected baseline group 
(a). OR values were not calculated for variables with any expected counts <5 (b). 
 
  






35-39 years    
40-45 years 
>45 yearsb 





































Family history of PND 
No 
1st degree relative 






Exploratory linear regression modelling identified the optimal model to predict 
antenatal EPDS score (Table 3.27). 
Table 3.27.  Results of a linear regression model with antenatal EPDS score as the outcome (N=285) 
with a number of selected predictor variables based on initial exploratory modelling. 
 B SE B β 
Constant 
Age (baseline -  30-34) 
18-24 




































R2 = .12. *p < .01. 
 
In the final model (R2 = .12*), three predictors made significant contributions to 
antenatal EPDS score in the Coventry cohort: Age 18-24, Mixed Ethnicity and 
Support. Young age and mixed ethnicity both increased EPDS score, whereas 
women who were supported had decreased EPDS scores, i.e. protected from PND. 
Despite the contribution of family history of PND to the model’s prediction, this 
variable was not statistically significant. 12% of the variance in antenatal EPDS 
scores can be explained by the final model. 
Due to a large proportion of missing data for this cohort, the model was re-run 
excluding variables with missing data to include N=448 (Table 3.28). This now 
excluded obstetric history, mode of delivery, gender, parity, supported, alcohol, 
drinking, smoking, cigarettes, family history and twin pregnancy. The variables now 







Table 3.28. Results of a linear regression model with antenatal EPDS score as the outcome (N=448) 
with a number of selected predictor variables. 
 B SE B β 
Constant 
Age (baseline -  30-34) 
18-24 
Ethnicity (baseline - White British) 
Asian 
Mixed 





























R2 = .08. *p < .05, **p < 0.01, ***p < .001 
 
In this final model (R2 =.08), four predictors contributed significantly to antenatal 
EPDS for this Coventry cohort: age 18-24, Asian/Mixed ethnicity and living in rented 
housing. Despite the inclusion of more participants in the model (N=448), due to 
the loss of variables only 8% of the variation in antenatal EPDS scores can be 
explained by the model.  
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3.4.2 Postpartum EPDS – exploratory analysis 
 
302 participants completed the postpartum follow-up EPDS with an identified 
prevalence of 10.6% for PND based on EPDS ≥ 10. Mean EPDS score was 4.57, with 
a range of 0-21, and standard deviation 4.047. Cohort characteristics of all 
participants who completed the postpartum EPDS are presented in Table 3.29. 
Table 3.29. Cohort characteristics of the study population for participants who completed 
postpartum EPDS from the Coventry cohort. Continuous variables are expressed as the mean 
(standard deviation) and categorical variables are expressed in N (%) at each factor level. 
Covariate N (SD) / Mean (%) 
Gestation - recruitment (days) 202.52 (23.06) 




















































































































Covariate N (SD) / Mean (%) 
























Family history of PND 
No 






Mode of delivery 
Normal vaginal birth 
Instrument assisted 
Elective C section 





















Women in this cohort were recruited on average at 28.9 weeks gestation. The mean 
delivery was at 38.8 weeks. Mean birth weight was 7.4lbs. The majority of women 
were primiparous, aged 25-29, White British, in full time employment, owning their 
own housing. Modal BMI was 18.5-24, 67.1% of women did drink alcohol in pre-
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conception but only 0.4% reported drinking alcohol during pregnancy. Women 
were generally non-smokers in both pre-conception (88.4%) and pregnancy 
(90.7%). 9.4% of women had a family history of PND. Normal vaginal delivery was 
the most common mode of delivery. 68.9% of women had no prior obstetric history, 
with 25.4% of women who had a history of miscarriage.  
Chi squared & correlation analysis 
A comparison of cases and controls was first carried out to identify variables 
displaying statistical significance between the two groups (Table 3.30). 
Table 3.30. Characteristics of study participants from the Coventry cohort cases and controls (EPDS 




Mean (SD) / N (%) 
Cases 
(n=32) 
Mean (SD) / N (%) 
p 
value 
Antenatal EPDS 5.32 (4.10) 9.25 (5.39) .000 
Positive antenatal screen 38 (14.1) 14 (43.8) .000 
Gestation - recruitment (days) 202.37 (23.35) 203.81 (20.69) .403 
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value 
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Mode of delivery 
Normal vaginal birth 
Instrument assisted 
Elective C section 
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Results of the bivariate analyses are presented in Table 3.31. Five covariates had 
significant associations with a positive postpartum screen: antenatal EPDS score, 
positive antenatal screen (EPDS ≥ 10), ethnicity, housing and employment status. 
Table 3.31. Significant values in chi-squared analysis - postpartum depression, Coventry cohort. For 
variables with >2 categories, odds ratios (OR) are presented to compare to a selected baseline group 
(a). OR values were not calculated for variables with any expected counts <5 (b). 
Covariate p value Χ2 Odds ratio 

















































Results of linear regression modelling are presented in Table 3.32. Variables were 
selected by exploratory backward elimination modelling, and entered into a final 
linear regression model based on the optimal model. 
Table 3.32. Results of a linear regression model with postpartum EPDS score as the outcome for the 
Coventry cohort (N=236) with a number of selected predictor variables based on exploratory 
modelling with the cohort. 
 B SE B β 
Constant 
Positive antenatal screening 
Age (baseline - 30-34) 
18-24 
Ethnicity (baseline – White British) 
Asian 
Employment status (baseline – Full time) 
Student 
BMI (baseline – 18.5-24) 
40-44 
Mode of delivery (baseline – NVB 









































































R2 =0.31.  *p < .01, **p < .001 
 
In the final model (R2 = .31*), seven predictors made significant contributions to 
antenatal EPDS score in the Coventry cohort: positive antenatal screening, 
ethnicity, employment status, BMI, mode of delivery, parity and housing status. 
Despite the contribution of age, support and twin pregnancy, these variables were 
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not statistically significant in the model. 31% of the variance in postpartum EPDS 
scores can be explained by the final model. 
To test whether raw antenatal EPDS scores are a better predictor than using the 
cut-off, the model was re-run replacing ‘positive antenatal screen’ with ‘antenatal 
EPDS (Table 3.33). This improved the model, which now explains 35% of the 
variance in postpartum EPDS scores, in comparison to 31%. The model was 
additionally compared to a model excluding antenatal EPDS score entirely, and the 
exclusion of this variable resulted in R2 of 20%. Overall, adding an EPDS screen to 
the model does improve its prediction, which is benefitted further by adding the 
raw score. 
Table 3.33. Results of a linear regression model with postpartum EPDS score as the outcome for the 
Coventry cohort (N=236) with a number of selected predictor variables. 
 B SE B β 
Constant 
Antenatal EPDS 
Age (baseline - 30-34) 
18-24 
Ethnicity (baseline – White British) 
Asian 
Employment status (baseline – Full time) 
Student 
BMI (baseline – 18.5-24) 
40-44 
Mode of delivery (baseline – NVB) 









































































Significant predictors in the final step of this model were antenatal EPDS score, 
Asian ethnicity, student occupation, emergency C section, parity, support and living 
in social housing. 
3.4.3 Differences and similarities between the cohorts 
 
The different study populations recruited from the two hospital sites, Coventry and 
Warwick, were largely similar. A more complete picture of risk factors is available 
for the larger Warwick cohort, with more data collected relating to mental health 
history and family history compared with the Coventry cohort. The Warwick cohort 
was also larger, and therefore statistical analyses have more power and scope to 
find significant results. A larger number of risk factors have been identified in the 
Warwick cohort. Both cohorts had similar average EPDS scores, with an antenatal 
average of 5.85 for Coventry and 5.68 for Warwick, although the postpartum 
average EPDS was slightly higher in Warwick at 5.96 compared with 4.57 in 
Coventry. In the Coventry population, a prevalence of 18.1% was identified in 
antenatal depressive screening, falling to 10.6% in postpartum depressive 
screening. In contrast, prevalence in the Warwick cohort was 16.7% for antenatal 
symptoms, rising to 19.8% for postpartum symptoms. When examining the 
demographics of the two cohorts, a couple of key differences stand out. The larger 
Warwick cohort is predominantly comprised of White British participants (80%), 
whereas this is less dominant in the Coventry cohort (70% White British). This is 
compared with a national average of 65%. Unemployment rates are notably higher 
in the Coventry population, with 20% of participants unemployed/student 





Three risk factors are in agreement across the cohorts for increased risk of 
antenatal depressive symptoms: young age, social status and lack of support. An 
age of 18-24 is a risk factor for antenatal EPDS in both cohorts, and in the Warwick 
cohort age 40-45 was identified as an additional risk factor. Social status is 
important in both cohorts for antenatal EPDS. Living in social housing or rented 
accommodation increased EPDS, and a social status of student/unemployed 
increased EPDS in the Warwick cohort. Identifying as ‘unsupported’ is another 
shared risk factor for antenatal EPDS between the two cohorts. Smoking status, 
both during and pre-pregnancy was a risk factor in the Warwick cohort only, and an 
Asian or Mixed Ethnicity was a risk factor in the Coventry cohort only. A family 
history of PND was a risk factor for the Coventry cohort only, and although personal 
mental health history was a risk factor for Warwick, this was not recorded for the 
Coventry cohort and therefore cannot be compared. 
Risk factors for postpartum EPDS differ between the two cohorts. For both cohorts, 
antenatal EPDS was the strongest predictor, but no other risk factors were shared. 
Warwick risk factors were education, past mental health history, parity and alcohol 
pre-pregnancy, whereas Coventry risk factors were ethnicity, housing status, 
unemployment, emergency C-section, lack of support and twin pregnancy. Findings 
from both cohorts point to social disadvantage as a risk factor for PPD. A depiction 
of similarities and differences in risk factors between cohorts is shown in Figure 3.6. 
  
Figure 3.6. A representative profile of key risk factors emerging from the analysis for antenatal EPDS 
(white) and postpartum EPDS (black), or both (grey), categorised into personal, social and health 
factors. Those present in the Coventry cohort are labelled ‘C’, and those present in the Warwick 
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4 Results: Circulating Biomarkers 
 
4.1 Chapter Four Abstract 
 
Depression and inflammation are linked by an intricate neuroimmune network, 
providing a means to assess the underlying inflammation as a proxy for depression. 
As described in detail in Chapter 1, both hyper- and hypo- activation have 
previously been associated with PND, and therefore the study of both pro- and anti-
inflammatory cytokines is warranted. Increasingly studies dissecting inflammatory 
responses highlight that both pro- and anti-inflammatory arms are important for 
the development and resolution of inflammation155 178 278. In this study of 
biomarkers and their predictive potential for PND two key cytokines were selected 
for analysis based on the literature, pro-inflammatory cytokine Interleukin-6 (IL-6) 
and anti-inflammatory cytokine Interleukin-10 (IL-10). These two cytokines can be 
measured independently to assess key markers of the inflammatory response, and 
can also be analysed as a ratio in order to assess the balance between pro- and anti-
inflammatory cytokines in circulation. The third selected biomarker is brain derived 
neurotrophic factor (BDNF), an important growth factor belonging to the 
neurotrophic family, for which a role in the pathophysiology of stress and 
depression is proposed.  
As detailed in the Methods chapter, all circulating biomarkers were measured in 
human plasma samples from 688 participants during pregnancy. Firstly, 
concentrations in individual samples were calculated based on a standard curve 
generated for each individual experiment. This was carried out for IL-6, IL-10 and 
BDNF. The ratio of IL-6/IL-10 was additionally calculated. Measurements for all 
biomarkers were recorded for every participant included in the biomarker study. 
Once measurements were complete and sample concentrations were calculated, 
concentrations were entered as continuous variables into the linear regression 
models described in Chapter 3.  
In Chapter 3, exploratory modelling of psycho-socioeconomic variables was carried 
out to determine the optimal models. The purpose of this present study is to assess 
whether additionally measuring selected biomarkers will improve the prediction of 
EPDS scores. This addresses aim 3 of the study – ‘Do cytokines and neurosteroids 
IL-6, IL-10 and BDNF act as markers for PND?’ In order to assess this, the new 
variables IL-6, IL-10, IL-6/IL-10 and BDNF will be included to expand on the 
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established model. This statistical modelling will utilise the participants for whom 
complete biomarker data plus full EPDS data at both time points is available. This 
modelling will be presented later in Chapter 6. Firstly, this present chapter explores 
the independent associations between the analysed biomarkers and EPDS score. 
The biomarker study revealed interesting associations for each of the selected 
markers. Raised IL-6 is associated with lower social status, and is highly correlated 
with maternal BMI. IL-10 levels are lower in participants at risk of major depression 
(EPDS≥10), and the ratio of IL-6/IL-10 is also associated with depressive risk, in 
particular the risk of depressive symptoms worsening in the postpartum period. 
The above biomarkers were assessed as indicators of depressive risk, and their 
usefulness as a negative predictor for those women at low risk of depression is 
promising. Levels of BDNF were similarly found to be associated with PND risk in 
this study, suggesting that a level of protection may be offered by high circulating 
BDNF, since women with raised BDNF scored low on the EPDS. It appears that this 
protection may be generated by both psychosocial and biological factors, which will 
be explored later in Chapter 6. Finally, a sub-study investigating DNA methylation 
and PND explores aim 5 – is there a difference observed in global DNA methylation 
patterns between women with and without PND? The findings of this experiment 
suggest that antenatal depressive symptoms are associated with methylation 
levels, which may be in turn related to relevant social factors such as social status 




4.2 Cytokines: IL-6 and IL-10 
 
Complete biomarkers were measured in 688 participants. IL-6 levels ranged from 
0.09-4.72pg/mL, with a mean concentration of 0.59pg/mL (SD 0.51). IL-10 ranged 
from 0.01-5.69pg/mL, with a mean concentration of 0.33pg/mL (SD 0.41). Mean IL-
6/IL-10 ratio was calculated as 2.88pg/mL (SD 3.35). 
IL-6 and IL-10 data were log transformed prior to statistical analysis to achieve 
normality (Figures 4.1 and 4.2).  
IL-6 levels were not found to be significantly different in cases vs. controls using 
EPDS ≥ 10. The analysis additionally experimented with other EPDS cut off values 
of 8, 13 and 15, none of which were found to be significantly associated with IL-6 
concentration. IL-6 was however significantly correlated with social status (r=.08), 
with the lowest levels observed in women of the highest social status. IL-6 had the 
Figure 4.1. (a) IL-6 data prior to log transformation and (b) post log transformation to achieve 
normality prior to statistical tests. 
Figure 4.2. (a) IL-10 data prior to log transformation and (b) post log transformation to achieve 
normality prior to statistical tests. 
(b) (a) 
(a) (b) 
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strongest and most significant observed relationship with BMI (Figure 4.3) (r=.301), 
significant at the .01 level.  
IL-10 levels were significantly correlated with EPDS score, and with severity 
category, as defined by EPDS score (Figure 4.4). Reduced IL-10 levels (r= -.10) are 
seen in the highest severity category (EPDS ≥ 15, risk of major depression). 
 
IL-6/IL-10 ratio was associated with depressive risk (r=.10, p=.01). Additionally, the 
ratio of these markers was significantly associated with a postpartum outcome, 
mode of delivery (r=.09). The ratio is lowest in women delivering normally, and rises 
in those who went on to have a more complicated delivery. Highest IL-6/IL-10 ratio 
Figure 4.4. The relationship between IL-10 levels and EPDS risk category as defined by EPDS score. 
A score under 10 represents a low depressive risk, whereas a score between 10 and 15 represents 
a risk of minor depression, and a score above 15 indicates a risk of major depression. Mean IL-10 
concentration was 0.33 (SD=0.36) for Low risk, 0.37 (SD=0.66) for Risk of minor depression, and 
0.23 (SD=0.32) for Risk of major depression. 





































Risk of minor depression 
≥15 
Risk of major depression 
166 
 
is observed in women who went on to have emergency caesarean section (C-
section) (Figure 4.5).  It has been reported that maternal BMI is associated with 
emergency C-section, leading to a 30% increased risk, which may explain the link 
between mode of delivery, BMI and IL-6 observed here279.  
 
As described in Chapter 3, in addition to exploring the effects of variables on either 
antenatal or postpartum EPDS scores, it is also possible to explore effects on either 
the average (APA) or difference in (DPA) EPDS scores. All biomarkers were analysed 
for significant relationships with APA and DPA scores, and it was found that the IL-
6/IL-10 ratio is significantly correlated with an increased DPA score (r=.09, p=.017). 
This can be interpreted as a likelihood of depressive symptoms worsening in the 
postpartum for women with a higher IL-6/IL-10 ratio during pregnancy. 
Relationships with DPA and APA scores were investigated for other biomarkers but 
significant no significant effects were seen. 
Following log transformation reference ranges were calculated for all biomarkers 
using the parametric method of mean ± 1.96 SD using data from healthy controls 
(Figure 4.6). For IL-6, the mean was calculated as 0.47pg/mL, the lower reference 
range as 0.14 and the upper reference range as 0.61. Published reference ranges 
for cytokine levels during pregnancy are not readily available, but the manufacturer 
of the kits used for analysis (MSD) suggests that normal human EDTA plasma 
samples test in the range of 0.12-0.99pg/mL. Calculation of reference ranges was 
repeated for IL-10 with a mean of 0.33pg/mL, lower limit of 0.06 and upper limit of 
0.98. Mean IL-6/IL-10 ratio was 2.88, with a lower limit of 0.33 and an upper limit 

















Mode of delivery 
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of 9.68. Any samples measuring outside of this range were referred to as 
‘abnormal’. 37 samples (5.4%) fell outside of this range for IL-6, and 40 fell outside 
for IL-10 (5.8%). Of the ‘cases’, 5% had abnormal IL-6 levels, 13% had abnormal IL-
10 and 7% had an IL-6/IL-10 ratio outside of the range. 
Due to the association found between these markers and antenatal EPDS score, the 
reference ranges were calculated to explore the use of a cut-off value for these 
biomarkers in screening. The positive predictive value (PPV) and negative predictive 
value (NPV) were calculated (Tables 4.1 and 4.2). IL-10 outside the reference range 
had a NPV of 86% for predicting antenatal depressive risk with a PPV of 29%, and 
IL-6/IL-10 ratio outside the reference range had NPV 86%, with a PPV of 18%. NPV 
describes the true negative rate, and therefore both tests perform well as a 
negative screen with 86% certainty they will be low risk for antenatal depression if 
they score within the reference range.  
 
 
Figure 4.6. Reference ranges calculate by the mean (central reference line) ± 1.96 SD (higher and 
lower reference lines). 
IL-10 
Table 4.1. A cross-tabulation of patients with abnormal IL-10 concentration and antenatal 
depressive risk as determined by the EPDS allows calculation of PPV and NPV. 
 Antenatal Depressive Risk 
IL-10 outside ref range High Risk Low Risk 
Yes 13 32 

















PPV= 13/ (13+32) = 29% 
NPV= 563/ (88+563) = 86% 
IL-6/IL-10 ratio 
Table 4.2. A cross-tabulation of patients with abnormal IL-6/IL-10 ratio and antenatal depressive 
risk as determined by the EPDS allows calculation of PPV and NPV. 
 Antenatal Depressive Risk 
IL-6/IL-10 outside ref range High Risk Low Risk 
Yes 7 32 
No 94 563 
 
PPV= 7/ (7+32) = 18% 
NPV= 563/ (94+563) = 79% 
 
Bayes’ theorem was applied to test the suitability of the biomarkers, a statistical 
rule based on probability theory which described the probability of an event based 
on prior knowledge of conditions that might be related to the event280. This 
equation was applied in this case to test the chance that somebody will have 
depression given that they have a biomarker reading outside the reference range 
(the positive test result). The probability of having depression given a positive test 
result (Pr(H│E)) was calculated using Bayes’ theorem with equation: 




Where P(E│H) is the chance of a true positive (having PND with a positive test 
result), and Pr(H) is the chance of PND (estimated as 15% in the general population). 
Using the probability of PND, this allows the suitability of the test in a real world 
population to be estimated. 
For an IL-10 test, based on those scoring outside of the calculated reference range, 
Pr(H│E) = 26.77%, and for the IL-6/IL-10 ratio test, Pr(H│E) = 13.14%, meaning 
around a quarter of those with ‘abnormal’ IL-10, and around 13% of those with 
‘abnormal’ IL-6/IL-10 ratio will have PND. Bayes’ theorem corrects for errors and 
accounts for false positives resulting in the relatively low chance of depression 
given a positive test. These results therefore suggests that these biomarker screens 
would be best used as a negative screen, to rule out those who are low risk for PND 





For each sample, raw OD was converted into its corresponding mean concentration 
and % CV was calculated as before with values <20 considered acceptable. Mean 
BDNF (N=688) was 2032pg/mL (SD 2246), with a range of 46-18370pg/mL. 
BDNF is significantly correlated with EPDS score (p=.025, r=.09). On visual 
inspection this appears to be a positive association, with BDNF levels increasing 
with depressive risk. On plotting a scatter plot of the BDNF data however, it was 
observed that although the correlation is a negative one, a downward trend is in 
fact apparent outside of the ‘normal’ data (Figure 4.7).  
 
Figure 4.7. A plot of EPDS score against BDNF concentration. The vertical reference line indicates 
EPDS cut-off 10, and a horizontal line indicates the upper BDNF reference range (mean ±1.96 SD). 
Figure 4.8. Plot of 'abnormal' data points - scoring either in the depressed category or outside 


































Data points inside the lower left quadrant are from participants scoring in the 
‘healthy’ EPDS category and the ‘healthy’ BDNF category (Figure 4.7). The vast 
majority of points lie within this quadrant (93.6%), however it is perhaps more 
interesting to view the ‘abnormal’ data (N=44) separately to explore the 
relationship between BDNF and PND (Figure 4.8). It is clear that the majority of 
samples with very high BDNF levels are from the non-depressed EPDS category.  
The reference range for BDNF concentration was determined with the healthy 
control group (low depressive risk). Values were log-transformed to achieve 
normality and the parametric method of reference range calculation was then 
used. This was calculated as 190-8260ng/mL, based on a mean of 1963ng/mL, and 
44 samples (6.4%) fell outside of this range. After calculating the reference range 
for BDNF, statistical associations between ‘abnormal’ samples and PND were 
investigated. For this analysis, only those with EPDS ≥ 10 or BDNF outside the 
reference range were included. The plot of this data can be seen in Figure 4.10. 
Using only these data points, the correlation, which is now visible from the 
scatterplot, is negative (r=-.25, p<.01). It is apparent that high BDNF levels are 
generally associated with low depressive risk, whereas low BDNF levels are 
associated with high depressive risk. A couple of data points do not follow this trend 
but the correlation remains significant. Figure 4.9 presents a comparison those at 
risk of depression in the antenatal period compared with the postpartum period, 
and BDNF levels are reduced in the postpartum risk group. 
 










Antenatal risk Postpartum risk 
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Using the calculated reference ranges to explore the use of a cut-off value for these 
biomarkers in screening, the positive predictive value (PPV) and negative predictive 
value (NPV) were calculated. For this investigation, the aim was to test whether a 
high BDNF value exceeding the reference range can predict low depressive risk 
(EPDS<10). This test has a specificity, or true negative rate, of 96.8%, (CI 95.04-
98.06) and a NPV of 85.5% (CI 85.01-86.06%). This means that we can say with high 
probability that if BDNF exceeds the upper reference range, this participant will be 
in the low depressive risk group. As a negative screen it performs with 96.8% 
certainty. The overall accuracy of this test is 83.29% (CI 80.3-85.99). 
Of the participants who had high BDNF levels above the reference range, case-wise 
analysis was carried out and observations recorded. Raised levels of BDNF are 
proposed to protect against PND. In this sample of women with high BDNF (N=23), 
the majority of the participants (N=19) screened negative on the EPDS. It is possible 
that the mechanism of protection is provided both by positive psycho-
socioeconomics and biological effects via high BDNF.  Another possible mechanism 
for protection is the role of BDNF alone, acting despite the presence of certain 
psycho-socioeconomic risk factors. This relationship will be explored later in 
Chapter 6. 
Figure 4.10. Plot of 'abnormal' data points - scoring either in the depressed category or outside 

















Summary of biomarker associations 
Table 4.3. All investigated biomarkers with their corresponding significant correlations, p-value to 
demonstrate significance level, and r to show the direction and magnitude of correlation. 
Biomarker Significant correlations p-value r 
BDNF Antenatal EPDS 





IL-10 Antenatal EPDS 











IL-6/IL-10 Antenatal EPDS 
EPDS risk category 
BMI 










Table 4.3 provides a summary of all significant associations identified between 
biomarkers and psychosocial factors or EPDS score. Statistical analysis and 
modelling did not reveal any significant association between the calculated 
combined biomarker z-score and EPDS score. No statistical associations between 
biomarkers and postpartum EPDS scores were found. No associations between IL-
6, IL-10 or their ratio with BDNF were found. Analysis of BDNF and DPA/APA score 




4.4 DNA Methylation 
 
A pilot study was conducted with a sub-group of participant samples to assess 
whether global DNA methylation changes are associated with perinatal depressive 
risk as determined by EPDS score. DNA methylation is characterised by the addition 
of a methyl group to the fifth cytosine ring, resulting in 5-methylcytosine (5-mC). 
The percentage of 5-mC in DNA from study participants was measured. 
Relationships with levels of folate and B-12 were additionally explored for 
participants with this data available, due to known links between folate and DNA 
methylation, and closely linked metabolic pathways between B-12 and the 
ingestion of methyl groups190 231. Genomic DNA was extracted from participant 
blood samples collected at 24-29 weeks gestation as described in the methods and 
assayed to calculate % 5mC. Absorbance measurements were compared against 
the generated standard curve to calculate % 5mC in the samples.  
Experiment 1 included 38 random samples from the study population. Antenatal 
EPDS score was significantly correlated with 5-mC% (r=0.39, p=.016); increased 
levels are observed in those with EPDS ≥ 10 (Figure 4.11). Mean 5-mC% in women 
in the low risk group was 3.81, compared with 5.98 in the high risk group. 
Methylation levels in this group were also found to be significantly correlated with 
social status (p=.046). 
 
Figure 4.11. Mean levels of global DNA methylation are significantly increased in women with 
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Experiment 2 included samples from the Coventry cohort (N=40). For these 
participants, Folate and B12 measurements were recorded and entered into the 
analysis. EPDS score was also significantly correlated with 5-mC% in this cohort 
(r=0.31, p=.025), and this remained significant in a linear regression model (p=.016). 
Despite an observed association between EPDS and Folate, this relationship failed 
to reach significance in this population (p=.059). No relationship with B12 was 
observed. 
A highly significant relationship was observed between methylation levels and 
housing status (r=0.46, p=.006), with twice the 5-mC% in women staying with 
friends compared with owning their home (Figure 4.12). No women in this group 







Figure 4.12. Global DNA methylation levels are associated with housing status, with the lowest 
%5-mC in women who own their home and the highest %5-mC in women who have no permanent 
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5 Results: Genotyping 
 
5.1 Chapter Five Abstract 
 
This thesis investigates risk factors for perinatal depression; in Chapter 3 psycho-
socioeconomic risk factors have been explored, and in Chapter 4 the involvement 
of an acute inflammatory response was investigated through the use of circulating 
biomarkers. Depression is related to a broad range of physiological processes in the 
body, some acute and short-term, such as the release of pro-inflammatory 
cytokines, and other more pre-determined factors, such as genetics. The acute 
response is in turn associated with genetic predisposition, and this may be true for 
the stress response as determined by the hypothalamic-pituitary-adrenal (HPA) 
axis.  
There is strong evidence for the existence of a predisposition to depressive risk, 
specifically relating to the HPA axis. Aim 4 of the study asks - ‘Does HPA axis 
sensitivity provide a marker for PND by genotyping target SNPs?’, and this will be 
addressed within this chapter. A link between three single nucleotide 
polymorphisms (SNPs) related to HPA axis function (Bcl1, rs242924 and rs242939), 
and risk of PND has been explored. The initial aim of this genetic study was to test 
whether previous findings were replicated in this larger cohort. A second aim was 
to test the clinical feasibility of genotyping in the laboratory. The overall aim was to 
test whether the inclusion of these genotyping results, when combined with the 
rest of the collected data, improves prediction of depressive risk. This study 
additionally aimed to test the feasibility of this analysis as a routine test in a hospital 
laboratory. 
As detailed in Chapter 2, DNA samples were extracted and purified from 
participant’s blood samples and women were genotyped for the presence of three 
key SNPs. In this Chapter, the results of the genotyping study are presented. 
Participants from the main Warwick cohort, for whom both biomarker and 
psychosocial variables were available, were included in the genetic sub-study 
(N=480). Genotyping was carried out for women from this cohort, 21% of which 
were at-risk of some form of PND, either antenatal or postpartum. This included 46 
women from Group 1, 30 from Group 2, and 25 from Group 3. In addition a further 
14 ‘high risk’ samples were included in the SNP analysis from the larger cohort in 
order to increase sample size in the smaller at-risk groups. SNP frequencies of each 
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of the 3 SNPs were determined and compared to published variant allele 
frequencies, and χ2 tests were used to test whether any difference between 
observed and expected genotypes is significant. Odds ratios and 95% confidence 
intervals were calculated for SNPs. A case-control analysis first compared EPDS 
scores between genotypes, assessing any significant associations with presence of 
the minor allele. Participants were categorised for this according to EPDS ≥ 10 to 
establish low risk and high risk groups. 
In the analysis of the whole study population, no statistically significant 
relationships were observed between the SNPs and PND risk. Participants were 
then split into those with and without a family history of PND, to further explore 
the genetic component of PND aetiology. This analysis reveals some interesting 
findings, such as a higher likelihood of past depression, a key risk factor for PND, in 
women with the Bcl1 minor allele. This was explored further, revealing an indirect 
association with IL-6/IL-10 ratio, which in turn has an effect on depressive risk as 
described in the previous chapter. The rs242939 SNP was also found to be 
associated with EPDS scores in women with a family history, more specifically with 
a likelihood of symptoms easing postpartum. This SNP could therefore be 
overrepresented in women at risk of antenatal depression rather than postpartum. 
Overall there is insufficient evidence from this genetic study to support the use of 
SNPs in the prediction of PND, although the findings related to family history are 
promising and warrant further investigation in a larger cohort of women with a 
family history of PND to better explore its genetics. 
5.2 SNP 1 - Bcl1 (rs41423247, NR3C1) 
 
The Bcl1 polymorphism is a G>C single nucleotide variation, with variant allele 
frequency 0.34. The population is in Hardy-Weinberg equilibrium (HWE) (2 = 0.34, 
p=0.85) calculated from the observed and expected frequencies of alleles (Table 
5.1). 
Table 5.1. Observed and expected genotype frequencies for Bcl1 SNP for calculation of HWE. 
Allele Observed frequency Expected frequency 
C/C 193 199 
C/G 209 205 




Mean antenatal EPDS for wild type (WT) carriers is 5.8, compared with 5.6 for 
heterozygotes (HET) and 4.4 from homozygotes (HOM). The minor allele for Bcl1 is 
protective (OR 0.74, CI 0.43-1.27). For postpartum EPDS scores, mean WT score was 
6.1, HET score 5.9 and HOM score 4.6. The minor allele appears to be somewhat 
protective with slightly lower EPDS for carriers, (OR 0.94, CI 0.57-1.53) but scores 
are reduced less postpartum than in the antenatal period. Chi-squared analysis did 
not find a significant association between genotype and EPDS score for Bcl1.  
 
The presence of one or two copies of the minor allele is considered ‘positive’ and 
analysis with this variable is the least stringent model which maximises chance of 
statistical significance in relatively small samples sizes. The mean EPDS scores for 
‘positive’ and ‘negative’ Bcl1 status is shown in Table 5.2. Considering the ‘positive’ 
SNP (Figure 5.1d), difference in mean EPDS score both at the antenatal and 
postpartum time points was negligible and was not found to be significant. 
 
Table 5.2. Mean EPDS score by time point, dependent upon Bcl1 status. 
Time-point EPDS Bcl1 status 
Antenatal 5.63 Negative 
Antenatal 5.86 Positive 
Postpartum 5.36 Negative 






To further investigate an association between the selected SNPs and family history, 
the participants were next split by whether they reported a family history of PND. 
It was found that in women who have a family history of PND (N=77), Bcl1 status 
was significantly associated with their personal history of depression in correlation 
analysis (r=.25, p=.035). In women without a family history, presence of the minor 
allele was associated with an 8% incidence of depression, whereas in women with 
a family history, the minor allele was associated with a 48% incidence of depression. 
It is possible that genetic status is acting indirectly by predisposing to depression 
outside of pregnancy, which is in turn a strong risk factor for developing PND. The 
presence of the Bcl1 minor allele may represent a predisposition to depression in 
general, most prominent when there is a family history. The sample size of women 
with a family history in this study is relatively low, although in line with other studies 
assessing family history as a risk factor for PND281, and a larger powered study 
would be required to further explore the effects of these SNPs. 
Figure 5.1. (a) Mean antenatal EPDS score split by bcl1 minor allele copy number. (b) Mean 
postpartum EPDS score split by bcl1 copy number. (c) The overall effect on EPDS score for bcl1 
copy number at both time-points. (d) The association between bcl1 status of ‘presence’ (MUT) or 
‘absence’ (WT) of the minor allele and the overall effect on EPDS score over time. None of the 
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When women with a family history are excluded, Bcl1 is significantly associated 
with a slightly reduced average EPDS score (r=-.09, p=.049), demonstrating a 
protective effect. When the associations with the measured inflammatory 
biomarkers were investigated in the group of women with a family history of PND, 
a link between Bcl1 and IL-6/IL-10 ratio was identified in correlation analysis (r=-
.22, p=.029). This link also remains significant in the whole study population (r=-.08, 
p=.041). The presence of the Bcl1 minor allele is significantly associated with a 
mildly reduced IL-6/IL-10 ratio, and may indirectly protect against symptoms of 
PND. Partial correlation analyses reveal that this association is mediated through 
IL-6/IL-10 ratio, and this has a greater influence on EPDS scores than the Bcl1 status.  
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5.3 SNP 2 - rs242924, CRHR1 
 
The rs242924 polymorphism is a G>T single nucleotide variation, with variant allele 
frequency 0.47. The population is in Hardy-Weinberg equilibrium. (2 = 0.27, 
p=0.87), as calculated from Table 5.3. 
Table 5.3. Observed and expected genotype frequencies for rs242924 SNP for calculation of HWE. 
Allele Observed frequency Expected frequency 
G/G 122 127 
G/T 228 225 
T/T 101 99 
 
 
Mean antenatal EPDS for WT carriers is 5.73 compared with 5.39 for HET and 5.22 
for HOM. The mean EPDS scores for ‘positive’ or ‘negative’ SNP status is shown in 
Table 5.4. The minor allele is associated with a mild reduction in antenatal EPDS 
(OR 0.88, CI 0.49-1.56).  For postpartum scores, WT mean is 5.93 compared with 
5.66 for HET and 6.27 for HOM (Figure 5.2). Overall, for all genotyped samples, the 
minor allele now associated with a slight increases risk of PPD (OR 1.06, 0.62-1.79). 
There was no significant association identified in Chi squared analysis for either 
antenatal or postpartum EPDS scores. 
 
Table 5.4. Mean EPDS score by time point, dependent upon rs242924 status. 
Time-point EPDS rs242924 status 
Antenatal 6.05 Negative 
Antenatal 5.64 Positive 
Postpartum 6.31 Negative 






An association between genetics and family history was explored by splitting 
participants according to family history. In women with a family history of PND, the 
rs242924 minor allele appears to be related to a personal history of PND. In the 
general population of women who report no family history, the prevalence of past 
PND is low at around 6%, however in those with a family history of PND, the 
prevalence of personal PND rises to 16%. Women with the rs242924 minor allele 
are more likely to have a personal history of PND, but this just fails to reach 
significance at p=.055. Although this SNP isn’t directly associated with EPDS, its 
effect may be indirectly acting through family and personal history of PND, a very 
important risk factor in the development of future PND. The lack of a confirmed 
relationship with depressive symptoms in this study may be attributed to the small 




Figure 5.2. (a) Mean antenatal EPDS score split by rs242924 minor allele copy number. (b) Mean 
postpartum EPDS score split by rs242924 copy number. (c) The overall effect on EPDS score for 
rs242924 copy number at both time-points. (d) The association between rs242924 status of 
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5.4 SNP 3 – rs242939, CRHR1 
 
The rs242939 polymorphism is a C>T single nucleotide variation, with variant allele 
frequency 0.06. Due to the rare frequency of genotype T/T, calculation of Hardy-
Weinberg with 2 is inappropriate in this sample size with an expected value <5. 
There is however some observed deviation from expected values as seen in Table 
5.5. 
Table 5.5. Observed and expected genotype frequencies for rs242939 SNP. 
Allele Observed frequency Expected frequency 
C/C 402 393 
C/T 39 54 
T/T 8 2 
 
 
Table 5.6. Mean EPDS score by time point, dependent upon rs242939 status. 
Time-point EPDS rs242939 status 
Antenatal 5.84 Negative 
Antenatal 5.10 Positive 
Postpartum 6.09 Negative 
Postpartum 6.43 Positive 
 
Participants WT for rs242939 have a mean antenatal EPDS score of 5.52, and a 
mean postpartum score of 5.80. This is compared with HET carriers with mean 
antenatal score of 4.77 and postpartum score 6.36. Mean EPDS score by ‘positive’ 
or ‘negative’ SNP status is shown in Table 5.6. Overall, for all genotyped samples, 
presence of the minor allele associated with a slight reduction in EPDS score in both 
the antenatal (OR 0.97) and postpartum (OR 0.65) time points, with the effect 
considerably more noticeable at the postpartum stage. Homozygotes for this SNP 
had antenatal mean score 4.88 and postpartum score of 5.84. The exploration of 
genotype effect on score is shown in Figure 5.3. Chi-squared analysis did not find a 






The relationship between the rs242939 SNP and family history of PND was 
investigated by splitting the participants into those with and without a family 
history. The analysis revealed that this SNP is significantly associated with an easing 
of depressive symptoms postpartum, known as the DPA score.  This SNP is 
associated with a difference of an average -1.6 points (p=.049), meaning that 
symptoms are likely to ease postpartum compared with in the antenatal period. 
This SNP may be more associated with ‘Group 1’ type women who are at high risk 
of antenatal but not postpartum depression. 
 
  
Figure 5.3. (a) Mean antenatal EPDS score split by rs242939 minor allele copy number. (b) Mean 
postpartum EPDS score split by rs242939 copy number. (c) The overall effect on EPDS score for 
rs242939 copy number at both time-points. (d) The association between rs242939 status of 
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A one‐way fixed effects analysis of variance (ANOVA) was conducted to evaluate 
the null hypothesis that EPDS means were equal across the 3 selected SNPs. A 
statistically significant difference was not found for any of the SNPs. Despite the 
lack of statistical significance, a protective effect by the presence of the minor allele 
was observed. For each of the three SNPs, mean antenatal EPDS score was lower in 
the presence of the minor allele. The largest protective effect was found for Bcl1 
(OR 0.74, 0.43-1.27), followed by rs2424924 (0.88, 0.49-1.56) and a very mildly 
protective effect was observed for rs242939 (0.97, 0.41-2.28). 
For postpartum EPDS scores, Bcl1 minor allele still exhibited a protective effect, but 
this was smaller in magnitude (0.94, 0.57-1.53). The rs242924 SNP mildly increased 
the risk of depression, (OR 1.06, 0.62-1.79), conversely to its protective effect on 
antenatal depression. The rs242939 minor allele remained protective, but now to 
a greater extent in the postpartum period (0.65, 0.28-1.53). These effects were not 
found to be statistically significant. Overall, there is not enough evidence in this 








In the previous three results chapters, relationships between a number of 
investigated factors and perinatal depressive risk have been explored. In Chapter 3, 
key psycho-socioeconomic risk factors were identified for both antenatal and 
postpartum depressive symptoms, based on exploratory regression modelling. As 
described in Chapter 4, the analysis of circulating biomarkers identified a 
relationship between cytokines IL-6/IL-10 ratio and antenatal depressive 
symptoms. Secondly, an association between Brain Derived Neurotrophic Factor 
and antenatal depressive symptoms was identified. In Chapter 5, the effect of 
genetic factors was explored, with observations suggesting that SNPs may offer 
some level of protection/risk for depressive risk, in particular in women with a 
family history of PND. Taken separately, the interpretation of each of the individual 
risk factors explored is limited. Taken together however, this analysis may start to 
unpick the relationships between the various factors and perinatal depressive risk 
as well as any interplay between risk factors. 
The aim of this Chapter is to combine the results from the previous three chapters 
into the final analysis. This analysis addresses aim 6 – do the investigated 
biomarkers improve the prediction of PND symptoms when compared with psycho-
socioeconomic risk factors? First the established model identified in Chapter 3 will 
be extended to this larger cohort of interest to validate findings and explore the 
value of the selected psycho-socioeconomic factors in predicting risk. Each of the 
circulating biomarkers analysed will then be added to this model in a stepwise 
approach to determine the optimal inclusion of variables. This will investigate 
whether adding this data improves the prediction of the model, and if so, the 
importance of each of the markers. The risk/protection provided by the biomarkers 
will be quantified by the subsequent effect on EPDS score. The approach to this 





6.1 Psycho-socioeconomic Factors 
 
As described in Chapter 3, psycho-socioeconomic risk factors were first modelled 
dependent upon time course and progression of depressive symptoms to 
categorise participants into risk groups. This was repeated for the larger group to 
now include N=696, all participants with biomarker data measured. 
Table 6.1. Results of the multinomial regression analysis which models risk factors 
dependent upon Group. For each significant variable, p values, Relative Risk scores, and 
confidence intervals (CI) are shown. 
Group Risk Factors Protective Factors 
1 – High Postpartum risk Past history of PND 
(p=.001, RR=4.10, CI 
1.801-9.28) 
Past history of 
depression (p=.009, RR= 
2.70, CI 1.28-5.69) 
Education (baseline 16) 
– professional level 
(p=.027, RR=0.14, CI 
0.03-0.80) 
2 – High Antenatal Risk Past history of anxiety 
(p=.002, RR= 3.20, CI 
1.54-6.67) 
 
3 – Overall high risk Past history of 
depression (p=.000, 
RR=7.86, CI 3.55-17.38) 
Past history of PND 




Figure 6.1. Schematic demonstrating the approach to analysis combining the optimal model for 
psychosocial risk factors with biomarker and SNP data. 
187 
 
Variables which reached significance in the model are shown in Table 6.1. For Group 
1, risk factors were a past history of PND and a past history of depression, adding 4 
and 3 points to EPDS score respectively. Higher educational level was a mildly 
protective factor. Other factors which did not reach significance but do contribute 
to EPDS score was a past history of anxiety (+1 point), age 30-34 (-0.8 points) and 
higher level of education (-0.7 points for degree level).  
For group 2 there was one significant risk factor, a past history of anxiety, which 
contributes 7 points to the score. Other risk factors which did not reach the level of 
significance were past history of depression (+1.8 points), past history of PND (+1.7 
points), feeling unsupported (+1.4 points), and smoking pre-pregnancy (+1.4 
points). Employment was a protective factor when compared with unemployment, 
with even a low level routine job decreasing EPDS by -0.7 points. Age >24 was also 
protective compared with women under 25.  
For group 3, the highest risk group, two factors were statistically significant: past 
history of depression (+7 points) and past history of PND (+4 points). Further 
notable contributing factors which increased score but did not reach significance 
were a past history anxiety (+1.7 points), age > 39 (+1.1 point), feeling supported (-
0.2 points), higher educational level (Diploma level +1 point), and employment 
(Supervisor level +0.8 points). All levels of employment were protective when 
compared with unemployment. Overall the findings of the group analysis in this 





6.1.1 Prediction of antenatal EPDS score 
 
For the second stage of the analysis, linear regression modelling was applied based 
on the optimal model established in Chapter 3 to the larger Cohort A. One factor 
from the optimal model (Education – no exams) was excluded from the model since 
no participants in this smaller cohort belonged to this level. This model with the 
psycho-socioeconomic variables alone accounted for 16.4% of the variance in EPDS 
scores in this cohort of N=696 (Table 6.2). 
Table 6.2. Results of a linear regression model to predict antenatal EPDS score with variables 
included based on the optimal model previously established. 
 B SE B β 
Constant 
Age 




Mode of delivery 
(baseline – normal vaginal birth) 
Elective C section 
Social status  
(baseline – Higher managerial/professional) 
Semi routine/routine work 
Unemployed/student 
 




Past history depression 
 























































































R2 = .16.4 F=18.253. *p<.05, **p < .01, ***p < .001.  
 
6.1.2 Prediction of postpartum EPDS score 
 
The linear regression model was repeated with postpartum EPDS score as the 
outcome based on the previously established optimal model. This model explains 
33.3% of the variance in EPDS scores in this study population (Table 6.3). This can 
be further increased to 35% when all levels of categorical variables are inputted 
into the model. 
Table 6.3.  Results of a linear regression model to predict postpartum EPDS score with variables 
included based on the optimal model previously established. 
 B SE B β 
Constant 
 
Antenatal EPDS score 
 
Past history depression 
 
Past history PND 
Parity (baseline – 0) 
4 
5 
Education (baseline – Degree) 
Diploma level 


































































Total gestational length 






















R2 = .33. *p < .05, **p < .01, ***p < .001. 
6.2 Addition of Biomarkers to Prediction Modelling 
 
The original model predicting antenatal EPDS scores included psycho-
socioeconomic variables only, and accounted for 16.4% of the variation in antenatal 
EPDS scores. In the next stage of the analysis laboratory data was additionally 
entered into the model to assess whether any of the biomarkers measured for the 
participants would improve the model’s prediction.  
6.2.1 Ratio of IL-6/IL-10 
 
IL-6/IL-10 ratio was added into the antenatal model’s predictor variables, with a 
resultant prediction of 17.4%. IL-6/IL-10 was then entered in a backward stepwise 
approach with the established predictor variables to assess its importance amongst 
the psycho-socioeconomic variables. The optimal model selected with the 
backward approach included IL-6/IL-10 as an important influence on the model. 
According to this approach, the 9 key factors to assess are: age 18-24, Elective C-
section (ELCS), unemployment, low level routine work, past history PND, past 
history depression, past history anxiety, BMI 30-34 and, interestingly, IL-6/IL-10 
ratio (Table 6.4). The ratio of these cytokines ranks above a Past history of PND, 
Elective C-section, and BMI 30-35 in this model. 
If all levels of the categorical variables are inputted into the model, for example all 
age categories rather than just the 18-24 category of interest, in addition to IL-6/I-





Table 6.4. Resuts of a stepwise linear regression model to predict antenatal EPDS score with the 
addition of IL-6/IL-10 ratio into the established psychosocial model. 
 B SE B β 
Step 1 
Constant 












Past history anxiety 
Social status (baseline Higher) 


























Past history anxiety 
Social status (baseline Higher) 


































Past history anxiety 
Social status (baseline Higher) 




Past history depression  













































 B SE B β 
Past history anxiety 
Social status (baseline Higher) 




Past history depression  
Age (baseline 30-34) 
18-24 





































Past history anxiety 
Social status (baseline Higher) 




Past history depression  
Age (baseline 30-34) 
18-24 



















































Past history anxiety 
Social status (baseline Higher) 


























 B SE B β 
 
Past history depression  
Age (baseline 30-34) 
18-24 






































Past history anxiety 
Social status (baseline Higher) 




Past history depression  
Age (baseline 30-34) 
18-24 



































































 B SE B β 
Step 9 
Constant 
Past history anxiety 
Social status (baseline Higher) 




Past history depression  
Age (baseline 30-34) 
18-24 









































































Note R2 = .07 for Step 1; ΔR2 = .046 for Step 2, ΔR2 =.020 for Step 3, ΔR2 = .017 for Step 4, 
 ΔR2 = .014 for Step 5, ΔR2 = .011 for Step 6, ΔR2 = .007 for Step 7, ΔR2 = .005 for Step 8, ΔR2 = .001 for 
Step 9. R2 at Step 9 = .195 
*p < .05, **p < .01, ***p < .001. 
 
In exploratory modelling, biomarkers were additionally inputted to determine 
order of importance. IL-6/IL-10 was the most important of the biomarkers, and 
made a small but significant contribution to EPDS score with p=.001. One other 




In the exploratory modelling stage, IL-6 made a significant contribution to antenatal 
EPDS prediction (p=.018). In contrast to the IL-6/IL-10 ratio, the relationship 
between IL-6 and antenatal EPDS score is negative, meaning a raised IL-6 score is 
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associated with a decreased EPDS score (B= -0.9). A model including both IL-6/IL-10 
and raw IL-6 now accounts for 19.9% of the variation in EPDS score. With IL-6 alone 
this slightly falls to 18.5%. Entered into a model containing all factor levels for 
chosen psycho-socioeconomic variables, in addition to IL-6 and IL-6/IL-10, 
prediction is highest at 20%. The two biomarkers are both significant in this final 
model.  
Contributions of IL-10 or BDNF were not found to be significant in the modelling 
analysis. A minor contribution to prediction was observed, however this was 
negligible and since these variables were non-significant they were excluded from 
the modelling. 
The optimal model to predict antenatal EPDS score has now been established. This 
includes the following variables: age, mode of delivery, social status, past history of 
PND, past history of depression, past history of anxiety, smoking pre-pregnancy, 
BMI, IL-6 concentration, and IL-6/IL-10 ratio. The significant levels of these variables 
are presented in Table 6.5. The addition of the biomarkers has raised the prediction 
of the model from 16.4% to 20%, as demonstrated in Figure 6.2. The overall 
significance level of the model is <.001 in ANOVA. 
Figure 6.2. Prediction of antenatal EPDS scores using the psychosocial model alone results in 
16.4% explanation of the variance. The prediction improves with the addition of IL-6 into the 
model, and IL-6/IL-10 ratio. When the psychosocial model is combined with these two biomarkers 
prediction has risen overall from 16.4% to 20%. 
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Table 6.5.  Resuts of a linear regression model to predict antenatal EPDS score with the addition of 
IL-6/IL-10 ratio and IL-6 concentration into the established psychosocial model. 
 B SE B β 
Constant 
Age 




Mode of delivery 
(baseline – normal vaginal birth) 
Elective C section 
Social status  
(baseline – Higher managerial/professional) 
Semi routine/routine work 
Unemployed/student 
 




Past history depression 
 




































































































R2 = .20. *p<.05, **p < .01, ***p < .001.  
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The most important risk factor in this model for antenatal depressive risk remains 
as a history of anxiety (p=<.001). This is closely followed by unemployment 
(p=<.001) and a past history of depression (p=<.001). IL-6/IL-10 ratio is the next 
most important risk factor in this model (p=.003), with an increased ratio in women 
with raised EPDS scores. Another factor which contributes to the model is ‘elective 
C-section (ELCS)’ (p=.006). This is an unusual variable in the model, since planned 
ELCS may represent increased levels of stress in anticipation of a more complex 
delivery and recovery period, however this finding must be interpreted with 
caution, since it is unknown whether the EPDS screen preceded the C-section being 
planned and may therefore be an invalid association to make. Other important 
factors in the model were young maternal age (p=.015), low social status indicated 
by occupation of low skill level (p=.003), and IL-6 concentration levels (p=.04). 
Biomarker concentrations were entered into regression models to test the 
prediction of postpartum EPDS scores in the same way, but it was found that this 
did not improve the postpartum model’s prediction. Since all circulating biomarkers 
were measured in blood samples taken during pregnancy, and postpartum samples 
were not available in this study, it was expected that any associations between 
circulating biomarkers and depressive symptoms would be acute and therefore 
predictive of current antenatal symptoms rather than symptoms occurring months 
later postpartum. 
Regression models were also used to predict the temporal patterns of depressive 
symptoms, using the average EPDS score (APA) and difference in EPDS score (DPA), 
but the addition of biomarkers to these models did not improve prediction. It was 
however found that the APA score, the average throughout, can be predicted in 
this cohort very well, with a model including a select number of significant 
psychosocial variables only based on exploratory modelling (EPDS, Parity, Past PND, 
Past Depression, Past Anxiety and BMI), explaining 75% of the variability in APA 
score. This can be interpreted as the psychosocial factors explaining the average 
EPDS score very well. The DPA, the change in EPDS score, was more difficult to 






Modelling was next applied to the cohort for which both SNP genotyping and 
biomarker analysis was carried out. The established antenatal model, described 
earlier in this chapter was first applied to this smaller cohort to test whether the 
same associations are true. 
The model was run with this dataset and prediction is the same as with the larger 
dataset, with 20% of variation in antenatal EPDS scores explained by the current 
model. The addition of SNP data for all three SNPs, based on presence of the minor 
allele, raised the prediction of the model slightly to 22%, p<.001. Individually 
however, the SNP data was not statistically significant. The presence of the minor 
allele for all three SNPs slightly reduced the EPDS score. The effect was minor for 
all SNPs (Bcl1 -0.4, rs242924 -0.4, rs242939 -0.6). When inputted into backward 
regression models, the optimal model does not include the SNP data. 
Experimental modelling further assessed whether additional genotyping data (WT, 
HET or HOM) would improve prediction in the model compared with presence or 
absence of minor allele alone. The model predicts 21% of the variance with this 
data, and is therefore not an improvement compared with simpler 
presence/absence data. This did however allow quantification of effect on EPDS 
score – it is noted that Bcl1 HET genotype exerts a very small effect (-0.1) whereas 
HOM genotype is 10 times more influential (-1.0), although non-significant here.  
This effect is not seen in the other two SNPs.  
Both IL-6 and IL-6/IL-10 remain in the optimal model for this smaller cohort (Table 




Table 6.6. Resuts of a linear regression model to predict antenatal EPDS score in subgroup of N=480 
with the addition of IL-6/IL-10 ratio and IL-6 concentration into the established psychosocial model. 
 B SE B β 
Constant 
Age 




Mode of delivery 
(baseline – normal vaginal birth) 
Elective C section 
Social status  
(baseline – Higher managerial/professional) 
Semi routine/routine work 
Unemployed/student 
 




Past history depression 
 




































































































R2 = .20. *p<.05, **p < .01, ***p < .001.  
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The findings in this smaller cohort are similar to those of the larger cohorts, but a 
few differences are observed. Age is no longer a significant factor (18-24 new 
p=.054), but remains influential in the model. Smoking pre-pregnancy has 
decreased in importance and is no longer significant and its influence negligible. 
Elective C-section has now increased in importance, as has social status. Past 
history of PND is not statistically significant in this model, but its influence remains 
similar and it improves overall prediction. IL-6/IL-10 ratio (p=.002) and IL-6 
concentration (p=.017) have both become increasingly important in this cohort. 
The rank of risk factor importance in this cohort is now slightly altered. A past 
history of anxiety remains as the most important factor to consider. The ratio of IL-
6/IL-10 is now the joint second most influential risk factor, alongside social status. 
Elective C section ranks next, followed by IL-6 concentration levels. Past history of 




6.2.4 Clinical transferability of biomarker data 
 
Within the clinical setting, it is important to consider the usefulness of biomarker 
data and how it can be adopted into screening for PND. Rather than inputting all 
data into models, in order for the results to be clinically relevant, a quick and simple 
method of assessing risk is needed. As described in Chapter 4, reference ranges can 
be calculated based on the standard deviation to assess samples testing within 
range and out of range, or normal and abnormal. The Positive Predictive Value 
(PPV) and Negative Predictive Value (NPV) of a screen can then be calculated to 
assess its suitability in detecting cases, or in detecting those who are low risk with 
the true negative rate. This can aid screening and prioritisation of resources to 
women who are most at-risk. 
In Chapter 4 the reference range was calculated for IL-6/IL-10 ratio, and use of this 
biomarker data alone results in NPV of 79% for antenatal depressive risk, 
performing fairly well as a negative screen. A two-step screen is an alternative 
which may provide an optimal screening test, combining both a key psycho-
socioeconomic factor and a biomarker test result. This might represent a useful and 
fast screening tool, which could be an alternative to the EPDS. 
A cross tabulation (Table 6.7) demonstrates the frequency of participants with 
either IL-6/IL-10 levels outside of the reference range, or with a history of anxiety 
(N=128). All participants with either of these two risk factors were coded 1. This 
new variable is ‘Antenatal Screen 1’. 
Table 6.7. Calculation of Positive Predictive Value and Negative Predictive Value based on a cross 
tabulation of true positive/negative results and false positive/negative results. 
 EPDS result 
Antenatal quick screen Positive Negative 
Positive 37 91 
Negative 64 504 
 
The Positive Predictive Value (PPV) and Negative Predictive Value (NPV) were 
calculated for this screening tool. PPV= 29% and NPV=89%. This true negative rate 
is 10% higher than using IL-6/IL-10 alone. This test was repeated using past history 
of anxiety alone as a screening tool, and the NPV is identical at 81%, indicating that 
if a woman does not have a history of anxiety, she is 81% likely not to develop PPD. 
The addition of the IL-6/IL-10 screening, based on scoring outside of the reference 
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range, brings this NPV value to 89% as a negative screen for those with IL-6/IL1-0 
inside the reference range. This is an example of a fairly simple method of 
combining a psychosocial variable with a biomarker to improve prediction of 
depressive risk. This could be used with relative ease in a clinical setting, and can 
be expanded to include other important risk factors. Here we have combined the 
most important biomarker from the analysis, IL-6/IL-10 ratio, and the most 
important psychosocial risk factor in terms of influence on prediction, a history of 
anxiety. Using this two-step approach screening can be done quickly and with ease, 
but additional risk factors can be added as required. Although 29% is relatively low 
as a predictive screen, 89% is a good negative predictive value, although in order to 
prevent 11% of women being incorrectly classified as low risk, screening with the 
EPDS would still be optimal.    
6.3 BDNF and Psycho-socioeconomics – Case Studies 
 
High levels of BDNF are thought to be protective of PND, based on both this present 
study and previous literature. Although BDNF did not play a significant role in the 
regression modelling part of the analysis, some interesting observations can be 
made from this data. On initial inspection, a statistical association between BDNF 
and antenatal EPDS suggests a positive relationship. As described in Chapter 4, the 
data is in fact skewed by the high proportion of participants scoring low on the 
EPDS. Reference ranges were calculated and the ‘abnormal’ data was inspected 
separately, elucidating a negative relationship between BDNF and EPDS in this 
sample (r=-0.25, p<.01). Those participants with high BDNF levels as determined by 
the reference range (N=23) were explored in more detail as case studies with an in 
depth assessment of their patient notes. The theory that high BDNF can protect 
against PND despite the presence of key risk factors was explored. 
Four participants with high BDNF did not fit with this theory, and screened positive 
on the antenatal EPDS (#196, #317 and #959). It was noted however that three of 
these women had a previous mental health history. For example, case study #959, 
had a history of depression, anxiety and also PND. Despite the high ‘protective’ 
BDNF, her personal mental health history is a very strong risk factor, as 
demonstrated by the present analysis, and appears to play a more important role 
in depressive risk. One participant, #196, who had a history of both depression and 
anxiety was also a smoker, and was therefore excluded from the BDNF analysis due 
to a link between smoking and BDNF levels282 283.  
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The other case study that did not fit with this theory was a woman of an ethnic 
minority (#84), and this participant screened positive on the EPDS despite high 
BDNF. No other key risk factors were present, but being of an ethnic minority was 
identified in our analysis of increasing depressive risk. High BDNF levels did not 
protect against screening positive in this case, although severity may have been 
reduced since the EPDS score was 10, the minimum score for a positive screen.  
Two case studies with high BDNF (#52 and #1154) had a history of anxiety but not 
depression, and these women screened negative on the EPDS. This suggests that a 
personal history of depression exhibits a more powerful effect on depressive risk in 
pregnancy than a history of anxiety. It may be possible that high BDNF can 
counteract the risk of anxiety, but not depression. A further case study #110 did 
have a history of PND, but despite this had high BDNF and also screened negative 
on the EPDS. High BDNF levels could be one possible explanation here for this low 
risk despite having a key risk factor. 
Three case studies (#437, #489 and #1154) had a family history of PND, an 
important risk factor, however all screened negative on the EPDS, suggesting the 
possibility that the detrimental effect of their family history was outweighed by 
protective high BDNF. Six case studies fell into the low social status risk categories. 
100% of these women screened negative on the EPDS despite this. Once again, this 
protection may be provided by high levels of BDNF. One case study (#437) identified 
as being unsupported in her pregnancy, one of the key risk factors for PND. Despite 
this, the EPDS screen was negative. High BDNF may have protected against the risk 
posed by this lack of support. Twelve women with high BDNF did not have any of 
the key risk factors and also screened negative on the EPDS. It is likely that these 
women have a combination of biological and psycho-socioeconomic protective 
effects, which are linked, leading to low EPDS scores. 
In summary, high levels of BDNF are proposed to protect against PND. In this 
sample of women with high BDNF (N=23), the majority of the participants (N=19) 
screened negative on the EPDS. The majority of these women appear to be 
protected by both positive psycho-socioeconomics and biological effects 
potentially via high BDNF. In some cases however we see a number of the risk 
factors typically associated with PND.  It is hypothesised that these women are 
protected from depression, despite their personal psycho-socioeconomic risk 
factors, due to their high levels of circulating BDNF. In particular, it seems that a 
history of anxiety, a history of PND, a family history of PND and low social status all 
204 
 
have their effects ameliorated by high BDNF levels, which is illustrated in Figure 6.3. 
In this way the individual threshold has been altered and the response to insults 
has a lesser effect. In contrast, women with a history of depression all screened 
positive on the EPDS despite their high BDNF levels. I have demonstrated in this 
study that depressive history is the strongest risk factor for PND, and therefore it is 
sensible to suggest that its effect is so strong that high levels of BDNF cannot 
counteract the subsequent increased risk.  
 
Figure 6.3. Women with risk factors including past anxiety, family history of PND and low social 
status are predicted to score highly on the EPDS, and have an increased risk of scoring ≥ 10 on the 
EPDS, the cut-off score for PND risk. It seems that in some women, high levels of circulating BDNF 
lead to amelioration of these effects and results in a lower than expected EPDS score. 
 
In Chapter 4 an interaction between DNA methylation and social status was also 
explored, identifying a further interaction between a biomarker and a psycho-
socioeconomic risk factor. A statistically significant relationship was found (p=.006) 
between global DNA methylation levels (5-mC %) and housing status. When 
compared with women owning their home, women without a permanent home 




6.4 Birth Weight & Gestational Length – Regression Modelling 
 
Birth weight, perinatal depression, and psycho-socioeconomic risk factors are 
complex and interlinked factors. A further aspect of this study explores whether 
data on risk factors for PND are also related to baby birth weight and could 
therefore be used in prediction of birth weight or gestational length. In Chapter 4, 
a significant correlation was identified between postpartum depressive risk and 
shorter gestational length, which is in line with previous studies finding that pre-
term infants increase maternal stress284 285. In linear regression modelling, shorter 
gestational length was also significantly associated with raised postpartum EPDS 
scores. Regression modelling was carried out to identify factors related to 
gestational length and birth weight.  
Prediction of birth weight 
The first exploratory model tested associations between risk factors for PND and 
birth weight. The optimal model included all variables included in Table 6.8. 
Table 6.8. Results of a linear regression model to predict birth weight outcome based on selected 
predictors including IL-6 concentration, BDNF concentration and selected psycho-socioeconomic 
variables. 









Smoking in pregnancy 
 
Age (baseline 30-34) 
40-45 
Education (baseline Degree) 
>16 




















































 B SE B β 
Social status (baseline Higher Managerial/Professional) 
Low level routine work 
Unemployed/Student 





















































R2 = .15. *p<.05, **p < .01, ***p < .001.  
Important factors were found to include two of the measured biomarkers: IL-6 and 
BDNF, which might play different roles. Higher concentrations of both markers 
were associated with lower birth weights. Other factors associated with lower birth 
weights are smoking during pregnancy, maternal age 40-45, and lower social status. 
Alcohol pre-pregnancy, lower educational level (>16), higher BMI and having 
previous children were all associated with increased birth weights.  
The initial exploratory modelling excluded gestational length, which is a known 
clear predictor of birth weight. The modelling was then repeated to include 
gestational length, and important factors were now slightly altered in order to 
adjust for the influence of gestational length. This can help to disentangle whether 
risk factors are directly associated with birth weight, or indirectly via gestational 
length. IL-6 and BDNF were no longer included in the optimal model for birth 
weight, nor were pre-pregnancy alcohol or educational level. This new model 
including gestational length greatly improves the model’s prediction from 15% to 




Table 6.9. Results of a linear regression model to predict birth weight outcome based on selected 
predictors including IL-6 concentration, BDNF concentration, gestational length and selected 
psycho-socioeconomic variables. 





Smoking in pregnancy 
 
Age (baseline 30-34) 
≥45 




Social status (baseline Higher Managerial/Professional) 
Low level routine work 


























































































R2 = .41. *p<.05, **p < .01, ***p < .001.  
Gestational length is by far the best predictor or birth weight in this model. Other 
important factors are parity, BMI, social status, mode of delivery, age ≥ 45 and 
smoking during pregnancy. The influence of biomarkers IL-6 and BDNF is now 
absent. This is likely due to an indirect relationship with gestational length, which 
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in turn influences birth weight. This was explored next in further modelling with 
gestational length as the outcome. 
Prediction of gestational length 
Modelling of gestational length identified a number of predictor variables, including 
BDNF, both with and without the inclusion of birth weight in the model. When 
birthweight is absent from the model, BDNF becomes increasingly significant, 
indicating that the influence of BDNF is acting mainly through effects on gestational 
length but also in part directly on birth weight (Table 6.10).  
Table 6.10. Results of a linear regression model to predict gestational length based on selected 
predictors including BDNF concentration and selected psycho-socioeconomic variables. 











Social status (baseline Higher Managerial/Professional) 
Low level routine work 
BMI (baseline 18.5-24) 
35-39 


























































R2 = .11. *p<.05, **p < .01, ***p < .001.  
BDNF concentration still improves the overall prediction of the model when 
birthweight is included as a predictor (Table 6.11). Postpartum EPDS was also 
identified as a significant variable in the optimal model which includes birthweight. 
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This model overall now has R2 of 0.40, accounting for 40% of the variation in 
gestational length. 
Table 6.11. Results of a linear regression model to predict gestational length based on selected 
predictors including BDNF concentration, birthweight and selected psycho-socioeconomic 
variables. 













Social status (baseline Higher Managerial/Professional) 
Low level routine work 
BMI (baseline 18.5-24) 
35-39 
































































R2 = .40. *p<.05, **p < .01, ***p < .001.  
Variables which were found to improve prediction of the model in exploratory 
backwards regression modelling were included in the final optimal model. 
Birthweight had the strongest association with gestational length, with a clear 
direct positive relationship which was expected. Other variables positively 
associated with gestational length in the model are Instrumental delivery (forceps) 
and lower social status. Variables with an inverse association with gestational 
length are Elective C-section, Emergency C-section, Parity, high BMI, postpartum 







This study had six central aims, outlined in Chapter One, which were designed to 
further understand and delineate the contribution of both biological and 
psychosocial risk factors to the prediction of perinatal depressive risk. Each of those 
aims has been addressed in this thesis. 
Aim 1 – Can psycho-socioeconomic risk factors predict antenatal and postpartum 
depressive symptoms?  
Previous studies have focused on prediction of postpartum EPDS scores, and a clear 
association between antenatal and postpartum scores has been previously 
identified276. The present analysis identifies the same relationship, and goes beyond 
previous work to analyse the contribution of psycho-sociodemographic covariates 
to antenatal, postpartum and perinatal EPDS scores and presents novel data. The 
AUC and correlation analyses in this study demonstrate that this relationship is also 
present in this dataset. The limited correlation of 0.50 between antenatal and 
postpartum EPDS scores, combined with the extreme differences between these 
two scores for some participants also indicated that there are other factors 
contributing to this difference.  
Initially EPDS scores were dichotomised to define a binary outcome of depressive 
symptoms in order to obtain estimates of effects and their significance that are 
more robust to potential misspecifications of the regression models. This approach 
is also more likely to be relevant for routine healthcare risk assessment approaches 
designed around the use of cut-offs; this was followed by development of 
regression models for the raw EPDS scores in order to increase exploratory power 
and to detect more subtle effects of covariates without the constraint of cut-offs. 
Finally the predictive performance of the regression models was evaluated in 
comparison to a state-of-the-art machine learning prediction method. This 
complementary but distinct statistical analysis identified a similar set of covariates. 
Both approaches to the analysis resulted in qualitatively similar conclusions about 
the contributions of various psychosocial covariates.  
It was next explored how far psychosocial factors alone could predict antenatal 
EPDS scores in a clinical setting. As a general pattern antenatal EPDS scores are 
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better explained by the available covariates and are associated with covariates 
indicating a general level of worry and anxiety, lack of support, overindulgence in 
alcohol and smoking and lower social status. These covariates also predict that signs 
of depression might ease after delivery. On the other hand, postpartum depression 
is less reliably predicted by the available covariates and is mostly associated with a 
previous history or a family history of depression and PND. These findings hinted at 
a possible genetic component for PND. Postpartum scores are however aided by 
the inclusion of antenatal scores in their prediction. 
In the main study population a prevalence of 16.7% was identified for antenatal 
depressive risk and 19.8% for postpartum depressive risk. These values slightly 
exceed the 10-15% estimate in the general population, although it is widely 
considered that the rates are underestimates. Other studies report similar rates23 
24. A possible explanation for this is that every woman partaking in the study is 
screened using the EPDS as part of the study protocol, whereas in normal clinical 
practice screening is not mandated and a number of cases will be missed. Study 
participants who screened positive on the EPDS in the study were referred on for 
further treatment. It is likely that a number of these women would not have been 
screened under their regular antenatal care, and this further emphasises the need 
to routinely screen for symptoms in all women under maternity care. 
Aim 2 – Is perinatal depression heterogeneous and can the timing of 
onset/remission be predicted? 
Previous studies have suggested that PND may not represent a homogenous 
disorder as previously thought, and instead exhibits different patterns of onset, 
severity and symptoms and aetiologies107 286. In order to explore the possible 
variable course of depression, the analysis also classified women into distinct sub-
groups dependent upon their risk of depression. Each at-risk group showed distinct 
trajectories of timings of onset and remission (ante/post-natal), in addition to 
different risk and/or protective factors which suggests that they may represent sub-
types of PND. The findings demonstrate that the course of perinatal depression can 




In an ongoing debate over whether differing trajectories represent distinct 
conditions, these findings support the heterogeneous view of PND. This 
heterogeneity may be due to different sensitivity thresholds, different ‘insults’ or 
‘stressors’, and different responses to these insults, which may include for example 
a detrimental inflammatory response. Studies to date have focused on postpartum 
depression (PPD), and one view is that PPD is biologically distinctive from major 
depressive disorder, with vulnerability due to increased sensitivity to gonadal 
hormone fluctuations, and that this increased risk is only present in the immediate 
postpartum. Alternatively PPD can be described more simply as an episode of major 
depression manifesting within the postpartum period. This debate in the field has 
important implications for disentangling contributing factors and better 
understanding the course of PND. This study further supports the theory of 
heterogeneity for PND, and explores the clinical problem as a whole where most 
studies have focused on exclusively postpartum depression. 
In addition to categorising into a risk group, EPDS scores were used to assess within-
person patterns of change of depressive symptoms severity at two distinct time 
points antenatally (T1) and postpartum (T2). Using a single score cut-off (≥10) we 
identified three subgroups according to onset and duration or remission of 








































































































Figure 7.1. The heterogeneity of perinatal depression can have a bidirectional course of 
progression, with risk either increasing, decreasing, or remaining consistent from the antenatal to 
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demonstrates that although there is a clear association, there is also a clear 
deviation of antenatal EPDS score from postpartum EPDS supporting the hypothesis 
of a multifactorial aetiology286. 
Aims 3-6 - Do biomarkers (circulating biomarkers, genetic SNPs and DNA 
methylation) act as markers for perinatal depression? 
A crucial aim of the analysis was to evaluate the additional predictive capacity with 
the inclusion of biomarker data from participants, utilising the ability of a statistical 
driven approach to further interrogate heterogeneous data and therefore the 
heterogeneity of PND. Biomarkers were further explored for their individual 
contributions to EPDS scores and associated psychosocial risk factors. The findings 
report that biomarkers can provide additional valuable information to predicting 
perinatal depressive risk. In particular, a role for inflammatory markers is 
supported. Findings related to each individual biomarker are discussed in section 
7.4. Biomarker data has been collected and analysed alongside the psychosocial 
variables, in a novel approach to combining a wide variety of data to interpret 
contribution to the risk of PND.  
In addition to the identification of risk factors, this study aimed to assess two 
important offspring consequences of PND, gestational length and birth weight, and 
the role that the neuro-inflammatory system plays by exploring the relationships 
between maternal biomarkers and these offspring outcomes. It is now established 
that two thirds of the costs relating to maternal mental illness in the UK are directly 
related to the child, including costs of pre-term birth, special educational needs, 
low educational attainment and emotional problems16. These detrimental and 
costly effects on offspring of affected mothers demonstrates that this research is 
urgently required, and addresses a specific gap in the knowledge identified in the 
current literature. The analysis suggests that biological markers of 
neuroinflammation are involved in the pathogenesis of developmental impairment 




7.2 Analysis – Benefits of Approaches 
 
The perinatal depression disease trajectory contains two main parts – one 
antenatal and one postpartum.  One of the main strengths of the approach to the 
analysis in this study is the focus on antenatal as well as postpartum depressive 
symptoms, since most studies do not approach the clinical problem as a whole in 
this way. The statistical analysis has utilised the data to its full potential, looking at 
both EPDS cut-off scores, which are clinically useful, and raw scores which can 
provide a more detailed picture of score prediction. Analysis focused firstly on EPDS 
score dichotomised using a cut-off value, and a second analysis utilised raw EPDS 
scores to increase power. Both analyses reached qualitatively similar conclusions 
made about the contribution of selected psychosocial variables, providing 
reassurance around these findings. 
The analysis employed different types of regression and machine learning methods. 
Initially EPDS scores were dichotomised to define a binary outcome of depressive 
symptoms in order to obtain estimates of effects and their significance that are 
more robust to potential misspecifications of the regression models. This approach 
is also more likely to be relevant for routine healthcare risk assessment approaches 
designed around the use of cut-offs; this was followed by development of 
regression models for the raw EPDS scores in order to increase exploratory power 
and to detect more subtle effects of covariates without the constraint of cut-offs. 
Finally the evaluation of the predictive performance of the regression models was 
carried out in comparison to a state-of-the-art machine learning prediction 
method. This complementary but distinct statistical analysis identified a similar set 
of covariates. 
The EPDS was used in multiple ways to assess risk, including a group analysis 
approach which would be appropriate for use in the clinic. The ‘quick screen’ 
approach was also explored, in order to simplify risk prediction with the use of 
Positive Predictive Values and Negative Predictive Values to test how far this 
approach could be used to classify risk. Overall the analyses performed in this study 
have been targeted towards clinical transferability, starting with more complex 
exploratory analysis and finishing with a simplified version of screening with the 







A number of study limitations should be considered in the interpretation of these 
results. A high majority of the main study population were White British and 
women were generally well educated, of a high social status and identified as 
‘supported’. The findings are therefore limited in their generalisation and care must 
be taken when comparing to other populations. Depressive symptomatology was 
assessed through the use of a self-report screening instrument rather than clinical 
assessment, although the EPDS has been reported to have high sensitivity in a large 
number of studies both in the antenatal period and postpartum. A number of 
recorded variables were binary (yes/no) limiting the level of detail and the 
conclusions for some covariates. A further weakness of the study is that there was 
no record of previous life experiences that could influence coping mechanisms and 
responses to stress. Additionally other medical factors such as gestational diabetes 
were not recorded which could act as confounding variables. 
Although the study design assessed depressive symptoms at two key time points 
during pregnancy and postpartum, this cannot capture the full temporal spectrum 
of symptoms onset or duration; for example women who experience transient 
symptoms during the first trimester or beyond 3 months postpartum since there 
was no follow-up post- 6–10 weeks postpartum, and therefore onset of depressive 
symptoms after the study period will not have been included in the analysis. The 
lack of multiple sampling points, including the measurement of postpartum 
biomarkers, also did not allow application of modelling tools for identifying multiple 
un-observed sub-populations, describing longitudinal change within each sub-
population, and examining differences in change among sub-populations. Such 
growth models typically require at least three repeated measures per individual. 
The completion rate of the postpartum EPDS screening was relatively low at 55% in 
this ongoing study, which also limited the sample size and statistical power of 
postpartum analyses. 
The findings of the statistical analyses are limited in their interpretation since the 
inclusion of a large number of variables can result in significant findings by chance 
alone. Corrections for multiple comparisons such as Bonferroni were not included 
here since it was an exploratory analysis to find all possible contributing factors, 




7.4 Risk factors – Interpretation and Implications 
 
Can psycho-socioeconomic risk factors predict antenatal and postpartum 
depressive symptoms? (Aim 1) 
Age 
The peak time in a woman’s life to experience depression is at childbearing age287. 
Young age, and more specifically teenage pregnancy, has previously been identified 
as a specific risk factor for depression, doubling a woman’s risk94. Recent reports 
suggests that the biological adolescent phase of life in current society continues to 
the age of 24, rather than a previously suggested age of 19288. In alignment with 
this, the findings of the present study indicate that women aged under 25 are 
particularly vulnerable to PND. It is thought that women of this age are still 
undergoing biological growth, including brain maturation, in addition to 
experiencing major social role transitions, meaning suitability for motherhood may 
be compromised. The implications of this finding point to the additional support 
required by young mothers, and expanding the risk category up to the age of 25 for 
prioritisation and close monitoring of depressive symptoms to better detect those 
at higher risk of PND.  
In the largest cohort analysed of this study (N=1579) the modal age category was 
30-34. Women belonging to this category were identified as most protected from 
antenatal depressive risk. Age is an important, highly significant variable in 
antenatal depressive risk (p=.001). 18-24 year olds were at the highest risk of raised 
antenatal EPDS in this cohort, 1.63 times more likely to fall into the ‘high risk’ 
category. Regression analysis identified an increase of 1.4 points to the antenatal 
EPDS score for women in this age category. Young maternal age consistently 
transpired to be a risk factor across the different cohorts, although age appears to 
have a diminished role in postpartum risk.  
The analysis reveals that is not only young maternal age that increases a woman’s 
risk of PND. Women over 40 were similarly found to be at increased antenatal risk, 
with 1.4 points also added to their EPDS scores for women aged 40-45. Therefore 
there is an optimum period of reduced vulnerability for depression following a U-
shaped pattern, with risk increasing at the lower and higher ends of the age 
spectrum. The 40-45 age category was also associated with lower birth weights in 
addition to depressive risk. Higher maternal age is associated with an increased risk 
of obstetric complications including gestational diabetes, pre-eclampsia, 
miscarriage, congenital abnormalities such as Down’s syndrome, babies small or 
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large for gestational age, and complications during delivery, and are also more likely 
to have undergone assisted conception289 290. The underlying reasons for older 
maternal age as a risk factor for PND may be related to other associated health 
complications acting indirectly to increase in stress during pregnancy.  Older 
maternal age, specifically in the same age category of 40-45, has been reported as 
risk factors for depression in previous studies291 292. 
Overall, young maternal age is a consistent risk factor for PND in this analysis, 
particularly in the antenatal period and this is true across different populations and 
cohorts. One preventative intervention for PND used in the UK involves specialist 
home visits for teenage mothers125, and it can be argued that this research points 
to expanding this programme to include first time mothers under 25 who clearly 
require additional support in their pregnancies. Likewise, older maternal age is 
apparent as a risk factor, and these mothers should also be prioritised. It is a 
common misconception that women in their 40s, with increased life experience, 
are better equipped to cope with the stress of pregnancy and the postpartum, yet 
this finding indicates that the opposite is true, and clearly support at either end of 
the age spectrum is warranted, and is corroborated by previous findings292 293. 
Anxiety 
Anxiety is a common disorder affecting at least 10% of Western populations, with 
the highest prevalence seen amongst women294 295. The impact of anxiety is all too 
often dismissed, and the impact on health misunderstood. It is generally considered 
less detrimental than depression, yet anxiety presents a great challenge for the 
biological stress systems, most notably that of the HPA axis. The influence of a 
history of anxiety on antenatal symptoms in this cohort is consistent with the noted 
dysregulation of the HPA axis associated with AND296. Long-term modification of 
HPA axis activity as a result of early life stress, which is highly related to anxiety, is 
thought to contribute to a heightened psychological vulnerability of perinatal 
women. There is strong evidence that maternal anxiety influences child 
development82 218. Maternal anxiety is thought to influence infant temperament, 
which in turn affects parental stress, and in this way the emotional states of mother 
and child interact with one another in a bidirectional mechanism of influence297. 
The way in which the stress system reacts to challenge can affect the developing 
foetus/infant and it is important to consider this when investigating the 
implications of perinatal anxiety.  
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In the study population, 19% of women had a past history of anxiety. Past anxiety 
indicates an underlying susceptibility to stress, and a likelihood of anxiety-related 
personality traits, which are known to be associated with the 5-HT system298. 
Certain personality types linked with anxiety such as neuroticism have also been 
associated with the development of PPD91.  In the women scoring high risk on the 
antenatal EPDS, rates of past anxiety were more than double that of healthy 
controls. Most notably, a history of anxiety stands out in the present analysis as the 
single strongest predictor of antenatal depressive risk. This finding has implications 
for both the developing offspring and the mother which are likely to contribute to 
PPD and the consequences that brings without intervention. The EPDS has been 
shown to be a good measure of anxiety in addition to depression and therefore may 
represent underlying anxiety worsening during the perinatal period299. An anxiety 
sub-scale within the EPDS questions has been previously identified, with specific 
anxiety dimensions addressed by particular questions on the screening tool300. 
Based on the findings of this study and previous studies, it can be recommended 
that healthcare professionals focus on these anxiety dimensions of the EPDS in 
order to identify a key risk factor for PND.  
Women with a history of anxiety were identified as 3.5 times more likely to be high 
overall risk for depression throughout pregnancy and postpartum (group 3), and 
regression modelling quantified an additional 2.1 points added to the EPDS score 
for women with past anxiety.  Anxiety was also a specific risk factor for antenatal 
depressive symptoms – women with a history of anxiety were 7 times more likely 
to be high risk for AND (group 2). In the analysis that did not split women into risk 
groups, anxiety was also one of the strongest risk factors for antenatal EPDS scores, 
but not postpartum scores. Interestingly, anxiety plays a lesser role postpartum in 
this analysis and appears only to contribute to prediction of scores in pregnancy. 
The importance of anxiety in pregnancy adds weight to the idea of a highly 
biological mechanism acting in the development of AND, relying heavily upon the 
increased HPA activation and higher cortisol levels likely in anxiety prone 
individuals.  
The lack of association postpartum indicates that during pregnancy is the time in 
which women with a history of anxiety require intervention for depressive 
symptoms, but the results show that these effects are likely to subside postpartum. 
This highlights the increased need to support and monitor this group of women 
antenatally, rather than postnatally when it is too late to mitigate the consequences 
for the child. The importance of anxiety is highlighted by its major role in AND, 
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which in turn is one of the biggest predictors of PPD. Anxiety is therefore also 
indirectly contributing to PPD, which carries its own risks for mother, child and 
family unit, including relationship breakdown and poor mother-infant attachment. 
If women who come into contact with maternity services are routinely asked about 
a history of anxiety, this will provide the optimal opportunity to intervene and offer 
additional support and guidance throughout pregnancy relating to any symptoms 
of PND which occur. This study, along with the previous literature55 301 302, 
demonstrates the increased risk of depression during pregnancy for this group of 
women who are prone to anxiety. Moreover, a number of women will come into 
contact with NHS professionals prior to conception to discuss family planning. The 
results here indicate that this family planning discussion could be the optimal time 
to recognise women with a history of anxiety. Mental health prior to conception is 
a good indicator of perinatal mental health, and prevention of PND is more likely 
with the right intervention pre-conception where possible. 
Past history of depression 
This analysis identified that women with a past history of depression are 
consistently at increased risk of both antenatal and postpartum depression. A past 
history of depression is additionally associated with higher average EPDS score 
between antenatal and postpartum periods, as well as bigger shifts between 
scores. This association is in agreement with the literature, and prospective 
population based studies suggest that the risk of PPD is more than 20 times higher 
for women with a history of depression compared to women without, as previously 
described in the literature23 293.   
A history of depression is one of the most influential and significant risk factors 
identified in this study, with an odds ratio of 4.4 of scoring 10 or above on the 
antenatal EPDS and 4.3 postpartum. In prediction modelling a history of 
depressions contributes over 2 points to the EPDS antenatally and around 3 points 
postnatally. In the group modelling, a past history of depression is a significant risk 
factor for two groups: high postpartum risk (group 1) and overall high risk (group 
3). It appears to play a stronger role in sub-types which involve depression in the 
postpartum, but not when only antenatal symptoms occur. The opposite was true 
for a past history of anxiety, with increased vulnerability in sub-types involving 
depression antenatally, demonstrating a further difference in underlying aetiology 
representing biologically distinct processes. 
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It is hypothesised that antenatal and postpartum depression represent different 
clinical sub-types. Two forms of depression are recognised, melancholic and 
atypical34. Melancholic depression is typically defined by a loss of pleasure, 
depressed mood worse in the morning, insomnia and weight loss, and is associated 
with HPA hyper-activation. In contrast, atypical depression symptoms involve 
retention of mood reactivity, weight gain, hypersomnia and depressed mood 
worsening throughout the day, and is linked to a hypo-responsive HPA axis and 
glucocorticoid suppression154. Differences in risk profile could be indicative of sub-
type, since the profile of antenatal depression is most similar to that of melancholic 
depression, and postpartum depression closer to the atypical type. This may explain 
the observed differences.  
Sub-groups of women may be genetically predisposed to depression of either the 
melancholic or atypical type, influencing their risk of depression at specific stages 
of the perinatal period. Atypical depression seems to be triggered postpartum45. 
Women with a vulnerability to the atypical type may be at-risk of PPD due to the 
withdrawal of cortisol, and there is some evidence for HPA axis changes similar to 
atypical depression seen in the postpartum period303. 
A past history of PND has been identified in the analysis as an additional important 
risk factor to consider, although not as influential as depression outside of this 
period. Past PND was a specific risk factor for postpartum symptoms. This does not 
however appear to play a role in antenatal symptoms. This finding suggests that 
women who have experienced PND previously should be closely monitored, 
especially in the postpartum period, as they are at increased risk following a future 
pregnancy. 
The highly influential nature of past depression and anxiety in the development of 
PND highlights the need to identify these two risk factors as early as possible during 
pregnancy, or pre-conception wherever possible. The positive aspect of these two 
risk factors is that they can be identified and targeted early on based on patients’ 
notes and history. The results of this analysis show that women with a history of 
mental illness, including anxiety and depression, are increasingly vulnerable in the 
perinatal period. In addition, sub-groups can be identified based on these risk 
factors, which can guide interventions accordingly. Further work to understand 
differences in their underlying pathology is required. 
If the three important variables discussed so far, ‘age’, ‘past history of anxiety’ and 
‘past history of depression’, are used alone in regression modelling to predict 
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antenatal EPDS score, it is noted that prediction is almost as accurate as when using 
the nine variables selected in the optimal model. The model with all nine variables 
explains 14% of the variation in EPDS scores (R2), whereas when these three 
variables alone are used in prediction, the R2 only reduces slightly to 12%, meaning 
that these variables have the majority of the influence on scores. Age, Anxiety and 
Depression history may therefore represent an easy initial screen for AND. When 
these three variables are used alone to predict PPD, prediction is less accurate, 
since antenatal EPDS is the best predictor of postpartum scores. 
Social status 
This study found that social status is an important risk factor for PND, which is in 
agreement with previous findings92. The analysis of the main cohort finds social 
status to be a highly significant covariate. Social status of ‘unemployed/student’ 
carries an odds ratio of 1.86 in relation to scoring high on the antenatal EPDS (≥ 10). 
Prediction modelling identifies an additional 1.5 points added to antenatal EPDS 
score for women in this category. This finding is in agreement with previous studies 
also reporting that AND is more prevalent in unemployed women56 270. Analysis of 
postpartum scores finds no association with social status. 
Lower social status, indicated in this study by level of occupation, often indicates 
adversity in life. Two main stress hypotheses exist, the traditional ‘cumulative 
stress’ hypothesis, where the vulnerability increases as life history of stress 
increases, and the ‘mismatch’ hypothesis (Figure 7.2)304. The two hypotheses can 
also be integrated into one model dependent upon an individual’s exposure to early 
programming effects. In the mismatch hypothesis, problems will only occur when 
(a) (b) 
Figure 7.2. Hypotheses of exposures to an adverse environment leading to either (a) cumulative 
damage and increased risk for disease or (b) a mismatch of early life programming experiences 
and adult experiences increases likelihood of disease, whereas a match of early life and adult 
conditions results in resilience due to early life programming. Figure adapted from Nederhof & 
Schmidt (2012) . 
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there is mismatch between the early life and adult environment, or the pre/post-
natal environment (Figure 7.2 (b). Adversity either prenatally or in early life adapts 
the individual to stress in later life as a protective mechanism. This could however 
render the individual maladapted to ‘normal’ environments, producing a stress 
response when unnecessary. If a mother with a low social status had also 
experienced early life adversity, this could help explain their increased vulnerability 
to depression. Further information regarding current and previous life 
circumstances would be required to investigate this in this cohort. 
A higher social status is protective against an overall risk of depression in this study. 
Social status is indicative of socioeconomic status (SES), which is a well-established 
risk factor for PPD55 95. These results show that unemployment is a key risk factor 
for antenatal depressive symptoms, which likely reflects financial worries and 
instability. Similarly in the smaller Coventry cohort, insecure housing was a 
significant risk factor for both antenatal and postpartum symptoms. Findings 
indicate that more options for working mothers would be beneficial, as women 
with a lower job level or in unemployment had a significantly raised likelihood of 
overall depressive risk. Additionally, the rising costs of childcare contributes to 
financial stress on families looking to return to work. Both employers and 
governments should consider this in their policies on parental leave and childcare 
support.  
Social status not only has an impact on a woman’s risk of PND, but also on the 
consequences of maternal depression for the child. Socioeconomic status (SES) has 
been found to be an independent risk factor for offspring depression into 
adulthood, indicating that treating the mother during pregnancy should be 
prioritised43. The extent of the consequences can be moderated by SES. The 
children of mothers with the same degree of PPD but higher SES are less likely to 
be affected, whilst the offspring of lower educated mothers have an increased risk 
of adolescent depression 43. Why this moderation exists is currently unknown.  
Interestingly, a low socioeconomic status (SES) has also been linked with altered 
placental mRNA levels of genes involved in glucocorticoid metabolism150. It is 
possible that the effects of maternal SES on the offspring are initiated in the womb. 
It seems that a higher SES can mitigate both maternal and offspring effects of PND. 
It is important to note that the moderation of outcome by SES is not evident in 
antenatal depression. This suggests a pathway predominantly involving biological 
consequences in utero, in contrast to a highly environmental mechanism for PPD. 
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Significant associations were found between social status and a number of the 
measured biomarkers related to stress adaptability in this study, including IL-6/IL-
10 and global DNA methylation. These biomarker associations will be discussed in 
more detail later in this chapter. 
Educational level 
Across almost all aspects of health, those with a higher educational level experience 
better outcomes, adopt healthier behaviours and live longer, and studies have 
shown that at least part of this relationship is considered causal305. Education is 
additionally indicative of multiple social factors. In general, previous studies find an 
inverse relationship between level of education and likelihood of PND. The findings 
related to this covariate in our study are somewhat ambiguous, but is likely 
influenced by the fact the main study population is generally highly educated, with 
over half of women educated to a minimum of degree level. The majority of studies 
in this area examine low education at a level without passing school examinations, 
yet only 1% of women in the study did not attain any qualifications, and therefore 
care should be taken when comparing to less educated populations. 
In the main study population, education was only significant for prediction of 
postpartum EPDS scores, which is similar to what is reported in the literature. 
Although not statistically significant, educational level did still play a role in 
antenatal EPDS score, and was in fact the inverse of the relationship postpartum, 
with lower educational attainment (no exams) associated with a slight decrease in 
EPDS score. Due to a lack of significance and the small number of cases (EPDS ≥ 10) 
in this category this result is considered negligible. The finding that education to 
aged 16 only is associated with a 1.5 point increase in EPDS score is more in fitting 
with what might be expected.  
Low maternal education has been highlighted as a risk factor for postpartum but 
not antenatal depression43. Low maternal education (indicative of low SES) has 
been shown to be associated with upregulation of placental glucocorticoid receptor 
and HSD11B1 gene expression152. Increased HSD11B1 expression results in 
glucocorticoid regeneration and therefore higher levels of glucocorticoid 
availability in the placenta. It is therefore hypothesised that this will in turn increase 
foetal exposure to glucocorticoids, providing a possible explanation for a number 
of associations between SES and offspring outcomes. 
Educational level, socioeconomic status and depressive risk appear to be 
interconnected. In terms of effects on offspring, the investigation of paternal 
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depression in fathers can help elucidate the different mechanisms. There is 
currently no evidence for an association between paternal antenatal depression 
and offspring depression, or that the effects are moderated by his education. There 
is however an association between paternal postpartum depression and offspring 
depression, which similarly to maternal depression and SES, is limited to offspring 
with low education43. This provides further indirect evidence that the pathways of 
antenatal and postpartum depression are different. SES is closely linked with 
educational level, which is an additional risk factor for PND indicated by the 
analysis. 
Cigarette and alcohol consumption 
Smoking is identified in the main cohort as a risk factor, specifically for antenatal 
depressive symptoms. Smoking uptake is known to be higher among those with low 
socioeconomic status and quit attempts are more likely to be unsuccessful306. 
Studies have also demonstrated educational inequalities in smoking, finding that a 
quarter of those with high school or less education smoke, compared with 11% of 
those with an undergraduate degree and 5.6% with a graduate degree307 308. Both 
SES and educational level are also implicated in perinatal depressive risk both in 
this study and in previous literature. Smoking both in the 12 months pre-conception 
and during pregnancy were significantly associated with EPDS scores ≥ 10, with 
respective odds ratios of 2.2 and 2.4. In terms of significance level, smoking pre-
conception was the most statistically significant. In the antenatal prediction model 
adjusting for a number of related covariates, smoking pre-conception remained a 
statistically significant influence at the p<.001 level, contributing 1.1 points to the 
score. Smoking during pregnancy is not included in the optimal regression model 
based on exploratory work after controlling for factors including social status and 
education level. In analysis of postpartum EPDS scores, smoking either pre-
pregnancy or in pregnancy, had no apparent association.  
Drinking alcohol during the 12 months pre-conception is associated with 
postpartum EPDS scores, but not antenatal scores, which is the reverse of the 
association with smoking. In the postpartum prediction modelling for the largest 
cohort, pre-pregnancy alcohol was a statistically significant influence on the 
modelling of score prediction, adding around 0.7 points to the score. This is a 
relatively small but significant contribution. Combined with a number of other key 




Both smoking and the consumption of alcohol are widely known to be detrimental 
to health. It is also widely accepted that smoking and drinking are especially 
harmful to an unborn child and women who are trying to conceive are advised to 
avoid these substances prior to conception. Alcohol consumption is often higher in 
those suffering with depression, and is additionally harmful to mental health, and 
therefore the direction of this association is difficult to assess since women scoring 
higher on the EPDS are experiencing symptoms of depression and anxiety309. The 
prevalence of smoking is also higher in people with major depression, and cessation 
more difficult and likely to lead to further depressive episodes310 311.  
Although research relating to harmful effects for the foetus are inconclusive, it is 
though that long-term health risks are greater the more a woman drinks. Clear 
evidence also shows that heavy alcohol consumption during pregnancy can lead to 
fetal alcohol spectrum disorder (FASD), affecting intellectual ability, birth defects, 
behaviour, fine motor skills and mental health312. For low-to-moderate alcohol 
consumption, the latest evidence suggests that this is related to increased risk of 
having a baby small for gestational age (SGA), which present numerous health 
detriments of its own, when compared with abstinence313. Until recently UK health 
guidelines advised avoiding alcohol while trying to conceive and during the first 
trimester, but also suggested consumption should be limited to ‘1 to 2 units, once 
or twice a week’314. This has now been updated and the Chief Medical Officers for 
the UK recommend that both pregnant women and those planning to become 
pregnant entirely abstain from alcohol to keep risks to a minimum as a precaution 
due to lack of robust evidence315. 
The association between alcohol consumption and symptoms of depression and 
anxiety has been identified by other studies, and may largely reflect the impact of 
other factors such as low socioeconomic status, lower education and smoking 
status316 317. In the current study, alcohol consumption pre-conception is a risk 
factor for PND. Although evidence into the reasons behind this is currently lacking, 
it is reasonable to suggest that women who report drinking alcohol pre-conception 
are more likely to have had an unplanned pregnancy, which carries its own risks 
relating to PND, and are less likely to adopt health promoting behaviours around 
the time of conception and pregnancy. Women who consume alcohol and 
cigarettes around pregnancy face compromising their own and their child’s health, 
and these behaviours may represent underlying symptoms of depression and 
anxiety309. It is important to note that detailed information on units of alcohol or 
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number of cigarettes is unavailable in the present study and so this analysis 
compares abstinence with any self-reported smoking/drinking. 
The identification of both smoking and drinking alcohol as risk factors for PND have 
implications which are readily transferrable to the clinic. It seems that the public 
consensus is that smoking and drinking in pregnancy are known to be harmful, but 
the risk of these factors pre-conception are misunderstood. Perhaps most 
importantly, all women of childbearing age should be aware of this association. It 
is important to emphasise this should be discussed prior to pregnancy, since the 
key factor here is the consumption of cigarettes and alcohol pre-conception, and 
therefore specifically women who are coming off contraception or planning a 
pregnancy should be targeted. In addition, an association with smoking in 
pregnancy is apparent in the analysis, highlighting the additional benefits of 
smoking cessation as early as possible in pregnancy. The current findings suggest 
that increased provision of support to stop smoking and drinking during pregnancy 
would be beneficial to maternal mental health. 
Mode of delivery 
The chosen mode of delivery is discussed with midwives and doctors administering 
a woman’s maternity care to decide the optimal type of delivery for their 
pregnancy. It is based on a number of factors including health of the mother and 
baby and any complications in a previous or current pregnancy. Some women will 
opt for a planned, or elective caesarean section (ELCS), meaning they know in 
advance that they will deliver their baby by section. In 2012-2013, over a quarter 
of all babies in England were delivered by caesarean, almost half of which were 
ELCS, and this has almost doubled in the previous decade318. There is further 
evidence that rates of ELCS are continuing to rise, with the latest reported national 
average at 30% caesarean births, half of which were ELCS277. Caesarean operations 
result in a prolonged stay in hospital when compared with spontaneous birth, 
normally a minimum of two days after the ELCS, representing a financial and care 
burden on the NHS associated with the peri- and post-operative care required for 
an ELCS.  
The increased recovery period for ELCS when compared with spontaneous delivery 
is likely to increase anxiety in an expectant mother, with increased worries about 
the procedure and difficulties in caring for a new-born child. It is also more likely 
that women opting for ELCS have experienced pregnancy associated complications. 
Mode of delivery has received little attention in the field of PND, although a small 
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number of studies suggest a link between mode of delivery and perinatal 
depressive symptoms and wellbeing319 320. The directionality of this relationship 
requires further investigation, and can perhaps be aided by the measurement of 
biomarkers, which has been applied here and will be discussed later in this chapter. 
In the present study, mode of delivery was a significant factor in antenatal 
depressive symptoms. Women opting for ELCS were 1.72 times more likely to score 
≥ 10 on the antenatal EPDS compared with those opting for normal vaginal birth 
(NVB). Delivery by ELCS is a significant factor influencing the optimal prediction 
model, increasing score by 0.8 points. No associations between postpartum scores 
and mode of delivery were identified. Although mode of delivery is a postpartum 
outcome which would not usually be taken into account in the prediction of 
antenatal symptoms, an exception was made for ELCS due to the planned nature 
of the procedure which may increase levels of anxiety and anticipation throughout 
the pregnancy. Additionally, there are confounding factors to consider such as 
health complications which may also act to increase risk of PND. It is also worth 
considering that the directionality of this association is the reverse, with antenatal 
depression leading to pregnancy complications which may in turn to result in opting 
for an ELCS. These findings must also be interpreted with caution since it is 
unknown whether the planning of the ELCS preceded the data at which the EPDS 
screening took place, since in some cases this will happen later in pregnancy, and 
therefore conclusions are limited. Further work would be required in order to 
investigate this relationship. 
Overall the influence on depressive symptoms antenatally point to the increased 
level of worry and anxiety during pregnancy surrounding thoughts of a more 
complex birth and prolonged recovery period. These findings indicate that women 
who are planning to deliver by ELCS are at increased risk of AND and require 
increased monitoring and support throughout pregnancy.  
Do cytokines and neurosteroids act as markers for PND? (Aim 3) 
Biomarkers 
A number of the relationships identified with the psychosocial covariates in this 
analysis are complicated by multiple associations with other social, psychological 
and physiological factors. The interrogation of biomarkers in this process aimed to 
help disentangle these effects and assess the underlying physiological response 
related to perinatal depressive symptoms. The three biomarkers of interest in this 
228 
 
study, IL-6, IL-10 and BDNF, all appear to have interesting associations with the 
selected psychosocial covariates. 
The analysis reports an inverse association between IL-6 and one of the key risk 
factors for PND, social status. On closer inspection, the relationship between IL-6 
and depressive symptoms was investigated. Although no clear association was 
identified between IL-6 and EPDS, when the ratio of IL-6/IL-10 is calculated, a 
significant association with antenatal EPDS is apparent. This finding demonstrates 
that the balance of pro- and anti-inflammatory cytokines is important in depressive 
pathophysiology, and is also related to sociodemographic factors such including 
social status. IL-10, the anti-inflammatory counterpart to IL-6, is significantly 
associated with EPDS in this study, and has an inverse relationship. High circulating 
IL-10 levels appear to protect against depressive symptoms while lower levels of IL-
10 were found in those at risk of major depression (EPDS ≥ 15).  
Raised IL-6/IL-10 in pregnancy was also found to be significantly associated with 
mode of delivery, with raised levels found in those with more complex deliveries. 
The highest ratio was found in women who went on to deliver by Emergency 
Caesarean Section (EMCS), and the lowest in women delivering by Normal Vaginal 
Birth (NVB). This high ratio of IL-6/IL-10 may represent a biomarker of general levels 
of inflammation and complications with the pregnancy that can result in a more 
complex birth requiring emergency intervention.  
Maternal BMI was highly associated with both IL-6 and IL-6:IL-10 in in this analysis. 
A BMI of 35-39, which falls into the obese category, was also a significant predictor 
of postpartum depressive risk in the optimal prediction model in this study, 
increasing EPDS score by 1.13 points. It has been reported that in overweight and 
obese women, there is a reduction in NVB rate with increasing BMI279. Obesity is 
associated with higher rates of EMCS, with an observed 30% increased risk, and 
therefore this may help to explain the links between mode of delivery, BMI, IL-6 
and IL-10 reported in this analysis. This finding could represent an indirect effect of 
high BMI, acting through increased circulating pro-inflammatory cytokines, 





Figure 7.3. Insults such as high BMI or low social status can alter the ratio of IL-6/IL-10. This likely 
results in subsequent effects on HPA axis sensitivity, explaining the relationship with antenatal 
depression (raised EPDS scores). This will in turn increase the risk of postpartum depression, both 
indirectly via antenatal depressive risk, in addition to the noted association between IL-6/IL-10 and 
shorter gestational length and increased risk of emergency caesarean section.  
As described in Chapter 1, the physiology of PND likely involves HPA variability and 
its role in the evoked inflammatory response. It is thought that some women 
possess an altered sensitivity to the inflammatory stimuli of pregnancy and 
childbirth which may contribute to the development of depression. The observed 
association between high circulating IL-10 and low risk of depression may represent 
the appropriate anti-inflammatory response taking place which is known to 
suppress inflammation168. On the other hand, in high risk women with low IL-10 
levels, the inflammatory circuit may instead be disrupted, ultimately resulting in 
dysregulated cytokine production and cortisol secretion and ultimately 
contributing to PND164 165.  
Previous studies have suggested that people with a lower SES are less able to adapt 
to stress than higher SES counterparts, with evidence for stress-induced increased 
in IL-6321. A study involving both animal and human subjects reported that early 
social experience moderates the effects of adult social status on IL-6 levels322. The 
finding in this study that a lower social status is associated with raised IL-6 
concentration in this study corroborate this, since lower social status is generally 
indicative of social disadvantages which often start in early life. A recent study 
investigating effects of perinatal stress also reports findings of raised IL-6 levels323. 
The activation of Toll-like receptor (TLR) 2 and 4 signalling and the NLRP3 
inflammasome in placental immune cells is a proposed mechanism occurring during 
PND33. The resultant shift to a predominant Th1/Th17 inflammatory response is 
associated with increased secretion of pro-inflammatory cytokines. Overall, a 
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pathway involving neuroendocrine and immune system function is becoming 
increasingly implicated in perinatal stress.  
Is there a difference observed in DNA methylation patterns? (Aim 4) 
The sub-study investigating global DNA methylation finds an association between 
%5-mC and social status. Additionally, 5-mC% and EPDS are associated with 
statistical significance. It can be argued that this effect is indirect, and is mediated 
through social status. Methylation levels are also correlated with housing status, a 
further indicator of social status. Further work to detail the impact of social status 
and a larger study investigating global DNA methylation would be required to 
investigate this. 
Of the biomarkers measured in this study, modelling demonstrates that IL-6/IL-10 
ratio most improves the prediction of EPDS score. Including all psychosocial factors 
measured, this biomarker falls in the top 10 predictive variables. IL-6 alone also 
improves the model, yet IL-6/IL-10 provides the optimal predictive power. The 
inclusion of these two biomarkers improves the prediction of antenatal EPDS score. 
The variation in score, explained by R2 in the regression models, rose from 14% to 
20% with the addition of these biomarkers, meaning that 20% of the variability in 
EPDS scores is now explained by the model in this analysis. Overall this means that 
the concentration of IL-6 and the ratio of IL-6/IL-10 does help to predict risk of 
antenatal depression. The finding of these markers improving prediction is 
consistent across cohorts, with smaller and larger sample numbers. When IL-6/IL-
10 is combined with a history of anxiety, the most important psychosocial risk factor 
identified, these two predictors alone can be used as a negative screen with 89% 
certainty. The inclusion of this biomarker raises prediction by 10%. 
The analysis of circulating BDNF concentration and its association with depressive 
risk revealed an interesting relationship in this study. It was expected that BDNF 
levels would be reduced in those with high depressive risk due to the reported 
associations with depression190 192. On initial analysis of the data the opposite effect 
was seen with a mild positive association, and so a number of possible reasons for 
this were first considered. The majority of previous studies have used post-mortem 
brain samples, and measurement in patient blood samples, especially human 
plasma samples, is not well studied188. It is possible that this method of detecting 
BDNF is unsuitable for the sample type available. A second possibility is that 
patients with raised EPDS were treated with antidepressants and this was not 
accurately recorded, since BDNF levels are known to normalise following 
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antidepressant treatment188. On further analysis however, reference ranges were 
used to separate ‘healthy controls’ from ‘patients’. This analysis then revealed an 
association that was expected, and an inverse relationship was reported between 
BDNF and depressive risk in ‘patients’. The study was biased towards a normal EPDS 
score, due to the prospective design. The relationship may therefore not have been 
apparent in the whole study population due to the large number of participants 
scoring very low on the EPDS resulting in low mean EPDS, and the role of BDNF 
concentration may only come into effect when depressive risk becomes higher. 
Does HPA axis sensitivity provide a marker for PND by genotyping target SNPs? 
(Aim 5) 
Genetics 
Both previous findings and the results of the current study suggest that 
demographic and psychosocial risk factors have a reduced predictive power for 
postpartum depression compared to antenatal depression14. This suggests a 
diminished contribution from environmental factors and hint at additional 
biological-genetic components for the development of PPD. A possible genetic 
component, as hinted at by the contribution of covariates indicating a family history 
of PND, was explored to assess whether this could lead to an improvement in 
prediction. This was designed to test at the clinical setting the potential use of SNPs 
in prospectively identifying women with high EPDS scores and thus increased risk 
of PND. This analysis also aimed to test whether findings from a smaller pilot study 
were replicated in this larger cohort. 
In the analysis of the whole study population, no significant associations between 
the selected three SNPs and depressive symptoms were observed, but associations 
were found when the study group was split by their family history. The Bcl1 minor 
allele of the glucocorticoid receptor was found to be associated with an increased 
risk of PND in patients with a family history of PND. Both the pilot study and a 
previous study in a non-pregnant population also found a significant association 
between the Bcl1 minor allele and high risk of PND, which appears to be due to a 
known association with glucocorticoid (GC) hypersensitivity131 324 325. In women 
without a family history, the reverse relationship was identified, and a mildly 
protective and significant effect was found for those testing positive for the minor 
allele. A relationship between the IL-6/IL-10 ratio and Bcl1 has also been identified 
in the whole study population. The relationship suggests that the presence of the 
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Bcl1 minor allele is associated with a lower IL-6/IL-10 ratio which may be in turn be 
related to GC hypersensitivity, induced by Bcl1, and its anti-inflammatory effects. 
The rs242924 SNP of the CRH-R1 was found to have no direct relationship with 
increased EPDS score. A relationship was instead observed between a family history 
and a personal history of PND in women positive for the minor allele. This therefore 
suggests that although a direct correlation between family history and EPDS score 
was not observed, a family history has had a previous effect on a former pregnancy 
depressive risk, which is in turn a risk factor for a future pregnancy, and can 
therefore be considered linked with PND risk. This SNP was not measured in the 
earlier pilot study and therefore results cannot be compared. 
The rs242939 SNP of the CRH-R1 was found to be significantly associated with the 
easing of depressive symptoms postpartum in women with a family history of PND. 
This SNP was associated with a DPA score of -1.6, meaning symptoms are likely to 
ease by an average of 1.6 points as measured on the EPDS in the postpartum period. 
This indicates that women with this SNP who also have a family history of PND may 
have an increased risk of depression during pregnancy, but symptoms are likely to 
ease postpartum. When considering the group analysis conducted in this study, 
these women are most aligned with those in Group 1.  
Overall, the genetic analysis did not reveal any strong associations with current 
depressive symptoms. This could partly be due to the small number of participants 
reporting a family history of PND, and future work should examine a large 
population of women with a family history of PND in order to accurately determine 
any genetic component to its intergenerational transmission.  Women with a family 
history of PND represent an especially vulnerable group and the elucidation of the 
related factors, whether directly genetic or acting through psycho-
sociodemographic covariates, requires further investigation. Future genetic studies 
with a focus on women with a family history of PND would improve our 
understanding of this element of heritability. This genetic study has also identified 
the relative ease of the method used in genotyping specific SNPs within a hospital 
laboratory setting. 
Gestational length/birth weight 
Seemingly inconsequential effects on birth weight can have long-term 
consequences for cognitive development and responses to stress, as well as general 
psychological wellbeing in later life52-54. PND is thought to be a risk factor for low 
birth weight, with more than half of publications finding a significant association 
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between prenatal depression and birth weight48. Much of the evidence has 
however been inconclusive. An association with gestational length has also been 
hypothesised although results are less consistent. Low infant birth weights pose 
risks for health and development, with an increased risk of mortality.  This study 
finds a significant inverse association between gestational length and both 
antenatal and postpartum EPDS, with a shorter gestational length in women at 
higher risk of PND. This finding adds weight to the hypothesis that PND 
compromises gestational length and therefore birth weights and child 
development. 
The regression model predicting birth weight finds that two of the measured 
biomarkers, IL-6 and BDNF, are both influential factors, playing statistically 
significant roles in birth weight. The observed relationship is inverse, with higher 
circulating concentrations of both IL-6 and BDNF associated with a smaller birth 
weight. The most influential factor in birth weight in this study is gestational length, 
but other important factors include maternal BMI and age, instrument assisted 
delivery, low social status and parity, as well as smoking and alcohol. The inclusion 
of two biomarkers in the optimal prediction model points to a highly physiological 
mechanism involving the neuro-inflammatory system, possibly related to 
depression. 
Due to the clear association between gestational length and birth weight, the 
model next controlled for gestational length to assess whether the associated 
variables remained significant predictors in the model. The influence of biomarkers 
IL-6 and IL-10 were no longer seen in this model, indicating that the observed 
association was instead with gestational length rather than birth weight. This was 
next investigated by prediction of gestational length in exploratory regression 
modelling. 
In predicting gestational length, circulating BDNF concentration is included in the 
optimal model and therefore improves its prediction. BDNF improves the 
prediction of gestational length both with and without the inclusion of birth weight 
in the model. A relationship between postpartum EPDS score and gestational length 
was also identified, with a shorter gestational length associated with raised EPDS 
scores following birth. This may represent an underlying level of stress during 
pregnancy which was not detected by the EPDS, since prenatal stress and 
associated glucocorticoid exposure is related to shorter gestation49, or alternatively 
could be a postpartum outcome of delivering baby earlier than expected. The final 
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model finds that 40% of the variability in gestational length is accounted for by the 
included covariates. Aside from birth weight, other predictive factors for 
gestational length were mode of delivery, social status, maternal BMI and parity. 
Since all these variables are also risk factors for PND, they are clearly interlinked 
and demonstrate the importance of monitoring these factors during pregnancy. 
The factors discussed above (age, past anxiety/depression, social status, education, 
smoking, alcohol, mode of delivery, and biomarkers) were the most consistent risk 
factors for PND coming out of the analysis. Other factors which did show some level 
of significant association but not consistently throughout the analyses were BMI, 
support, past PND, family history of PND and ethnicity. Women who identified as 
‘unsupported’ were at increased risk of AND in both the Warwick and Coventry 
cohorts, and this is fitting with the literature demonstrating a lack of social support 
as a predictor of PND55. Increased support from the mother’s partner, family and 
social environment is thought to act as a buffering effect against parental stress and 
protect maternal mental health98 326.  
Past PND was an additional risk factor for postpartum symptoms in the Coventry 
cohort. Past PND was a risk factor across the main Warwick cohort for both 
antenatal and postpartum depressive risk, which is in line with the literature finding 
that recurrence of PND is common in future pregnancies23.  A family history was not 
a risk factor in the main cohort, which may indicate why genetic factors were not 
found to be associated, but in the smaller sub-study family history was a significant 
risk factor for both antenatal and postpartum depressive risk. Family history was 
additionally risk factor for antenatal depressive symptoms in the Coventry cohort. 
Finally, ethnicity was identified as a risk factor in the Coventry cohort, with women 
of Asian or Mixed ethnicity at the highest risk of depressive symptoms, which is in 
fitting with the finding that Black Asian and minority ethnic (BAME) women are at 






Overall, the findings of this study fit well with the conceptual framework describing 
stress vulnerability and depression in women14. Previous history of relevant illness 
might contribute to individual chronic and acute burdens and accumulation of life 
stressors that prevent effective adjustment of regulatory mechanisms. Previous 
studies that employed structural equation modelling to integrate variables such as 
stressful life events, social support, personality traits, anxiety and coping strategies 
with postpartum depressive symptoms in a conceptual model of vulnerability to 
PPD, suggest that women with specific personality traits are more sensitive to the 
depressogenic effects of adversity and stress events328.  
Similarly, socioeconomic deprivation is another factor clearly linked to stress 
vulnerability, as observed in low-income populations that exhibit higher levels of 
stress and impaired coping and depression. Therefore, our findings support and 
expand the biopsychosocial model of perinatal depression as proposed by Leigh 
and Milgrom329; a modified version of the model incorporating our findings is 
presented in Figure 7.4. The complex interplay of stress vulnerability factors, 
precipitating factors associated with adjustment in pregnancy and antenatal 
stressors, personal resources and coping behaviours and predisposing factors result 
Figure 7.4. A modified version of the Leigh and Milgrom biopsychosocial model 
of perinatal depression, incorporating findings from the analysis of this study. 
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in a heterogeneous presentation of PND with affected women experiencing distinct 
patterns of onset of symptoms, severity, duration and recurrence. 
In light of the previous state-of-the-art of the field, this research study introduces 
valuable findings, with noted implications which upon further refinement could be 
directly transferrable to the clinic. Key risk factors have been identified and 
validated, and a novel approach shows quantifiable contributions to EPDS scores. 
Information regarding a woman’s risk of PND would benefit the complex decision 
making process surrounding choice of intervention, such as whether 
pharmacological intervention is required despite any risks. Ease of prediction in the 
clinic is an important outcome underpinning this study, however future work could 
also utilise this data in the generation of a prediction algorithm. 
Future research could include a qualitative study consisting of interviews with 
stakeholders, health professionals and patients relevant to perinatal mental health 
services. Increased patient and public involvement (PPI) would help to ensure that 
any changes to the service provision are suitable for all involved and any barriers 
for using this type of approach in the clinic are identified. Additionally future work 
could collect more detailed information for key variables, for example the number 
of cigarettes smoked and units of alcohol consumed. Inclusion of additional 
variables such as a history of trauma and initiation of breastfeeding would also be 
useful to collect.  
Already in progress is work to explore the diets of participants of this study, and 
possible relationships between nutrient intake and the EPDS as well as biomarkers, 
in particular DNA methylation levels due to an association with B12 and folate. 
Additional data on nutritional supplements taken, especially folic acid, will be 
recorded. As described earlier, a larger cohort of women with a relevant family 
history should be recruited to further investigate the genetic of PND. A larger and 
more diverse study population is now necessary to further investigate these 
promising findings. Biomarker studies could be improved by adding a longitudinal 
element, utilising a study design with multiple sampling points, in particular with 
the inclusion of a postpartum sample. It would also be beneficial to assess how the 
biomarkers might predict other disorders of maternal mental health such as anxiety 
and OCD. 
The risk factors identified in this study such as low social status, lower educational 
level, and housing status point to the prioritisation of the most disadvantaged 
women in society when it comes to PND. Socioeconomic depravation is an 
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established risk factor which we also find to increase the prevalence of PND in 
agreement with other studies56 99. At a time when the National Health Service is 
extremely stretched, the appropriate prioritisation of resources is crucial. With this 
in mind, this study has demonstrated that data which is routinely collected in the 
NHS can be utilised in prediction of depression, limiting the impact on resources if 
a new PND patient pathway is to be introduced. The cost of intervention and most 
importantly prevention, is far less than the cost of treating the myriad of health, 
social and economic consequences brought about by the impact of maternal 
depression16. The findings of this study galvanise the need to prioritise women’s 
mental health and promote the awareness of key predictors in order to reduce 
depression and the associated outcomes for mothers and children. 
This study provides novel evidence for distinct profiles of psycho-socio-
demographic characteristics associated with within-person heterogeneity of 
perinatal depressive symptoms severity, timing of onset and remission. These 
results identified key predisposing factors that affect individual’s chronic/acute 
burden and stress vulnerability and influence depressive risk trajectories during 
pregnancy and postpartum. The findings here indicate that as women move from 
the antenatal to the postpartum period, sociodemographic and lifestyle risk factors 
appear to play a smaller role in risk, and a personal and family history of mental 
health become increasingly important. Inclusion of covariates, shown to be most 
predictive of PND as demonstrated in this study, in a predictive screening system 
could prioritise resources such as specialist assessment for women most at-risk. 
Do investigated biomarkers improve prediction of PND symptoms when 
compared with psychosocial risk factors? (Aim 6) 
Previous studies suggested that despite acceptable overall discriminatory power, 
the EPDS has limited predictive accuracy for absolute PPD risk stratification, 
regardless of the cut-off value used or the trimester of administration276. This 
appears to be related to the presence of multiple risk factors that are not currently 
included in antenatal screening instruments110. To address this, one approach could 
be to combine screening for specific psychosocial or biological risk factors alongside 
EPDS administration. For example, the addition of prior history of anxiety and IL-
6/IL-10 ratio to antenatal EPDS seems to yield a more accurate overall prediction of 
PPD. 
This study provides a unique insight into the combination of biological and psycho-
sociodemographic predictors of PND. This novel approach has combined 
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biomarkers with psychosocial risk factors in order to explore the contributions to 
PND (Figure 7.5). The findings of this thesis are clinically relevant and can be directly 
translated into the clinic in order to improve the currently inadequate detection of 
































Figure 7.5. A summary of the key factors involved in antenatal and postpartum depressive risk 
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